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ALCOHOL USE, HIV INFECTION, AND ANTIRETROVIRAL ADHERENCE 
Lauren Matukaitis Broyles, PhD 
University of Pittsburgh, 2008
 
 Alcohol use appears to negatively impact antiretroviral (ART) adherence, though conclusions 
about its effects are inconsistent, and the mechanisms of these effects are unclear.  Accurate 
assessment of alcohol use is important for adherence counseling in HIV/AIDS. This secondary 
data analysis aimed to 1) determine if positive alcohol screening tests can predict ART 
adherence; 2) compare the effects of two ART adherence interventions with usual care across 
alcohol screening status; 3) explore mediation by self-efficacy in the relationship between 
adherence and several psychosocial variables; and 4) evaluate the psychometric properties and 
factor structure of the Alcohol Use Disorders Identification Test—Consumption (AUDIT-C). 
The sample included 310 HIV+ adults on ART.  
Over 25% of the sample was AUDIT-C positive. Through sequential multiple linear 
regression analyses, AUDIT-C status (but not AUDIT-3 status) significantly added to the 
prediction of dose adherence (p=.005) and days under-dosing (p=.021) after controlling for 
confounders and covariates. In repeated measures analysis to determine if alcohol use impacts 
the effect of the interventions on dose adherence over time, only main effects for time and 
alcohol screening status were significant. Adherence was significantly lower at Time 2 than at 
baseline, F (1, 236.287) = 25.595, p = .000, and significantly lower for AUDIT-C positive 
individuals than for AUDIT-C negative individuals, F (1, 340.338) = 12.304, p = .001. In path 
analysis, near-significant results suggest partial mediation of the relationship between adherence 
and conscientiousness by self-efficacy. The internal consistency and test-retest reliability of the 
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AUDIT-C were high. Multi-sample confirmatory factor analysis revealed factor invariance for 
sex, but the best-fitting model for race allowed partial invariance where AUDIT-C item 3 
(episodic heavy drinking) was free to vary across whites/nonwhites, X2 (3, 310) = 1.818, p = 
.6111. Inconsistent AUDIT-C data and missing Time 2 adherence data were significantly related 
to baseline opioid use.  
In conclusion, positive AUDIT-C status may serve as an indirect indicator for ART 
nonadherence. The AUDIT-C appears to reliably assess alcohol use in PWHIV, but common 
modifications may risk compromising validity, particularly in drug users. Further attention to the 
cultural equivalence of the AUDIT-C across racial groups may be warranted. 
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1.0  INTRODUCTION 
Previous research on alcohol use and HIV/AIDS has primarily addressed alcohol consumption 
within the context of risky sexual behavior and HIV transmission (Caetano & Hines, 1995; Ryan, 
Huggins, & Beatty, 1999; Stall, McKusick, Wiley, Coates, & Ostrow, 1986). However, in the 
last ten years, as treatment and survival for persons with HIV/AIDS (PWHIV) has dramatically 
improved, attention has slowly turned toward understanding the impact of alcohol use on 
antiretroviral (ART) medication adherence. Although approximately 40-55% of PWHIV 
acknowledge various degrees of alcohol use (Chander, Lau, & Moore, 2006; Galvan et al., 2002; 
Lucas, Gebo, Chaisson, & Moore, 2002; Tucker, Burnam, Sherbourne, Kung, & Gifford, 2003), 
understanding the influence of alcohol use on adherence continues to be limited (Chander, 
Himelhoch, & Moore, 2006).  The National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) has recently identified the need for increased research on improving medication 
adherence among HIV+ individuals who use and misuse alcohol, including the development of 
explanatory models that “increase understanding of the multidimensionality of the relationship 
between alcohol use and “abuse” and adherence to HIV therapeutic regimens. . .” (Bryant, 2006, 
p. 1492), i.e., models which include the variety of individual, social, and contextual factors 
affecting alcohol use and health behavior.  
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Suboptimal ART adherence contributes to decreased viral suppression and drug 
resistance, and subsequently, the potential for higher healthcare costs and the proliferation of 
resistant strains of HIV in the community. While attention to ART adherence among illicit drug 
users has appreciably increased in recent years, few ART adherence investigations have focused 
on the impact of alcohol use, in particular, on its impact independent from that of drug use.  
Studies exploring the relationship between alcohol and ART adherence report inconsistent 
findings, and often require careful evaluation in light of various methodological limitations, e.g., 
inconsistent or ambiguous definitions and measurement of “alcohol use” and “adherence,” and 
the exclusive use of self–report data for assessment of adherence patterns (Chander, Himelhoch 
et al., 2006; Cook et al., 2001). Finally, a limited number of studies have heretofore attempted to 
elucidate the role of various psychological and environmental factors in the alcohol-adherence 
relationship such as self-efficacy, depressive symptoms, social support, and personality 
(Braithwaite et al., 2005; Parsons, Rosof, & Mustanski, 2007; Tucker et al., 2004), and only a 
few studies have described tailored adherence interventions aimed at PWHIV who drink 
(Parsons, Golub, Rosof, & Holder, 2007; Samet et al., 2005).  
Important questions remain about how different patterns of alcohol consumption interfere 
with ART adherence, the mechanisms through which this interference might occur, and the 
effectiveness of ART adherence-enhancing interventions among PWHIV who consume alcohol.  
Given the prevalence of alcohol use, the significant personal and public health implications of 
suboptimal ART adherence, and the fact that alcohol use is a modifiable behavior, a more 
comprehensive understanding of the interplay between alcohol use, adherence, and various 
personal, behavioral, and environmental factors is warranted. 
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Within the framework of Social Cognitive Theory, the overall purpose of this secondary data 
analysis (SDA) was to further elucidate the impact of alcohol use on the ART adherence of 
PWHIV. The primary aims of the study were to: 1) characterize the sample; 2) determine if 
positive screening results on the Alcohol Use Disorders Identification Test—Consumption 
(AUDIT-C) provide additional prediction of ART dose adherence, day adherence, days under-
dosing, days over-dosing and days with null dosing after controlling for various 
sociodemographic, substance use, and psychosocial variables; and 3) explore whether self-
efficacy mediates the effects of depressive symptoms, social support, and conscientiousness on 
dose adherence, and to determine if any meditational relationships were moderated by alcohol 
screening status (AUDIT-C positive/negative). Secondary aims were to 1) explore whether self-
efficacy mediates the effects of depressive symptoms, social support, and conscientiousness on 
the dose adherence of PWHIV with positive alcohol screening tests, and 2) evaluate selected 
psychometric properties of the AUDIT-C.  
4 
 
2.0  BACKGROUND  
Medication-taking is an essential component of self-management in HIV/AIDS. Antiretroviral 
therapy (ART) is the combination of drugs designed to inhibit the proliferation of HIV, improve 
the patient’s immunological status, and prolong life (Hogg, 1997; Palella, 1998). Medication 
adherence refers to the degree to which an individual follows or conforms to the prescribed 
therapeutic regimen. Although often referred to as “compliance,” the less problematic term 
“adherence,” is used here, with the recognition that “adherence” nonetheless retains many of the 
same conceptual and ethical limitations (Broyles, Colbert, & Erlen, 2005). Suboptimal adherence 
to ART regimens (generally understood to be <95%) (Paterson et al., 2000) contributes to viral 
resistance, poorer clinical outcomes for the individual, and the potential public health crisis of 
resistant strains of HIV (Bayer & Stryker, 1997; Lerner, 1998; Nieuwkerk et al., 2001; 
Plettenberg et al., 2001; Wainberg & Friedland, 1998).  
Antiretroviral medication adherence is associated with multiple interwoven patient-, 
medication-, disease-, environment-, and system-related factors.  Substance abuse is a common 
factor associated with ART nonadherence, though focused investigation on alcohol use and 
medication-taking practice in HIV/AIDS is relatively recent and limited compared to research 
examining the impact of illicit drug use. Reasons for this disparity may be related to the general 
social acceptability of alcohol use over illicit drug use, perceptions that alcohol use is the “lesser 
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of two evils” when compared to other substance use, or increased attention to drug use because 
of its more overt relationship to HIV transmission. Nonetheless, understanding the extent of 
alcohol use among persons with HIV/AIDS remains important because of its apparent roles in a 
variety of interwoven HIV-related processes and outcomes (Conigliaro, Justice, Gordon, & 
Bryant, 2006).  Among HIV-infected individuals, alcohol use has been associated with decreased 
viral suppression and/or immune status (Chander, Lau, et al., 2006; Conigliaro, Gordon, 
McGinnis, Rabeneck, & Justice, 2003; Samet et al., 2007), decreased survival (Braithwaite et al., 
2007), increased rates of comorbid medical illness (Justice et al., 2006), decreased 
neurocognitive function (Durvasula, Myers, Mason, & Hinkin, 2006), and potential medication 
interactions and toxicities (Department of Health and Human Services, 2008). 
Importantly, alcohol may exert its effect on HIV-related processes and outcomes directly, 
or, more indirectly, i.e., through its impact on ART adherence. Alcohol use is generally 
associated with decreased ART adherence and a dose-response effect appears to exist where 
greater alcohol consumption is associated with greater likelihood of taking medications off-
schedule or missing medication doses/days (Braithwaite et al., 2005; Chander, Lau et al., 2006; 
Samet, Horton, Meli, Freedberg, Palepu 2004; Tucker et al., 2003).  The exact mechanisms 
through which this nonadherence occurs are heretofore unclear but presumably involve the 
interplay of numerous interrelated factors in addition to alcohol and medication-taking. 
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2.1 THEORETICAL FRAMEWORK 
Social Cognitive Theory (SCT) guided the development of the parent study (PS) interventions 
and the selection of variables and analytic strategies for the current study.  SCT is well-suited for 
understanding medication adherence in the context of chronic illness because it calls attention to 
the complex synergistic relationships between dimensions of the individual, the environment, 
and the behavior.  More specifically, SCT asserts that behavior acquisition and maintenance are 
based on the idea of “reciprocal determinism,” i.e., the bidirectional dynamic interplay between 
individual person factors (affective, cognitive, biological), environmental (social, physical) 
factors, and the behavior itself (Bandura, 1997). The primary causal processes in the acquisition 
and maintenance of a given behavior are driven by self-efficacy.  
Formally defined as “beliefs in one’s capabilities to organize and execute the courses of 
action required to produce given attainments” (Bandura, 1997, p. 3), self-efficacy is commonly 
understood as confidence in one’s own ability to perform a specific behavior or task, i.e., to influence 
or control a given behavioral outcome. Self-efficacy beliefs influence one’s choices, effort 
expenditure, perseverance/resilience, thoughts, and emotional reactions (Bandura, 1997).  
Additionally, behavior change and maintenance are functions of the individual’s expectations 
about his/her ability to perform a behavior (efficacy expectations), as well as of the expectations 
that the behavior will in fact lead to the desired outcome (outcome expectations) (Bandura, 
1997). Efficacy expectations mediate the process between the person and the enactment of the 
behavior, and outcome expectations do the same for the process between behavior enactment and 
the outcome. Importantly, in contrast to more global constructs such as self-esteem, self-efficacy 
is behavior-specific and context-specific (Bandura, 1997); one may possess considerable self-
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efficacy for behavior A, but not for behavior B, or one may possess high self-efficacy for 
behavior A in context Y but not in context Z. 
Self-efficacy can be acquired through mastery experiences, vicarious experience, social 
persuasion, and somatic/emotional states (Bandura, 1997).  Mastery experiences are the most 
effective source of creating a sense of self-efficacy; an individual’s prior successes with a specific 
behavior lead to a belief in one’s capability to execute it in the future.  Vicarious experience, 
observing the social modeling of others, raises one’s beliefs in his/her own abilities, so long as the 
“others” possess perceived similarity to the individual.  Social persuasion, or conveying positive 
appraisal, can also help people increase their self-efficacy, though its effects are the weakest of the 
four sources.  Finally, one’s perceptions of physiologic and emotional cues can enhance or hinder 
self-efficacy as one transcends or succumbs to various physical and emotional responses to the 
activity (Bandura, 1997) .   
With its attention to sociostructural and personal determinants of behavior and its focus 
on self-regulation, SCT fully considers the multiple spheres of influence on medication-taking, 
speaks to the self-regulatory and adaptive management skills needed by individuals with chronic 
disease, and fits well with the undulating nature and persistent demands of chronic illness itself. 
In Specific Aim #2, SCT guided the current study’s broad inclusion of confounders and 
covariates in the multiple linear regression models designed to predict adherence. These 
confounders and covariates represent the three previously mentioned interactive realms of person 
factors (affective, cognitive, biological), environmental (social, physical) factors, and behavior. 
This modeling of adherence also recognizes the numerous intersecting influences on medication-
taking.  In Specific Aim #3, the current study evaluated the effectiveness of the PS interventions 
which were rooted in SCT and which aimed to improve ART adherence through self-efficacy 
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enhancement and skill-building in habit development, self-monitoring, and problem-solving. The 
current study also sought to determine if the intervention effectiveness varied (i.e., was 
moderated) by person factors such as alcohol use. Finally, in Secondary Aim #1, the potential 
mediational role of self-efficacy on the process(es) between the person/environment and the 
behavior was evaluated, as was the potential for moderation of these relationships by alcohol use. 
2.2 ALCOHOL USE AMONG PERSONS WITH HIV/AIDS 
Estimates of the prevalence and degree of alcohol use among persons with HIV/AIDS (PWHIV) 
vary depending on the sample and assessment strategy used.  However, in general, 
approximately 40-55% of persons with HIV/AIDS endorse alcohol use of some kind, with 10-
20% of those individuals consuming alcohol at hazardous or risky levels (Arnsten et al., 2002; 
Braithwaite et al., 2005; Chander, Lau et al., 2006; Conigliaro et al., 2006; Cook et al., 2001; 
Galvan et al., 2002; Halkitis, Parsons, Wolitski, & Remien, 2003; Lucas et al., 2002; Samet, 
Horton, et al., 2004; Tucker et al., 2003; Waldrop-Valverde et al., 2006) (for additional 
references, see Appendix A).  In a large study based on data from the HIV Cost and Services 
Utilization Study (HCSUS), Galvan et al. (2002) noted that 53% of the participants acknowledged 
drinking in the past month; of those who drank, 15% were heavy drinkers (>5 drinks on >4 
days/week in the previous 4 weeks).  Among studies using the National Institute on Alcohol Abuse 
and Alcoholism (NIAAA) categorization of alcohol use, i.e., where “hazardous use” is defined as >7 
drinks/week or >3 drinks per occasion for women and as >14 drinks/week or >4 drinks per occasion 
for men, and where “moderate use” is defined as any alcohol use at less than these levels (National 
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Institute on Alcohol Abuse and Alcoholism, 2005), rates of moderate use range from 24-35%, and 
rates of hazardous use range from 11-16%  (Chander, Lau et al., 2006; Samet, Horton, et al., 2004).  
In one study of over 800 HIV-infected veterans, 20% were classified as hazardous drinkers (i.e., a 
score of >8 on the Alcohol Use Disorders Identification Test) and 33% as binge drinkers. 
Additionally, 27% had at least one International Statistical Classification of Diseases (ICD-9) 
alcohol-related diagnosis in the previous 5 years (Conigliaro et al., 2003).  Cook et al. (2001) 
classified 19% of its HIV-infected outpatient sample as “problem drinkers” (i.e., >1 of the following 
consumption profiles—binge, heavy, or hazardous drinking) and 33% as mild-moderate drinkers.  
Determining the rate and impact of alcohol consumption among PWHIV is complicated 
by several factors.  Given the general tendency to under-report alcohol use, and the fact that 
some large-scale studies did not specify for participants the amount of alcohol constituting “a 
drink” (Galvan et al., 2002), general alcohol consumption by PWHIV may, in fact, be higher. Of 
note, other studies of HIV-infected persons have reported rates of alcohol use as high as 67-80% 
(Chesney et al., 2000; Justice et al., 2006; Lefevre et al., 1995), with rates of “alcoholism” (as 
defined by Michigan Alcoholism Screening Test scores >5) exceeding 40% (Lefevre et al., 
1995). Finally, concomitant drug use/abuse is common among HIV-infected persons who consume 
alcohol (Chander, Himelhoch et al., 2006; Galvan, Burnam, & Bing, 2003).  The realities of 
polysubstance use make determining the independent effects of alcohol on ART adherence 
challenging; however, disentangling these effects remains important given the wide spectrum of 
alcohol use and its ubiquitousness within Western culture. 
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2.3 GENERAL ASSOCIATIONS BETWEEN ALCOHOL USE AND ART 
ADHERENCE 
From investigations focused on alcohol users to broad studies of predictors/correlates of ART 
adherence, alcohol use is generally, though not entirely consistently, associated with poorer ART 
adherence (see Appendix A for overview).  In the earliest of studies specifically examining 
alcohol use and ART adherence, both hazardous and heavy alcohol use were significantly 
associated with taking ART medications off-schedule in the previous week, and problem 
drinkers (binge, heavy, hazardous) were significantly more likely than non-problem drinkers to 
report drinking and/or using drugs as a reason for missing ART doses in the previous 24 hours 
(Cook et al., 2001). Likewise, in a cohort of persons with lifetime alcohol problems, alcohol 
consumption emerged as the most significant predictor (p < .0001) of 3-day self-reported dose 
adherence. At-risk and moderate drinkers were significantly less likely than non-drinkers to 
report 100% dose adherence for the previous 3-day period (Samet, Horton, et al., 2004). An 
additional investigation using the same cohort similarly reported that the use of alcohol and/or 
drugs in the previous 30 days was negatively associated with > 95% adherence (Palepu, Horton, 
Tibbetts, Meli, & Samet, 2004).  In a study of men who have sex with men, those who drank 
several times per week had significantly more missed medication days than infrequent drinkers 
and non-drinkers (Halkitis et al., 2003).  
Like their quantitative counterparts, qualitative investigations of adherence generally 
support the notion that alcohol interferes with ART self-administration. Persons with HIV/AIDS 
have reported that immediate substance cravings often take precedence over ART medication-
taking (Laws, Wilson, Bowser, & Kerr, 2000; Malcolm, Ng, Rosen, & Stone, 2003; Remien et 
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al., 2003); that they often avoid taking ART because of concerns that the medication will be 
rendered ineffective by alcohol or drugs (Malcolm et al., 2003; Pach, Cerbone, & Gerstein, 2003; 
Sankar, Wunderlich, Neufeld, & Luborsky, 2007), and that “drinking and drugging” is a 
significant barrier to taking ART (Powell-Cope, White, Henkelman, & Turner, 2003). 
On the other hand, other investigators have found no relationship between ART 
adherence and a variety of alcohol use patterns.  For example, in two studies of individuals 
enrolled in methadone maintenance, frequent or binge alcohol use was not associated with 
median ART adherence rates (Arnsten et al., 2002; Berg et al., 2004). In one study, baseline 
alcohol consumption of >1 unit/day of alcohol was not significantly associated with adherence 
(Spire et al., 2002), while in another, neither was consuming >14 drinks/week (Kleeberger et al., 
2001). Studies using electronic event monitors, multiple measures of adherence, and 
comprehensive assessments of substance use (e.g., the Substance Use module of the SCID for 
DSM-IV) have also reported no significant relationship between alcohol use and ART adherence 
(Halkitis, Kutnick, & Slater, 2005; Hinkin et al., 2004; Paterson et al., 2000; Waldrop-Valverde 
et al., 2006). Again, these somewhat contradictory results are likely due to the substantial 
differences in how adherence and alcohol use are defined and measured across studies. However, 
among nonintervention studies demonstrating a significant relationship between alcohol use and 
ART adherence, several themes emerge related to dose and time. 
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2.4 DOSE-RESPONSE AND TEMPORAL ASSOCIATIONS 
First, a general dose-response relationship appears to exist, where increasing levels of alcohol 
consumption are associated with increasing odds of nonadherence. For example, Tucker and 
colleagues reported that the percentage of  adherent persons consistently decreased as alcohol 
consumption level increased, i.e., 52% of nondrinkers were adherent, compared to 43% of 
nonheavy drinkers, 39% of heavy drinkers, and  31% of frequent heavy drinkers.  Additionally, 
in multivariate analysis, all three levels of alcohol consumption significantly increased the odds 
of nonadherence (Tucker et al., 2003).  Similarly, among veterans with fluctuating alcohol 
consumption patterns (i.e., combination binge/nonbinge), missed medication doses were more 
likely to occur on binge days, followed by nonbinge days, and non-drinking days. Additionally, 
in multivariate analysis (controlling for drug use, age, education, and depression), compared to 
HIV+ non-drinkers, HIV+ nonbinge and binge drinkers had significantly greater odds of 
nonadherence  (Braithwaite et al., 2005). Even more recently, Chander, Lau, and Moore (2006) 
reported that both hazardous and moderate alcohol use were associated with decreased odds of 
self-reported 2-week ART adherence compared to no use. Finally, further dimensionalizing 
alcohol use, Parsons, Rosof, & Mustanski (2007) reported that in a sample of persons with 
alcohol problems (score >8 on the Alcohol Use Disorders Identification Test [AUDIT]) the 
number of drinks consumed significantly predicted adherence, but negative consequences of 
alcohol use or one’s total AUDIT score did not.  
Second, a temporal relationship between alcohol use and medication adherence has also 
been reported, further suggesting a degree of causality between alcohol use and ART 
nonadherence. Among HIV-infected veterans, alcohol consumption on a given day was 
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significantly associated with decreased medication (ART and non-HIV) adherence on that day as 
well as the two days immediately thereafter. This pattern was consistent for nonbinge drinkers 
and binge drinkers, and remained significant even after removing individuals who endorsed 
concomitant illicit drug use from the analysis (Braithwaite et al., 2005).   
2.5 RATES OF ADHERENCE/NONADHERENCE AMONG PWHIV WHO USE 
ALCOHOL 
Despite the apparent effects of alcohol on medication-taking, rates of ART adherence among 
PWHIV who use alcohol appear to mirror estimates of ART adherence among PWHIV in 
general.  In studies specifically examining the relationship between alcohol use and ART 
adherence, and among those intentionally using samples of HIV-infected persons with alcohol 
problems, overall or baseline rates of ART nonadherence range from approximately 15-55% 
(Braithwaite et al., 2005; Cook et al., 2001; Parsons, Rosof et al., 2007; Samet, Horton, et al., 
2004). In one study which classified individuals as hazardous, heavy, or binge drinkers based on 
the AUDIT and two quantity/frequency questions, 30% of participants reported not taking their 
ART medication(s) as scheduled in the previous week, and 14% acknowledged an ART dose in 
the previous 24 hours (Cook et al., 2001). In a sample from the Veterans Aging Cohort Study 
(VACS) where the Time Line Follow Back (TLFB) method was used to assess drinking over the 
previous 30 days, 44% of participants acknowledged missing or taking late (>2 hours) doses 
(Braithwaite et al., 2005). Rates of nonadherence also vary considerably  
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(~30-60%) in studies which examined the impact of alcohol use on adherence within more 
heterogenous samples (Haubrich et al., 1999; Spire et al., 2002; Waldrop-Valverde et al., 2006).   
In general, however, rates of ART adherence among PWHIV who use alcohol are 
somewhat difficult to ascertain due to 1) wide variation in definitions and operationalization of 
both adherence and alcohol use, 2) the common practices of assessing alcohol and drug use 
simultaneously, treating alcohol and drug users as a single population (e.g., “substance users”), 
or combining alcohol and drug use into a single variable (e.g., “alcohol or drug dependence”), 
and 3) the simple underreporting of such numbers. Furthermore, these rates of 
adherence/nonadherence are not always delineated by factors such as alcohol consumption level, 
or by demographic factors such as race/ethnicity and gender.  
2.6 GENDER DIFFERENCES 
An understanding of alcohol’s impact on adherence among women is particularly limited, and 
may in fact be underestimated. Women consistently constitute less than 50% of the sample in 
existing studies, and some studies have used instrument cut-off scores or alcohol use 
classifications which fail to accurately capture or categorize female drinkers.  For example, 
several studies used a general cutoff score of 8 for the AUDIT (Lucas et al., 2002; Parsons, 
Golub et al., 2007; Parsons, Rosof et al., 2007), which reduces sensitivity for detecting 
problematic drinking in women; subsequently, these studies may have only captured the most 
severe female drinkers. While the low percentage of women enrolled in ART adherence studies 
may in part simply reflect the epidemiology of HIV/AIDS, their under representation limits the 
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generalizability of findings with respect to alcohol use and adherence; several studies suggest 
that gender differences are present (Berg et al., 2004; Howard et al., 2002; Lazo et al., 2007).   
 In a multicenter study of HIV+ women where 85% of the sample belonged to 
racial/ethnic minority groups, and almost one-fourth were enrolled in methadone maintenance, 
significantly poorer adherence (via EEM) was found among women with alcohol use greater 
than or equal to once/week (mean adherence rate 46% vs. 56%).  Alcohol use once/week or more 
remained significantly associated with adherence in multivariate analysis (Howard et al., 2002). 
Although the operationalization of alcohol use employed in the study by Howard and colleagues 
is atypical and potentially reflects a wide variety of frequency and consumption patterns, their 
results raise questions about the harmful impact of even small or relatively infrequent degrees of 
alcohol use, particularly for women, women of color, and/or women with polysubstance use 
problems. Using a similar sample and EEM, another study exploring gender differences in ART 
adherence found no significant differences in adherence between those with and without 
“problem alcohol use” (>5 drinks/occasion or drinking “several days per week” or “every day”); 
however, a significant interaction between gender and alcohol use was detected where women 
with “problem alcohol use” were significantly less adherent than men meeting this criterion 
(Berg et al., 2004).  Finally, in a large-scale analysis of data from the Multicenter AIDS Cohort 
Study (MACS) and the Women’s Interagency HIV Study (WIHS), Lazo and colleagues (2007) 
recently reported that binge drinking, moderate to heavy alcohol consumption, and low alcohol 
consumption were all independent predictors of decreasing ART adherence, but only among 
women.  Similarly, binge drinking and low alcohol consumption emerged as independent inverse 
predictors of increasing adherence in women only; however, the use of two or more illicit drugs 
was an inverse predictor of increasing adherence for both genders (Lazo et al., 2007). 
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Collectively, these studies generate new questions about the web of intersections between 
sociodemographic characteristics, alcohol, adherence, and other psychosocial and environmental 
factors. 
2.7 MECHANISMS AND MEDIATORS  
Although the previously described dose-response and temporal effects of alcohol on ART 
adherence lend support to the notion of some degree of causality between alcohol use and 
nonadherence, the underlying mechanisms for this relationship remain unclear. Additional gaps 
exist with respect to the larger constellation of interrelated variables affecting alcohol and 
adherence. These gaps include various person-level and environmental factors suggested to be 
important by Social Cognitive Theory, namely, self-efficacy, depressive symptoms, social 
support, and personality characteristics. 
2.7.1 Self-efficacy 
Self-efficacy is an integral component of major theoretical frameworks addressing health 
behavior change, including SCT and the Health Belief Model. Self-efficacy for taking ART is a 
consistent predictor of ART adherence (Ammassari et al., 2002).  In one study of correlates to 
HAART adherence, each reduction in standard deviation unit of self-efficacy was associated 
with more than twice greater odds of ART nonadherence (Catz, Kelly, Bogart, Benotsch, 
McAuliffe, 2000). In another study of men who have sex with men, low self-efficacy and high 
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avoidance coping were both related to poorer adherence, and individuals with >95% adherence 
had significantly higher self-efficacy levels than those with adherence ranging from 80-90% and 
<80% (Halkitis et al., 2005). Additionally, a mediational role for self-efficacy in ART adherence 
has been demonstrated whereby self-efficacy mediates the role of other factors such as social 
support, depressive symptoms, and patient-provider relationships (Cha, Erlen, Kim, Sereika, & 
Caruthers, 2007; Johnson et al., 2006; Luszczynska, Sarkar, & Knoll, 2007; Simoni, Frick, & 
Huang, 2006). In contrast, one study of ART adherence predictors among individuals with 
alcohol problems reported that adherence mediated the relationship between self-efficacy and 
HIV viral load (Parsons, Rosof, & Mustanski, 2008). However, the precise nature of self-
efficacy’s relationship to other psychosocial variables and outcomes in PWHIV remains unclear, 
particularly for PWHIV who consume alcohol. Alcohol and other substance use may reduce self-
efficacy for self-care behaviors such as ART adherence. 
2.7.2 Depressive symptoms 
Depression has also been associated with ART adherence, though less consistently (Ammassari, 
et al., 2002; Berger-Greenstein et al., 2007; Chander, Himelhoch et al., 2006). In a large study 
based on HCSUS data, individuals with depression had greater odds of nonadherence (Tucker et 
al., 2003), but in other studies, significant relationships between depression and adherence were 
not sustained in multivariate analysis (Catz et al., 2000). Antidepressant treatment appears to 
improve ART adherence; however, these findings are not conclusive (Chander, Himelhoch et al., 
2006). The intersection of alcohol, depression, and ART adherence has also been a recent focus 
of investigation.  In one study of adherence among PWHIV with alcohol problems, no significant 
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differences in depressive symptoms were detected across drinking groups (abstinent, moderate, 
at-risk), though depressive symptom scores did emerge as a significant factor associated with 
decreased odds of having 100% adherence in the previous three days (Samet, Horton, et al., 
2004). The nature of these relationships remains imprecisely defined, particularly in light of the 
established interrelationships between self-efficacy and depression, and depression and 
problematic alcohol use. 
2.7.3 Social support 
Social support is consistently associated with ART adherence (Ammassari et al., 2002; Catz et 
al., 2000; Murphy, Marelich, Hoffman, & Steers, 2004; Vyavaharkar et al., 2007), and its 
presence in mediational models has been noted above. Importantly, numerous path analyses and 
other modeling studies have revealed the parallel and inverse relationships between social 
support and negative affect/depressive symptoms, and their subsequent impact on coping, self-
efficacy, and in turn, on ART adherence (Simoni et al., 2006; Vyavaharkar et al., 2007; Weaver 
et al., 2005).  These complex interrelationships have not been specifically examined in the 
context of alcohol use among PWHIV. Nonetheless, understanding the linkages between these 
variables is essential for guiding the development of adherence interventions for individuals who 
use alcohol, a subgroup of PWHIV which has only recently begun to receive special attention.   
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2.7.4 Personality characteristics 
Individual differences in personality may contribute to differences in medication adherence 
because of their impact on processes such as motivation, coping, problem-solving, and self-
regulation. The Five Factor model of personality provides a popular conceptualization of 
personality structure where five overarching factors (Openness, Conscientiousness, Extraversion, 
Agreeableness, and Neuroticism) represent the broadest dimensions of personality and 
summarize more specific characteristics/traits. For example, the dimension of conscientiousness 
represents personality traits such as competence, efficiency, organization, self-discipline, and 
deliberation (Costa & McCrae, 1992) Although the five factors can be considered “basic 
tendencies” which drive the development of “characteristic adaptations,” responses, or attitudes 
in the individual, five factor models are best considered “grand theories” of human functioning 
(Costa & McCrae, 1999).   
Relationships between five-factor personality traits and medication adherence in chronic 
illness have previously been reported. High conscientiousness has been associated with 
adherence to cholesterol-lowering medications (Stilley, Sereika, Muldoon, Ryan, & Dunbar-
Jacob, 2004), and among renal patients, with adherence to phosphate binders (Christensen & 
Smith, 1995). Low levels of another trait, Agreeableness, have been associated with poor 
adherence to medication regimens for inflammatory bowel disease (Ediger et al., 2007). 
Examination of personality and medication adherence among PWHIV, however, is 
relatively new (Cruess, Minor, Antoni, & Millon, 2007; Johnson & Neilands, 2007; Penedo et 
al., 2003).  Johnson & Neilands (2007) reported that greater Neuroticism scores on the NEO-FFI 
were associated with greater frequency and severity of ART side effects. They suggest that this 
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finding is important with respect to adherence insofar as side effects play a major role in altered 
patterns of medication-taking (Johnson & Neilands, 2007).  In a study exploring variables 
associated with quality of life in HIV/AIDS, Penedo et al (2003) found no direct relationship 
between personality traits and ART adherence.  The authors however, specifically acknowledge 
that the lack of expected findings in this realm may have been attributable to sampling and 
measurement decisions, i.e., the exclusion of persons with alcohol/drug use, the use of a self-
report measure for adherence (as opposed to EEM), and the limited window of adherence 
examined (previous four days) (Penedo et al., 2003).  
Another study of PWHIV investigating personality and ART adherence used a measure 
which included an assessment of coping styles, described as “similar to personality 
characteristics. . .the  pervasive ways in which patients habitually approach and deal with their 
life experiences” (Cruess et al., 2007, p. 281). These authors reported a variety of coping styles 
to be significantly associated with overall ART adherence and/or specific medication-taking 
behaviors. For example, the Dejected coping style (persistently disheartened, easily disposed to 
give up) was significantly associated with < 95% adherence, taking more medications than 
prescribed, and skipping medications. Similarly, the Oppositional (unpredictable, difficult) and 
Nonconforming (unconventional arbitrary, impulsive) styles were also significantly associated 
with skipping medications. Of note, individuals with alcohol and drug use disorders were 
excluded from the sample (determined by the Structured Clinical Interview for DSM Disorders 
[SCID]), the mean number of alcoholic drinks consumed in the previous 3 months was 13.92 
(SD =  36.19), and multiple analyses controlled for alcohol and/or drug use (Cruess et al., 2007).  
In one of its exploratory aims, the secondary data analysis (SDA) pursued this relatively 
new avenue of inquiry (i.e., personality characteristics and ART adherence), and addressed some 
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of the limitations in the earlier studies by including individuals who use alcohol and drugs, and 
by using EEM for longitudinal adherence assessment. 
2.8 ART ADHERENCE INTERVENTIONS FOR ALCOHOL USERS 
Two randomized controlled trials (RCTs) have specifically aimed to improve ART adherence, 
reduce alcohol consumption, and improve clinical outcomes in PWHIV who have alcohol 
problems.  Important differences, however, exist not only in terms of study results, but with 
respect to theoretical underpinnings; study design (i.e., selection of comparison group); 
intervention design, duration, and intensity; and alcohol and adherence dimensionalization and 
assessment (see Appendix B). 
Using a sample of “hazardous drinkers,” Parsons, Golub, et al. (2007) compared a 
theoretically-driven ART adherence intervention with an ART/alcohol education condition. The 
adherence intervention consisted of motivational interviewing for alcohol reduction, as well as 
tailored self-assessment, monitoring, and skills-building, while the education condition used a 
didactic approach (discussion, videotapes) on ART, alcohol, and adherence. Significant 
improvements in dose and day adherence in both groups from baseline to three months were 
reported, with the intervention group reporting significantly greater improvements in both 
compared to the education group.  Adherence improvements were not sustained at the three 
month time point, but alcohol consumption significantly decreased in both groups at three 
months and six months (Parsons, Golub et al., 2007). 
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This study possessed several characteristics previously noted to be associated with 
intervention efficacy, namely the study’s low baseline percentage of adherent individuals and 
intervention design. One meta-analysis of ART adherence interventions reported that 
intervention studies targeting persons with low adherence at baseline showed larger effect sizes 
than those that did not enroll in this manner (Amico, Harman, & Johnson, 2006).  While the 
study by Parsons et al. did not target low adherers during enrollment, baseline adherence was 
38% for the sample.  Another meta analysis reported that interventions incorporating “interactive 
discussion of cognitions, motivations, and expectations regarding adherence” also showed 
greater effect sizes than those that did not (Simoni, Pearson, Pantalone, Marks, & Crepaz, 2006, 
p. S31). Due to its complexity, however, this intervention may be challenging to replicate in the 
clinical setting; adjusting the intervention may be necessary.   
Samet et al (2005) compared the effect of an adherence-enhancing intervention with 
usual care in a sample of persons with current or lifetime alcohol abuse/dependence and found 
no significant differences in ART adherence, alcohol consumption, CD4 count, or viral load. The 
four-session study intervention was clinically feasible in terms of duration and intensity, and 
combined information needs (ART) and readiness to change (substance use), with practical, life-
relevant dimensions, elements previously noted to be important and effective components of 
ART adherence interventions (Rueda et al., 2007). Nevertheless, the lack of significant findings 
is potentially attributable to a lack of statistical power, incomplete intervention administration for 
~25% of the sample, and a large percentage of adherent individuals at baseline (Samet et al., 
2005). Furthermore, broad inclusion criteria (“current or lifetime alcohol abuse or dependence”) 
may have also influenced the results.  Information about severity of drinking, current alcohol 
consumption patterns, and the distribution of alcohol use categories was not reported, and limited 
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information about the theoretical underpinnings and specific content of the intervention leave 
questions about the role of intervention design in the study’s lack of significant findings.  Given 
these various limitations, the authors’ conclusions about the potential need for directly observed 
therapy (DOT) in this population are potentially premature. 
The use of a “directly observed” or “directly administered” intervention for improving 
ART adherence among alcohol and drug users has been examined elsewhere as well, though 
primarily among injection drug users or individuals on methadone maintenance (Altice, Maru, 
Bruce, Springer, & Friedland, 2007; Chander, Himelhoch et al., 2006; Conway et al., 2004; 
Lucas et al., 2007).  Macalino et al. (2007) conducted a randomized controlled trial of 
antiretroviral DOT for substance users where 17% of the sample misused alcohol exclusively, 
and reported that individuals on DOT were more likely to achieve viral suppression than 
individuals receiving standard care (Macalino et al., 2007).  In another DOT study where 36% of 
the injection drug-using sample consisted of problematic drinkers, adherence was significantly 
higher for supervised versus unsupervised doses (Altice et al., 2004). These studies suggest that 
DOT may be an effective adherence promotion strategy in certain conditions and circumstances; 
however, when samples are comprised of active drug and alcohol users, differentiating the 
effects of DOT for each subgroup is somewhat compromised. Additional research is needed to 
uncover the conditions, circumstances, and patient populations best suited for this type of 
adherence intervention. 
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2.9 ALCOHOL SCREENING IN PERSONS WITH HIV/AIDS 
In order to select the most appropriate, patient-centered care and individualized adherence 
enhancement interventions for PWHIV, HIV/AIDS care providers need accurate and efficient 
assessment of alcohol risk behavior (Conigliaro et al., 2003; Cook et al., 2001; Petry 1999; 
Samet, Phillips, Horton, Traphagen, & Freedberg, 2004). One alcohol screening instrument with 
the advantages of brevity and sensitivity is the Alcohol Use Disorders Identification Test—
Consumption (AUDIT-C) (Bush, Kivlahan, McDonell, Fihn, & Bradley, 1998). The AUDIT-C is 
an alcohol screening tool based on the first three (consumption-related) items from the full 10-
item Alcohol Use Disorders Identification Test (AUDIT), a screening questionnaire developed 
by the World Health Organization and validated internationally for the detection of “hazardous 
and harmful drinking patterns” (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001). The 
sensitivity and specificity of the AUDIT-C for the detection of hazardous drinking and active 
alcohol abuse/dependence parallels or exceeds that of comparable instruments used in clinical 
and research settings (e.g., standard quantity/frequency questions, CAGE, full AUDIT) (Bradley, 
et al., 2003; Bradley et al., 2007; Bush et al., 1998; Frank, et al., 2008; Gordon, et al., 2001).  
Additionally, the third question on the AUDIT-C which addresses episodic heavy/binge drinking 
(AUDIT-3) generally demonstrates slightly lower, but highly adequate sensitivities when used 
alone as a single alcohol screening question (Bradley, et al., 2003; Bradley et al., 2007; Gordon, 
et al., 2001).  Because of its psychometric properties and the ease of its administration and 
scoring, the AUDIT-C is one of the alcohol screening tools recommended by the NIAAA; a 
single screening question similar to the AUDIT-3 is also recommended (NIAAA, 2005). 
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Interestingly, scores on the AUDIT-C and the AUDIT-3 have also been directly 
associated with the incidence of other health-related outcomes such as risk of hospitalizations for 
gastrointestinal conditions such as liver disease, upper GI bleeds, and pancreatitis (Au, Kivlahan, 
Bryson, Blough, & Bradley, 2007) and general 5-year mortality rates (Bradley, Maynard, 
Kivlahan, McDonell, & Fihn, 2001). Given these findings, a reasonable question is whether the 
AUDIT-C and AUDIT-3 might also predict health behaviors such as ART adherence. While 
various versions of the AUDIT have been used by adherence researchers for assessing alcohol 
use, no published study has heretofore considered the potential for this type of dual purpose.   
 In order to proceed with such multi-function use of the AUDIT-C, additional 
psychometric evaluation of the instrument is also needed. While the full AUDIT (from which the 
AUDIT-C is derived) was validated on primary care patients in six different countries and 
appears to perform relatively well across gender and race/ethnicity (Babor, et al., 2001; Reinert 
& Allen, 2007), limited psychometric data is available on the AUDIT-C as a stand-alone 
instrument, particularly with the inclusion of gender/race evaluations, and no psychometric 
evaluations to date have used samples of PWHIV. Limited research has demonstrated that the 
sensitivity and specificity of the AUDIT-C also varies across gender and race, however, only the 
use of gender-specific cut-points has been explicitly recommended (Bradley et al., 2003; Bradley 
et al., 2007; Dawson, Grant, Stinson, & Zhou, 2005; Frank et al., 2008).  Nonetheless, wide 
variation in alcohol consumption patterns, alcohol-related social norms, and alcohol-related 
biopsychosocial problems both across and within racial/ethnic groups (Caetano, Clark, Tam, 
1998) and across gender (Collins & McNair, 2002; Green, Perrin, & Polen, 2004; Wilsnack & 
Wilsnack, 2002) suggests that further examination of the reliability, validity, and factor structure 
of the AUDIT-C by gender/racial subgroups is warranted.  
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2.10 SIGNIFICANCE 
This study answered the NIAAA call for elucidating and explicating the impact of alcohol on 
ART adherence by 1) exploring the baseline and post-intervention differences in ART adherence 
across alcohol screening status, i.e., AUDIT-C positive/negative, AUDIT-3 positive/negative;   
2) explicating some of the avenues through which a variety of person-level and environmental 
factors affect optimal medication-taking among PWHIV who screen positive on alcohol 
screening tests; and 3) expanding knowledge about the accuracy and validity of alcohol 
screening instruments in PWHIV and across gender and race. 
This study had numerous strengths. The use of the AUDIT-C to identify potential 
problem drinkers was clinically relevant, feasible, and recommended, thus increasing the 
translatability of the research for HIV care providers partnering with patients for optimal, 
individualized medication management.  If positive screens on the AUDIT-C are predictive of 
ART adherence, the implementation of a systematic alcohol screening program using the 
AUDIT-C could improve the detection of both risk behaviors; in particular, by reminding 
clinicians to be alert to the greater risk of suboptimal adherence in those who screen positive for 
at-risk drinking. Finally, this study’s use of EEM data provided accurate measurement and 
additional dimensionalization of medication adherence behavior. EEM is considered to be the 
near “gold standard” for adherence assessment, not only in terms of its reliability, but also in its 
ability to reveal various adherence patterns as opposed to simply identifying whether or not one 
is “adherent” (Sereika & Dunbar-Jacob, 2001).  
Additionally, while extant studies demonstrate what appears to be a dose-response 
relationship between alcohol use and ART nonadherence, the processes through which this 
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occurs have remained unclear, thus limiting adherence intervention design and testing for 
persons who drink alcohol.   Numerous questions remain about the optimal ways to address ART 
adherence in the context of alcohol use. Should ART adherence interventions simultaneously 
aim to reduce alcohol consumption across all levels of alcohol intake? If so, what is the best way 
to concurrently address adherence and drinking behavior? Results of this study have the potential 
to guide the development of personalized adherence enhancement interventions which integrate 
established adherence-improvement strategies with individual factors such as alcohol 
consumption level, mood, personality characteristics, self-efficacy, gender, and existing patterns 
of medication-taking. Results may provide further empirical evidence for the expansion of 
clinical guidelines about the general use of alcohol among PWHIV.  
Finally, widespread screening for alcohol problems in clinical practice rests on the 
reliability and validity of alcohol screening instruments across subpopulations of patients. The 
results of this study’s psychometric evaluation of the AUDIT-C speak to the appropriateness of 
its use in PWHIV, in women, and in racial/ethnic minorities. 
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3.0  RESEARCH DESIGN AND METHODS 
3.1 SECONDARY DATA ANALYSIS 
In order to address the aforementioned primary and exploratory aims, a secondary data analysis 
(SDA) was conducted using existing data from the study “Improving Adherence to Antiretroviral 
Therapy,” R01NR04749—the “parent study” (PS).  Secondary data analysis was an appropriate 
choice for this study insofar as the SDA and PS shared the same conceptual framework, an 
understanding of the variables of interest, and common co-investigators/consultants who have a 
longstanding history of professional collaboration.  Additionally, SDA reduces participant 
burden; helps address recruitment and retention challenges associated with ill and/or substance-
using populations; and reduces overall research costs (Ashery, 1992; Nicoll, 1999; Pollack, 
1999; Schroeder, 2001).   
3.2 PARENT STUDY OVERVIEW 
Based on Social Cognitive and Self-Efficacy Theories (Bandura, 1986, 1997), the PS tested a 
cognitive behavioral ART adherence intervention over time. The study also examined the impact 
of adherence on clinical outcomes and quality of life, and the impact of self-efficacy on 
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adherence.   Parent study participants were required to be > 18 years old, on combination ART 
therapy, English-speaking, free from significant cognitive impairment, and community-dwelling 
with telephone access.  Additionally, individuals were excluded from participation if they were 
living with another individual already enrolled in the study, had upper extremity or visual 
impairments which precluded self-administration of medication, or if they had hearing 
difficulties without adaptive telephone equipment for delivery of the telephone intervention. 
Participants were recruited from multiple sites (a university-based clinic, community and 
veterans’ hospitals, and comprehensive care centers) in southwestern PA and northeastern OH. 
3.2.1  Parent Study Design 
The PS  was a randomized controlled trial involving a three-arm design where participants were 
randomized to a structured adherence intervention condition, individualized adherence 
intervention condition, or usual care (control) condition using permuted blocks within strata 
(gender, race, CD4 count, viral load).  Additionally, individuals in the two intervention groups 
were further randomized to receive three “booster” sessions of the intervention after the 
maintenance phase of the intervention. 
In order to track medication-taking behaviors, participants were given an electronic event 
monitor (EEM) and a medication bottle and were instructed in the use and purpose of the EEM.  
For a one month induction period, PS participants used the EEM for a randomly selected ART 
medication (the monitored drug). Data from the last two weeks of this induction period were 
considered the baseline adherence assessment and were used to determine PS participants’ 
general adherence status.  Individuals with perfect adherence at baseline (i.e., “100% adherers”) 
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were extracted for separate analysis by the PS as they were presumed to be unable to “improve” 
their ART adherence any further through the intervention being tested. The remaining 
participants with less than 100% adherence at baseline were then randomized to the three 
aforementioned conditions, and continued to use EEMs for adherence monitoring of the 
designated drug.  
     Based on Social Cognitive Theory, the 12-week structured adherence intervention 
addressed HIV/AIDS medication regimens, medication-taking barriers, side effects, and social 
support and was comprised of skill-building in habit development, self-monitoring, problem-
solving, self-reflection, and reinforcement strategies. At the beginning of each session, the 
weekly concept was introduced by the interventionist, with a mutually agreed-upon aspect for 
application to the individual’s own medication management; this allowed for differences in 
personal situations, lifestyles, and educational backgrounds. Nine sessions involved homework 
activities.  Sessions were delivered weekly by telephone, followed a pre-determined format, and 
lasted approximately 15-30 minutes.  For consistency, the same interventionist delivered all 12 
sessions for each participant, and all sessions were delivered in the same order for all 
participants.   
The inclusion of an individualized adherence intervention was based on exit interviews 
from an earlier phase of the PS. Participant responses indicated that some individuals found the 
content in the structured intervention sessions to be repetitive or no longer relevant to their lives 
after a certain point in time (e.g., participants had already addressed side effects issues related to 
their medications or had already developed effective habit strategies for medication-taking).  
Additionally, participants desired feedback about their adherence.  Rooted in the principle of 
respect for autonomy, the individualized intervention was intended to address the 
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aforementioned issues, and was designed to be patient-specific and patient-driven. It contained 
the following elements: a needs assessment, content matching key characteristics/needs of the 
individual, a decision process for matching the intervention message to the individual’s key 
characteristics, a specific means for delivering the intervention, and personalized feedback (Ryan 
& Lauver, 2002). Participants were contacted weekly for 12 weeks, and sessions averaged 20-30 
minutes in duration. Broad discussion topics in the intervention included involvement in 
healthcare decision-making, adherence, disclosure of HIV status resources, care giving 
responsibilities, and knowledge of HIV and ART. Consistent with SCT, the discussions 
promoted skill-building in problem-solving, self-monitoring, self-reflection, reinforcement, and 
modeling. As with the structured intervention, the same interventionist delivered all 12 sessions 
for each participant.  
Across sites, the usual care condition included physical examination; laboratory tests; 
medication teaching at each visit with a physician, a registered nurse, and/or pharmacist; 
adherence instruction; attention to drugs/dosing, and side effects; mental health and social 
services,  general HIV education, and follow-up/referrals. The availability of these components 
of usual care was generally consistent across sites, with the exception of social services (5 out of 
7 sites) and medication teaching by a pharmacist (available at 2 out of 7 sites). Of note, certain 
sites also had special programs (e.g., for women, or for family members). 
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3.3 SDA SAMPLING 
For the SDA, no sampling exclusions were made based on race, gender, ethnicity, or sexual 
orientation, however, only randomized participants were included i.e., individuals deemed 
“100% adherers” were omitted from the current analysis (n=8), as were individuals who were 
removed from medications by their physicians during the induction phase (n=2) and individuals 
who did not return the EEM cap at the end of the induction phase (n=2). Because missing or 
inconsistent responses on AUDIT items 1-3 at baseline would impede categorization of 
individuals as AUDIT-C positive/negative and/or AUDIT-3 positive/negative by requiring 
incompletely justified interpretations about their response intentions, PS participants with 
completely missing (n=6) or inconsistent (n=18) AUDIT data on these items at baseline were 
removed from the sample prior to analysis. Inconsistent responses included, for example, a 
response of “never” to AUDIT question 1 (“How often do you have a drink containing 
alcohol?”) and the simultaneous selection of a quantity greater than zero in response to AUDIT 
question 2 (“How many drinks containing alcohol do you have on a typical day when you are 
drinking?”). A description of individuals with missing and inconsistent data appears in a later 
section.  
 The final sample size for the baseline time point was 310 individuals.   This dataset was 
used for description of the baseline sample (Specific Aim #1), for regression analyses involving 
the prediction of baseline adherence (Specific Aim #2), and for internal consistency estimation 
and confirmatory factor analysis (Secondary Aim #2). This sample was also used for path 
analysis (Secondary Aim #1), however, six univariate outliers were removed. 
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 The sample for repeated measures analysis (Specific Aim #3) was reduced to 287 due to 
the additional extraction of individuals with missing (n=3) or inconsistent (n=30) AUDIT-C data 
at Time 2.  The sample for examining the test-retest reliability of the AUDIT-C (Secondary Aim 
#2) was reduced (n=88) due to the exclusive use of control subjects with complete AUDIT-C 
data at baseline and Time 2 data. Discussion of the impact of reduced sample sizes and 
generalizability of the findings follows in later sections. 
3.4  VARIABLES AND MEASURES 
The variables and measures for the secondary data analysis are limited to those used in the PS. 
ART adherence was measured with electronic event monitoring (EEM). Sociodemographic data 
were extracted from a comprehensive standard instrument developed by the Center for Research 
in Chronic Disorders at the researcher’s home institution. Disease profile parameters (CD4 
count, detectable/undetectable HIV RNA) and ART regimen characteristics were obtained from 
the PS-designed Medical Record Review. The Alcohol Use Disorders Identification Test—
Consumption (AUDIT-C) was used to categorize alcohol use. All AUDIT-C data was extracted 
from the first three questions of the full 10-item Alcohol Use Disorders Identification Test 
(AUDIT) used by the PS to assess alcohol use.  Drug use was assessed through drug-related 
questions to the AUDIT by the PS, specifically regarding the use (yes/no) and frequency of use 
(# days per week) of tobacco and various illicit substances:  cocaine/crack, heroin, opioids, 
marijuana, stimulants, inhalants, and other “club drugs.” 
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 Self-efficacy was measured with the HIV Self-Efficacy Scale (SES). Depressive 
symptoms were assessed with the Beck Depression Inventory II (BDI-II).  Social support was 
evaluated using the total score from the Interpersonal Support Evaluation List (ISEL), and 
personality characteristics were measured with each of the five scales comprising the NEO Five-
Factor Inventory (NEO-FFI). A description of each variable and its respective instrument 
follows; please contact the PS principal investigator, Dr. Judith Erlen, for specific information 
about the measures. 
3.4.1 Primary outcome variable 
The primary outcome variable of interest was adherence. Adherence is the degree to which a 
patient follows or conforms to the prescribed therapeutic regimen (Sackett & Haynes, 1976); in 
this case, medication adherence focused on an antiretroviral (ART) regimen.  Specifically, five 
types of medication adherence served as the primary set of ART adherence variables: dose 
adherence, day adherence, days under-dosing, days over-dosing, and days with null dosing. 
These variations on adherence were added in order to capture phenomena such as weekend “drug 
holidays,” and over-administration of medications, especially as toxicity issues may be 
particularly salient for individuals with impaired hepatic function due to alcohol use and/or 
hepatitis B/C co-infection. Table 1 describes the five adherence variables and their mode of 
calculation in the PS.  
In each case, adherence was treated as a continuous variable and was measured by EEM 
(MEMS 6 TrackCap, AARDEX, Ltd.) for the randomly selected “monitored drug.”  EEM uses a 
special medication container cap which electronically records and stores each time the cap on the 
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medication bottle is opened. Data from the “chip” inside the cap is downloaded to a computer 
program for analysis by the researcher. In the PS, raw data from the EEM caps were 
downloaded, visually reviewed, and arranged for analysis by the PS staff. Pocket dosing data 
from participants’ medication diaries were inserted, where applicable. The PS statistician then 
created and applied analytic algorithms for the specific types/categories of adherence, and 
performed adherence analysis.  
 
Table 1: Definition and calculation of adherence variables-A 
Adherence  
 
variable 
                 Definition              Calculation 
Dose  
adherence 
 
% of medication administrations  Doses taken/doses prescribed 
Day adherence % of days with correct # of pills 
taken 
Days correct/total number of days 
prescribed 
Days under-
dosing  
 
% of days with less than prescribed 
number of administrations taken 
Days taking less than prescribed/total 
number of days prescribed 
Days over-
dosing 
 
% of days with more than prescribed 
number of administrations taken 
Days taking more than prescribed/total 
number of days prescribed 
Days with null 
dosing  
% of days with no medication 
administrations at all 
Days taking no doses during a 24 hour 
period/total number of days prescribed 
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3.4.2 Primary independent variable 
3.4.2.1 Alcohol screening status 
The primary independent variable, alcohol screening status, had two separate dimensions based 
on participant responses to the Alcohol Use Disorders Identification Test—Consumption 
(AUDIT-C) (Bush, et al., 1998). The first dimension of alcohol screening status involved 
categorization as AUDIT-C positive or AUDIT-C negative for at-risk drinking. This 
classification is consistent with the NIAAA approach used in alcohol screening algorithms for 
clinicians, where individuals are considered “at-risk drinkers” if they have a positive alcohol 
screen on a self-report tool such as the AUDIT or AUDIT-C, or if they endorsed having one or 
more heavy drinking days (>5 drinks/day for men, >4 drinks/day for women) (NIAAA, 2005, p. 
5). It is important to recognize that this categorization of at-risk drinking includes individuals 
with alcohol abuse/dependence disorders as well as individuals with hazardous drinking patterns. 
In the current study, determination of AUDIT-C positive/negative status was based on 
total AUDIT-C score. Men with total AUDIT-C scores >4, and women with total scores >3 were 
classified as “AUDIT-C positive” and those with scores below the threshold were considered 
“AUDIT-C negative” (Bradley et al., 2003; Bradley et al., 2007; Reinert & Allen, 2007).   
The second dimension of alcohol screening status, AUDIT-3 positive versus AUDIT-3 
negative for at-risk drinking, captured “binge” drinking. Participants were classified as AUDIT-3 
positive or negative based on their individual scores for this item, which ranged from 0 to 4. 
Participants with AUDIT-3 scores of zero (i.e., the “never” response) were categorized “AUDIT-
3 negative,” while participants with AUDIT-3 scores from 1 (less than monthly) to 4 (daily or 
almost daily) were considered “AUDIT-3 positive” (Bradley et al., 2007; Gordon, et al., 2001).  
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3.4.2.2 The Alcohol Use Disorders Identification Test--Consumption (AUDIT-C) 
The AUDIT-C is an abbreviated version of the Alcohol Use Disorders Identification Test 
(AUDIT), the instrument used by the PS to assess alcohol use. Initially developed by the World 
Health Organization as a screening tool for the detection of “hazardous and harmful drinking 
patterns” in primary care patients, the full AUDIT assesses the conceptual domains of alcohol 
consumption (3 questions), alcohol dependence (3 questions), and alcohol-related consequences 
or problems (4 questions) over the past year (Babor, et al., 2001).  The AUDIT-C consists of the 
first three, consumption-related items from the full 10-item AUDIT, and assess frequency of 
drinking, number of drinks per drinking occasion, and frequency of binge drinking (>6 
drinks/occasion) over the past year.  Based on 5 Likert-style response alternatives, a range of 0-4 
points is possible for each item; total scores are calculated by summing the three items and thus 
range from 0-12.  
Sensitivity and specificity ranges for the AUDIT-C depend on the diagnostic standard 
(alcohol abuse, alcohol dependence, hazardous drinking, at-risk drinking) and cut point used (>3, 
>4, >5), however, for the detection of hazardous drinking and active alcohol abuse/dependence, 
the sensitivity and specificity of the AUDIT-C parallels or exceeds that of comparable 
instruments used in clinical and research settings (e.g., standard quantity/frequency questions, 
CAGE, full AUDIT) (Bush, et al., 1998; Bradley et al., 2003; Bradley et al., 2007; Gordon, et al.,  
2001; Frank, et al., 2008). For any alcohol use disorder or risk drinking, at a cut point of >4, 
sensitivities generally range from 0.76-0.99, and specificities from 0.65-0.98. A cut point of  >5 
provides somewhat decreased sensitivity (range= 0.63-0.91), with slightly increased specificity 
(range = 0.83-0.98) (Reinert & Allen, 2007). Based on numerous sensitivity and specificity 
analyses, AUDIT-C cut-off scores of 3 for women and 4 for men have been recommended for 
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the detection of alcohol misuse (Bradley et al., 2003; Bradley et al., 2007; Reinert & Allen, 
2007).  
In the interest of clinical expediency (i.e., save time and reduce reliance on scoring 
schemes), the third question on the AUDIT-C which addresses episodic heavy/binge drinking 
(“AUDIT-3”) has generated interest as a single-item alcohol screening question; it generally 
demonstrates slightly lower, but highly adequate sensitivities when used alone (Bradley et al., 
2003; Bradley et al., 2007; Gordon, et al., 2001).   
 Other psychometric evaluations of the AUDIT-C are limited, and to date, none have 
been conducted using samples of PWHIV. In general, test-retest reliabilities of 0.98 over a 3-4 
week interval, and 0.57-0.85 over a 3-month interval have been reported (Bergman & Kallman, 
2002; Bradley et al, 1998). Additionally, internal consistencies (Cronbach’s alphas) ranging from 
0.56-0.91 have been reported (Maisto, Conigliaro, McNeil, Karemer, & Kelley, 2000; Reinert & 
Allen, 2007; Shields, Guttmannova, & Caruso, 2004;). In the current study, internal consistency 
of the AUDIT-C was excellent, with an estimate of .838 for the total sample. By subgroup, 
estimates were higher for females (.851) than for males (.831), and higher for whites (.851) than 
for nonwhites (.828). 
3.4.3 Additional independent variables—confounders and covariates  
3.4.3.1 Sociodemographic, disease-related, and drug use variables 
Sociodemographic data were extracted from a comprehensive standard instrument developed by 
the Center for Research in Chronic Disorders at the researcher’s home institution. Disease profile 
parameters (CD4 count, detectable/undetectable HIV RNA) and ART regimen characteristics 
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were obtained from the PS-designed Medical Record Review. The PS added drug-related 
questions to the AUDIT, specifically regarding the use (yes/no) and frequency of use (number of 
days per week) of tobacco and various illicit substances:  cocaine/crack, heroin, opioids, 
marijuana, stimulants, inhalants, and other “club drugs.” These questions were intended for 
descriptive purposes only and thus have not undergone psychometric evaluation; they were used 
descriptively in the current study in order to characterize polysubstance use in the sample. 
3.4.3.2 Self-efficacy for ART adherence 
Self-efficacy is defined as “beliefs in one’s capabilities to organize and execute the courses of 
action required to produce given attainments” (Bandura, 1997, p. 3) , i.e., antiretroviral 
medication adherence. The HIV Self-Efficacy Scale (SES) was used to measure self-efficacy for 
ART-taking at the ordinal level as an exploratory, and potentially mediating independent 
variable. The PS developed this 26-item tool because at the time, no comparable measure could 
be found related to the use of protease inhibitors. Participants are asked to rate their confidence 
from 1 (not at all confident) to 10 (totally confident) in their ability to take their monitored 
medication as prescribed during the week, at work, a party, etc., as well as some general 
questions regarding their perceived ability to follow the overall medication regimen.  Total 
scores and two subscale scores (Self-efficacy Beliefs and Outcome Expectancy) can be 
calculated. In each case, higher scores indicate greater self-efficacy. In the current study only 
HIV-SES total scores were used; the internal consistency (Cronbach’s alpha) for the total score 
was 0.947 for the total sample, at baseline (n=288).   
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3.4.3.3 Depressive symptoms  
Depression encompasses a wide variety of symptoms such as sadness, self-dislike, 
indecisiveness, and concentration difficulty. The 21-item Beck Depression Inventory II (BDI-II) 
(Beck, Steer, & Brown, 1996) was used to assess the degree of self-reported depressive 
symptoms, the third exploratory independent variable. Assessing depressive symptomatology 
over the previous 2 weeks, the BDI-II yields ordinal level data where each item is scored from 0-
3, with higher scores indicating greater depressive symptoms. While total score cut-points are 
properly set based on the characteristics of the sample, the general guidelines are total scores of 
0-13 minimal depression; 14-19 mild depression; 20-28 moderate depression, and 29-63 severe 
depression. While the latest version of the BDI-II was developed to correspond with the 
Diagnostic and Statistical Manual of Mental Disorders—4th Edition, this tool is not meant to 
formally diagnose depression, but to indicate the presence and severity of depressive symptoms 
(Beck, 1996).  Despite its widespread use in studies of PWHIV (Barroso & Sandelowski, 2001), 
psychometric evaluations of the BDI-II have primarily been conducted in samples of psychiatric 
outpatients and college students, the two populations on which the BDI-II was normed (Brantley, 
Dutton, & Wood, 2004).  In the current study, the internal consistency (Cronbach’s alpha) of the 
BDI-II was 0.940 for the total sample at baseline (n=299). 
3.4.3.4  Social support 
Social support is the perception of resources provided by others, and as an exploratory 
independent variable, was measured with the 40-item Interpersonal Support Evaluation List 
(ISEL) (Cohen, 1985).  The ISEL contains four subscales which assess different dimensions of 
perceived social support:  Appraisal (perceptions of having another for emotional support and to 
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discuss problems with); Belonging (the perception of having others to do things with); Self-
esteem (the perception of having a positive evaluation when comparing one’s self to others); and 
Tangible (the perception of available material aid)  (Cohen, 1985).  This instrument yields 
ordinal-level data on a 4-point Likert scale ranging from “definitely false” to “definitely true.”  
Total and subscale scores can be calculated, with higher scores indicating greater perceived 
social support.  While previous studies of PWHIV have used the ISEL (Catz, et al., 1999; 
Holmes, Bilker, Chapman, & Gross, 2007; Rogers, Hansen, Levy, Tate, & Sikkema, 2005; 
Weaver et al., 2005), limited psychometric data are available on its use in populations of HIV-
infected persons.  Cronbach’s alphas for the total scale have been reported from .74 to .94 
(Bastardo & Kimberlin, 2000; Rogers et al., 2005; Sikkema et al., 2000), and one medication 
adherence study reported a Cronbach’s alpha of .82 for the Tangible subscale (Weaver et al., 
2005).  Internal consistency (Cronbach’s alpha) for the ISEL total score and subscales scores in 
the current study were as follows: ISEL total score, .950 (n=294); Tangible, .877 (n=304); Self-
esteem, .798 (n=300); Belonging, .865 (n=302); Appraisal, .884 (n = 307).  
3.4.3.5 Personality factors 
Personality consists of emotional, interpersonal, experiential, attitudinal, and motivational styles 
which affect mind, behavior, and action. As an exploratory independent variable, personality 
factors were dimensionalized and measured using the five domains of the NEO Five-Factor 
Inventory (NEO-FFI) (Costa & McCrae, 1992). The NEO-FFI  consists of five 12-item scales 
addressing the domains of Neuroticism (negative affect, self-reproach); Extroversion (positive 
affect, sociability, activity); Openness (aesthetic interests, intellectual interests, 
unconventionality); Agreeableness (non-antagonistic orientation, prosocial orientation), and 
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Conscientiousness (orderliness, goal-striving, dependability).  Higher scores indicate a greater 
degree of the corresponding characteristic (Costa & McCrae, 1992).  Psychometric evaluations 
of the NEO-FFI using samples of PWHIV have not been previously reported, though the NEO-
FFI and its longer, parent instrument, the NEO Personality Inventory-Revised (NEO-PI) have 
been recently used in studies of HIV-positive individuals (Ironson, O’Cleirigh, Weiss, 
Schneiderman, & Costs, 2008; Johnson & Neilands, 2007; O’Cleirigh, Ironson, Weiss, & Costs, 
2007). In the current study, internal consistency estimates (Cronbach’s alpha) for the NEO-FFI 
scales at baseline were as follows: Neuroticism, 0.853 (n=307); Extroversion, 0.796 (n=304); 
Openness, 0.629 (n=303); Agreeableness, 0.656 (n=306); Conscientiousness, 0.849 (n=305). 
3.5 PROCEDURES 
3.5.1 Human Subjects Protections 
The SDA involved the study of existing data which were de-identified by the PS data manager 
according to guidelines established by the Complete Health Insurance Portability and 
Accountability Act (HIPAA) of 1996. The study thus met criteria for Exemption-4 status under 
Health and Human Services regulations in 45 CFR 46.101(b)(4), and was granted exempt 
approval by the University of Pittsburgh Institutional Review Board (IRB) (Appendix C). The PS 
was previously approved by the University of Pittsburgh IRB and other site boards. All PS 
participants provided written informed consent.  
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3.5.2 Data preparation 
The PS collected data longitudinally at five time points, however, only baseline and Time 2 
(post-intervention—3 months) data were used for the SDA. All PS data were collected from 
2003-2008, and were coded and processed using Teleform DesignerTM, a Windows-based 
software for automated data entry/verification which can be used to input scannable, precoded 
forms, and to verify the incoming data against investigator-set parameters. This process reduces 
the likelihood of data entry errors and ensures data quality. Data sets by measure were de-
identified and extracted from the PS master database/server and merged into a common file for 
analysis by the PS data manager using SPSS, version 15.0 (SPSS Inc., 1989-2004).  
3.5.3 Data screening 
All screening and analytic procedures were also conducted in SPSS by the principal investigator. 
Missing data analysis, outlier examination, and checking of statistical assumptions were 
performed prior to analysis.  
 Univariate and multivariate outlier analyses were performed by group, i.e., AUDIT-C 
positive/negative and AUDIT-3 positive/negative status, and by variable for the extent of their 
impact.  In order to reduce the influence of extreme univariate outliers, the highest three scores 
for dose adherence (scores >155% where mean=79%) were score altered, as were the three 
lowest scores the HIV Self-efficacy Scale total score (scores below 55, where mean=216) 
(Tabachnick & Fidell, 2001). The inherent statistical assumptions for each analytic strategy (i.e., 
the normality, linearity, homoscedasticity, and independence of residuals; and absence of 
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multicollinearity/singularity) were assessed using univariate descriptive statistics and visual plots 
(e.g., histograms, partial plots). Due to the violation in the assumption of normality, in all 
analyses by AUDIT-C and AUDIT-3 status, reflected square root transformations were applied 
to the dose and day adherence variables, and a regular square root transformation was applied to 
days under-dosing. Additionally, the days over-dosing adherence variable could not be suitably 
transformed, and was dichotomized as adherent/nonadherent using a 1-day cut point (i.e., over-
dosing 1 or more days during the 14 day assessment period was considered nonadherent; this is 
equivalent to a score of 7.14% on the continuous EEM measure of adherence).  
Missing data analysis was conducted to determine the frequency and patterns of any 
missing values. As the number of cases with missing data for each of the psychosocial and 
sociodemographic variables was small (i.e,, 3-6), only complete cases were used. The situation 
was more complex with respect to the primary outcome variable (adherence) and the primary 
independent variables (AUDIT-C and AUDIT-3 status. As the implications of these issues vary 
by analysis, a brief summary is provided here, with more detailed analysis and discussion 
appearing in later sections where the impact is most significant.  
Individuals with missing AUDIT data at baseline were omitted from the analysis because 
they could not be categorized for the main independent variables. Similar issues related to 
inconsistent AUDIT data were described earlier; in some respects, this data could also be 
considered missing because these individuals were omitted from the sample. More detailed 
evaluation of the inconsistent AUDIT data appears in section 5.3.3.2. AUDIT and/or adherence 
data were also missing at Time 2, primarily affecting analyses like AUDIT-C test-retest 
reliability in Secondary Aim #2 and Specific Aim #3 which tested the effect of the PS adherence 
interventions. More detailed evaluation of these problems thus appears in section 6.1.2. 
45 
 
3.6 STATISTICAL ANALYSIS 
3.6.1 Primary Aim #1 
Descriptive statistics (i.e., measures of central tendency and variability for continuous variables; 
frequency distributions for categorical variables; parametric and nonparametric correlations) 
were used to characterize the sample. These measures ensured the appropriate selection of 
statistical analysis procedures, allowed for characterization of the sample in terms of 
sociodemographic, substance use, psychosocial, and disease/regimen factors; and allowed for the 
examination of bivariate relationships between these variables.  Bivariate analyses were 
performed to identify possible confounders and covariates of the relationship between alcohol 
screening status and each type of adherence. Given the non-normal distribution of the majority of 
variables, Mann Whitney U tests were used to assess the degree of association between 
continuous variables and each of the two sets of alcohol screening statuses. Chi square tests of 
independence, the Fisher exact test, and the Spearman rank correlation coefficient were used for 
categorical variables.  An alpha level of .05 was used for all tests. Additionally, internal 
consistency was estimated for the AUDIT-C, HIV-SES, BDI-II, NEO-FFI, and ISEL, 
particularly given the limited data on the use of several of these multi-item self-report tools in 
samples of PWHIV.  
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3.6.2 Primary Aim #2  
A series of sequential multiple linear regression analyses were performed in order to determine if 
AUDIT-C positive status and AUDIT-3 positive status improved the prediction of each ART 
adherence pattern after controlling for various sociodemographic, drug use, and psychosocial 
variables. Regression analyses were conducted only for adherence variables demonstrating 
significant or trend results in initial Mann Whitney U testing; no further analysis of days with 
null dosing was performed as it was highly insignificant (this finding was not unexpected given 
that days with null dosing is subsumed under the larger category of days under-dosing). Separate 
regression analyses were performed by group (AUDIT-C positive/negative, AUDIT-3 
positive/negative) for each of the four remaining adherence variables, first, controlling for 
confounding variables, then, controlling for confounding variables and covariates.  
For model entry, potential sociodemographic, drug use, and psychosocial confounding 
variables were required to demonstrate a significant or trend (<.10) relationship in bivariate 
analysis with both AUDIT-C status and the given type of adherence, or with both AUDIT-3 
status and the given type of adherence. The following variables entered one or both sets of 
original regression models as potential confounders: CD4 count; crack use yes/no, marijuana use 
yes/no; Agreeableness score (NEO-FFI), conscientiousness score (NEO-FFI), and HIV Self-
Efficacy Scale total score.  Significant confounding variables were then entered as a single block 
into a backward regression model [p-IN (.05) p-OUT (.10)]; confounding variables significant at 
this step were then retained as the first block, with AUDIT-C status entered as the second block.  
A similar, but separate set of analyses then allowed both potential confounders and 
covariates to enter the models. For model entry, variables were considered potential covariates 
if, in bivariate analysis, they demonstrated a significant or trend (<.10) relationship with the 
adherence outcome variable of interest only. In addition to the aforementioned potentially 
confounding variables, the following variables entered one or both of the initial regression 
models as potential covariates: age, race (white/nonwhite), HIV viral load 
detectable/undetectable, CD4 count, and health insurance status (insured/uninsured). All 
confounder and confounder-covariate models were estimated hierarchically using adjusted R-
squared and parameter estimates with confidence intervals, and model assessment strategies 
included residual, outlier, and influential case analysis.  
3.6.3    Primary Aim #3 
Repeated measures analysis (e.g. covariance pattern models using linear mixed modeling 
methods) was used in order to determine if alcohol screening status impacts the effect of the 
adherence interventions on dose adherence over time, i.e., baseline to 12 weeks follow-up. 
Alcohol screening status was represented in the same manner described for Primary Aim #1, 
however, to assess possible moderation by AUDIT-C screening status on the relationship 
between the intervention and dose adherence, an interaction term between group and AUDIT-C 
screening status (AUDIT-C positive/negative) was included in the repeated measures model, 
with AUDIT-C negative status serving as the reference group.  Main effects (treatment group, 
time, AUDIT-C status), 2-way interactions (treatment group X time, treatment group X AUDIT-
C status, AUDIT-C status X time), and the possible 3-way interaction (treatment group X time X 
AUDIT-C status) were estimated in the model.  Again, models were estimated hierarchically and 
subsequent model assessment strategies included residual, outlier, and influential case analyses. 
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Models were re-run with different nested covariance structures (compound symmetry, AR1, 
Toeplitz, and unstructured) and compared using Akaike’s Information Criterion (AIC), where the 
lowest AIC indicated the best fit. An alpha level of .05 was used for all tests. 
3.6.4 Secondary Aim #1 
Path analysis was used to identify the role of ART adherence self-efficacy as a potential 
mediator of the relationship between baseline dose adherence and depressive symptoms, social 
support, and conscientiousness, while considering alcohol screening status as a potential 
moderator of any mediational relationship(s). Exploring mediation (i.e., the “how” and “why” of 
the relationship between variables) is most appropriate when the case can be made for relatively 
strong relationships between the predictors and the criterion variable (Baron, 1986); as 
previously indicated, depressive symptoms, social support, and to a lesser extent, personality 
characteristics, have demonstrated relationships to health regimen adherence.  To test mediation 
in this study, models considering both the direct (unmediated) effect of each of the predictors on 
adherence, as well as their indirect effects through self-efficacy were fitted.  In order to assess 
possible moderation by alcohol screening status (AUDIT-C positive/negative) on any 
mediational relationships, interaction terms between AUDIT-C status and depressive symptoms, 
social support, and conscientiousness were generated for inclusion in the final mediational 
models. 
 Baron and Kenny’s (1986) three criteria for mediation served as the standard to be met, 
i.e., 1) variations in levels of depressive symptoms, social support, and conscientiousness will 
significantly account for variations in self-efficacy, 2) variations in self-efficacy will 
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significantly account for variations in dose adherence, and 3) when these paths are controlled, 
any previously significant relationship between depressive symptoms, social support, 
conscientiousness, and dose adherence will diminish in magnitude, ideally becoming 
insignificant, where approaching zero provides stronger evidence for principal mediation by  
self-efficacy. As recommended by several authors (Kenny, 2008; MacKinnon, 2002; Preacher & 
Hayes, 2004; Sobel, 1990) the Sobel test was also performed in order to confirm the statistical 
significance of any mediational effects evidenced by these criteria. The SPSS macro for the 
Sobel test (with bootstrapping) developed by Preacher and Hayes (2004) was used. Due to 
violations in the assumption of normality, reflected square root transformations were 
satisfactorily applied to dose adherence and self-efficacy. 
As the sample size of individuals screening AUDIT-C positive was relatively modest, the 
aim was considered exploratory, and only path analysis models were considered where 
individual measured variables were used.  Verification of the assumptions of interval-level data, 
one-way casual flow in the model, multivariate normality, absence of outliers, linearity, the 
absence of multicollinearity/singularity, and residuals small and centered around zero 
(Tabachnik & Fidell, 2001) were nonetheless evaluated.  
3.6.5 Secondary Aim #2 
Internal consistency of the AUDIT-C was estimated using Cronbach’s alpha. Due to non-normal 
distribution of AUDIT-C total scores at the baseline and 12 week (3 month) time points, the test-
retest reliability of the AUDIT-C was determined using the Wilcoxon signed-rank test. Because 
alcohol use could have feasibly been impacted by the adherence interventions (particularly the 
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individualized intervention), only participants from the control group with complete AUDIT-C 
data at both time points were used in the test-retest estimation for the AUDIT-C (n=88). 
Multi-sample confirmatory factor analysis (CFA) (Byrne, 1989; Joreskog, 1979) was 
used to examine the hypothesized single factor structure of the AUDIT-C, first using the entire 
sample of PWHIV, then using cross-validation samples based on gender (male/female) and 
race/ethnicity (white/nonwhite).  Specifically, a single, invariant factor pattern and invariant 
factor loadings were hypothesized across males and females and across whites and nonwhites.  
Baseline models were estimated for each group, followed by a series of confirmatory factor 
analyses which used means and variance adjusted weighted least squares (WLSMV) estimation.  
(This approach is most appropriate for small sample sizes and for categorical data.) Models for 
each group were tested hierarchically; factor structures and factor loadings were then constrained 
to be equal (invariant) across gender and racial groups and these more restrictive models were 
compared to the baseline model(s). Model evaluation and goodness of fit were assessed with 
multiple criteria, e.g., chi square statistic, Root Mean Square Error of Approximation (RMSEA), 
and Weighted Least Square Mean Residual (WRMR). Goodness-of-fit was indicated by a 
nonsignificant chi square statistic, RMSEA values < .05 - .08, and WRMR values < .90 (Loehlin, 
2004; Muthen & Muthen, 2007). 
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4.0  MANUSCRIPT #1—THE PREDICTION OF HIV ANTIRETROVIRAL 
MEDICATION ADHERENCE BY POSITIVE SCREENS ON THE ALCOHOL USE 
DISORDERS IDENTIFICATION TEST—CONSUMPTION (AUDIT-C) 
NOTE: This is a pre-publication version of this manuscript; please contact the 
primary author prior to citation.  
 
4.1 ABSTRACT 
Background: Alcohol use appears to negatively impact antiretroviral (ART) adherence, though 
conclusions about its effects are inconsistent, and the mechanisms of these effects are unclear.  
Accurate, efficient assessment of alcohol risk behavior is thus an important issue, particularly for 
adherence counseling in HIV/AIDS. The primary aim of this study was to determine if positive 
screening results on the Alcohol Use Disorders Identification Test—Consumption (AUDIT-C) 
and its single binge-related question (AUDIT-3) predicted ART adherence. Methods: A 
secondary data analysis was conducted using data from a randomized controlled trial which 
tested the efficacy of two cognitive-behavioral ART adherence interventions over time and 
tracked medication adherence with electronic event monitoring. A series of sequential multiple 
linear regression analyses were performed to determine if positive alcohol screening results 
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added to adherence prediction after controlling for various biopsychosocial factors. Results: In 
models controlling for confounding variables, a positive AUDIT-C screen significantly added to 
the prediction of dose adherence (p=.013) and days under-dosing (p=.023). A positive screen on 
the AUDIT-3 did not predict any type of adherence. When potential covariates also entered the 
models, prediction of dose adherence, day adherence, and days under-dosing by AUDIT-C status 
and AUDIT-3 status improved.  AUDIT-C status again significantly predicted dose adherence 
(p=.005) and days under-dosing (p=.021), with a trend towards prediction of days over-dosing 
(p=.089). AUDIT-3 status demonstrated trend significance for predicting dose adherence 
(p=.086). Conclusions: The AUDIT-C shows potential as a screening tool for the identification 
of at-risk drinking and, indirectly, for ART nonadherence. Additional study is needed on the 
interrelationships between alcohol, adherence, personality and self-efficacy.  
4.2 INTRODUCTION 
Because of its direct relationship to successful viral suppression, antiretroviral (ART) medication 
adherence is a critical component of self-management in HIV/AIDS, and adherence is associated 
with multiple interwoven patient-, medication-, disease-, environment-, and system-related 
factors (2008 NIH guidelines).  While substance use is among these predictors and correlates of 
ART adherence, until recently, researchers exploring the effects of substance use on ART 
adherence have focused on the impact of illicit drug use (Chander, Himmelhoch et al., 2006). 
Subsequently, there is an incomplete and inconsistent understanding of the overall impact of 
alcohol on adherence. Full understanding of the interplay between alcohol use, 
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sociodemographic, clinical, and other adherence-related psychosocial factors such as drug use, 
depression, social support, self-efficacy, and personality is also limited. The National Institute on 
Alcohol Abuse and Alcoholism (NIAAA) has identified alcohol use as a probable “key 
determinant” in ART adherence, and has called for research efforts to 1) focus on a greater 
“understanding of the multidimensionality of the relationship between alcohol use and abuse and 
adherence,” and 2) to focus on improving medication adherence among PWHIV who use and 
abuse alcohol (Bryant, 2006, pp. 1492-1493). 
This call for additional research is warranted for several reasons. Alcohol use is common 
among persons with HIV/AIDS (PWHIV); 40-55% of PWHIV acknowledge some degree of 
alcohol use (Chander, Lau et al., 2006; Galvan et al., 2002; Lucas et al., 2002; Tucker et al., 
2003), and 10-20% of these individuals consume alcohol at hazardous or harmful levels (Arnsten 
et al., 2002; Braithwaite et al., 2005; Chander, Lau et al., 2006; Conigliaro et al., 2006; Cook et 
al., 2001; Galvan et al., 2002; Halkitis et al., 2003; Lucas et al., 2002; Samet, Horton, et al., 
2004; Tucker et al., 2003; Waldrop-Valverde et al., 2006). Considerable but inconclusive 
evidence exists regarding alcohol’s deleterious effects on viral replication, immune suppression, 
central nervous system impairment, progression of comorbid illnesses, the effectiveness and 
toxicity of ART, and ART adherence (Bryant, 2006).   
While numerous investigators have found that alcohol consumption at all levels appears 
to negatively impact adherence (Braithwaite et al., 2005; Chander, Lau et al., 2006; Cook et al., 
2001; Halkitis et al., 2003; Parsons, Golub, et al., 2007; Samet, Horton, et al., 2004; Tucker et 
al., 2003), other researchers report conflicting or mixed findings (Arnsten 2002, Berg 2004, 
Halkitis 2005, Waldrop-Valverde, 2006, Hinkin, 2004, Paterson, 2000). Significant 
methodological differences across studies, i.e., differences in the definition and assessment of 
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alcohol use and adherence (Chander, 2006), leave unanswered questions about the extent to 
which alcohol predicts adherence over and above the impact of sociodemographic, psychosocial, 
and illicit drug use factors. Resolving these gaps and incongruities is important given that 
alcohol is clearly a significant risk behavior in the overlapping clinical realms of HIV/AIDS 
treatment and progression.   
Accurate, efficient assessment of alcohol risk behavior is thus an important issue for 
HIV/AIDS care providers, particularly with respect to individualized ART adherence counseling 
(Cook, 2001; Conigliaro et al., 2003; Petry 1999; Samet, Phillips, et al., 2004).  One alcohol 
screening instrument with the advantages of brevity and sensitivity is the Alcohol Use Disorders 
Identification Test—Consumption (AUDIT-C) (Bush et al., 1998). The AUDIT-C is an alcohol 
screening tool based on the first three (consumption-related) items from the full 10-item Alcohol 
Use Disorders Identification Test (AUDIT), a screening questionnaire developed by the World 
Health Organization and validated internationally for the detection of “hazardous and harmful 
drinking patterns” (Babor et al., 2001). The sensitivity and specificity of the AUDIT-C for the 
detection of hazardous drinking and active alcohol abuse/dependence parallels or exceed that of 
comparable instruments used in clinical and research settings (e.g., standard quantity/frequency 
questions, CAGE, full AUDIT) (Bradley et al., 2003; Bradley et al., 2007; Bush et al., 1998; 
Frank et al., 2008; Gordon et al., 2001).  Additionally, the third question on the AUDIT-C which 
addresses episodic heavy/binge drinking (AUDIT-3) generally demonstrates slightly lower, but 
highly adequate sensitivities when used alone as a single alcohol screening question (Bradley et 
al., 2003; Bradley et al., 2007; Gordon et al., 2001).  Because of its psychometric properties and 
the ease of its administration and scoring, the AUDIT-C is one of the alcohol screening tools 
55 
 
recommended by the NIAAA; a single screening question similar to the AUDIT-3 is also 
recommended (NIAAA, 2005). 
Interestingly, scores on the AUDIT-C and the AUDIT-3 have also been directly 
associated with the incidence of other health-related outcomes such as risk of hospitalizations for 
gastrointestinal conditions such as liver disease, upper GI bleeds, and pancreatitis (Au et al., 
2007) and general 5-year mortality rates (Bradley, et al., 2001). Given these findings, a 
reasonable question is whether the AUDIT-C and AUDIT-3 might also help predict health 
behaviors such as ART adherence. While various versions of the AUDIT have been used by 
adherence researchers for assessing alcohol use, no published study has heretofore considered 
the potential for this type of dual purpose.  If positive screens on the AUDIT-C are predictive of 
ART adherence, the detection of both risk behaviors could potentially be improved in the context 
of a regular alcohol screening program. In particular, increased attention to the intersection of 
alcohol use and chronic medical illness would remind clinicians to be alert to the greater risk of 
suboptimal adherence in those who screen positive for at-risk drinking. 
The overall purpose of this study was to determine if alcohol use predicts specific 
patterns of ART adherence behavior. The primary aim was to determine if positive screening 
results on the AUDIT-C and/or AUDIT-3 provide additional prediction of ART dose adherence 
based on electronic event monitoring (EEM), including day adherence, days under-dosing, days 
over-dosing, and days with null dosing after controlling for various sociodemographic, substance 
use, and psychosocial variables.  
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4.3 MATERIALS AND METHODS 
4.3.1 Parent Study Overview 
This study is an analysis of existing data from the randomized controlled trial entitled 
“Improving Adherence to Antiretroviral Therapy” (R01-NR04749), National Institute of Nursing 
Research, Principal Investigator, Dr. Judith Erlen. The “parent study” (PS) tested the efficacy of 
two cognitive-behavioral ART adherence interventions over time and examined the impact of 
adherence on clinical outcomes and quality of life. Parent study data were collected in two 
phases from 1998-2002 (Phase I) and from 2003-2008 (Phase II). This study uses baseline data 
from Phase II.  
Parent study participants were randomized to a structured adherence intervention 
condition, individualized adherence intervention condition, or usual care, and were provided with 
an electronic event monitor (EEM) and a medication bottle.  For a one month induction period, 
PS participants used the EEM and medication bottle for a randomly selected ART medication in 
their regimens (i.e., the monitored drug). Participants also maintained medication diaries, 
recording time of medication removal, time of medication ingestion, and any instances of pocket 
dosing. Data from the last 2 weeks of this induction period were considered the baseline 
adherence assessment and were used to determine PS participants’ general medication adherence 
status.  Individuals with perfect adherence at baseline (i.e., “100% adherers”) were extracted for 
separate analysis by the PS and were not randomized to the aforementioned treatment conditions. 
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4.3.2 Participants/setting 
Parent study participants were required to be > 18 years old, on combination HIV therapy, 
administering their own medications, English-speaking, free from significant cognitive 
impairment, and community-dwelling with telephone access.  Participants were recruited from 
multiple sites (a university-based clinic, community hospitals, and comprehensive care centers) 
in western Pennsylvania and eastern Ohio. Individuals were excluded from participation if they 
were living with another individual already enrolled in the study, had upper extremity or visual 
impairments which precluded self-administration of medication, or had hearing difficulties 
without adaptive telephone equipment for possible delivery of the telephone intervention.  
The PS was approved by the University of Pittsburgh Institutional Review Board (IRB), 
and other site boards; all PS participants provided written informed consent. The current study 
was granted exempt approval by the University of Pittsburgh IRB because it involved the study 
of existing data de-identified according to guidelines established by the Complete Health 
Insurance Portability and Accountability Act (HIPAA) of 1996. 
4.3.3 Measures 
4.3.3.1 Primary outcome variable 
The primary outcome variable of interest was ART adherence. More specifically, five types of 
medication adherence served as the primary set of ART adherence variables:  dose adherence, 
day adherence, days under-dosing, days over-dosing, and days with null dosing.  Table 2 
describes the five adherence variables and their mode of calculation in the PS. In each case,  
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Table 2: Definition and calculation of adherence variables-B 
Adherence  
 
variable 
                 Definition              Calculation 
Dose  
adherence 
 
% of medication administrations  (Number of doses taken/number of doses 
prescribed) * 100 
Day adherence % of days with correct # of pills 
taken 
(Number of days with the correct number 
of doses/total number of days prescribed) 
* 100 
Days under-
dosing  
 
% of days with less than prescribed 
number of administrations taken 
(Number of days taking less than 
prescribed/total number of days 
prescribed) * 100 
Days over-
dosing 
 
% of days with more than 
prescribed number of 
administrations taken 
(Number of days taking more than 
prescribed/total number of days 
prescribed) * 100 
Days with null 
dosing  
% of days with no medication 
administrations at all 
Days taking no doses during a 24 hour 
period/total number of days prescribed 
 
 
adherence was treated as a continuous variable and was measured by EEM (MEMS 6 TrackCap, 
AARDEX, Ltd.) for the monitored drug. EEM uses a special medication container cap which 
electronically records and stores each time the cap on the medication bottle is opened. Data from 
the “chip” inside the cap is downloaded to a computer program for analysis by the researcher. In 
the PS, raw data from the EEM caps were downloaded, visually reviewed, and arranged for 
analysis by the PS staff. Pocket dosing data from participants’ medication diaries were inserted, 
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as necessary, and when possible. The PS statistician then applied programmed analytic 
algorithms for the specific types/categories of adherence to yield the adherence summary indices 
for analysis.  
4.3.3.2 Independent variable—Alcohol screening status 
The primary independent variable, alcohol screening status, had two separate dimensions based 
on participant responses to the Alcohol Use Disorders Identification Test—Consumption 
(AUDIT-C) (Bush, 1998). The first dimension of alcohol screening status involved 
categorization as AUDIT-C positive or AUDIT-C negative for at-risk drinking. This 
classification is consistent with the NIAAA approach used in alcohol screening algorithms for 
clinicians, where individuals are considered “at-risk drinkers” if they have a positive alcohol 
screen on a self-report tool such as the AUDIT or AUDIT-C, or if they endorsed having one or 
more heavy drinking days (>5 drinks/day for men, >4 drinks/day for women) (NIAAA, 2005, p. 
5). It is important to recognize that this categorization of at-risk drinking includes individuals 
with alcohol abuse/dependence disorders as well as individuals with hazardous drinking patterns. 
In the current study, determination of AUDIT-C positive/negative status was based on 
total AUDIT-C score. Men with total AUDIT-C scores >4, and women with total scores >3 were 
classified as “AUDIT-C positive” and those with scores below the threshold were considered 
“AUDIT-C negative” (Bradley et al., 2003; Bradley et al., 2007; Reinert & Allen, 2007).   
The second dimension of alcohol screening status, AUDIT-3 positive versus AUDIT-3 
negative for at-risk drinking, captured “binge” drinking. Participants were classified as AUDIT-3 
positive or negative based on their individual scores for this item, which ranged from 0 to 4. 
Participants with AUDIT-3 scores of zero (i.e., the “never” response) were categorized “AUDIT-
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3 negative,” while participants with AUDIT-3 scores from 1 (less than monthly) to 4 (daily or 
almost daily) were considered “AUDIT-3 positive” (Bradley et al., 2007; Gordon, 2001).  
4.3.3.3 The Alcohol Use Disorders Identification Test—Consumption (AUDIT-C) 
The AUDIT-C is an abbreviated version of the Alcohol Use Disorders Identification Test 
(AUDIT), the instrument used by the PS to assess alcohol use. Initially developed by the World 
Health Organization as a screening tool for the detection of “hazardous and harmful drinking 
patterns” in primary care patients, the full AUDIT assesses the conceptual domains of alcohol 
consumption (3 questions), alcohol dependence (3 questions), and alcohol-related consequences 
or problems (4 questions) over the past year (Babor, 2001).  The AUDIT-C consists of the first 
three, consumption-related items from the full 10-item AUDIT, and assess frequency of 
drinking, number of drinks per drinking occasion, and frequency of binge drinking (>6 
drinks/occasion) over the past year.  Based on 5 Likert-style response alternatives, a range of 0-4 
points is possible for each item; total scores are calculated by summing the three items and thus 
range from 0-12.  
Sensitivity and specificity ranges for the AUDIT-C depend on the diagnostic standard 
(alcohol abuse, alcohol dependence, hazardous drinking, at-risk drinking) and cut point used (>3, 
>4, >5); however, for the detection of hazardous drinking and active alcohol abuse/dependence, 
the sensitivity and specificity of the AUDIT-C parallels or exceeds that of comparable 
instruments used in clinical and research settings (e.g., standard quantity/frequency questions, 
CAGE, full AUDIT) (Bush, 1998; Bradley et al., 2003, 2007; Gordon, 2001; Frank, 2008). 
Based on numerous sensitivity and specificity analyses, AUDIT-C cut-off scores of 3 for women 
and 4 for men have been recommended for the detection of alcohol misuse (Bradley et al., 2003; 
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Bradley et al., 2007; Reinert & Allen, 2007). In the current study, internal consistency of the 
AUDIT-C was excellent, with an estimate of .838 for the total sample. By subgroup, estimates 
were slightly higher for females (.851) than for males (.831), and slightly higher for whites 
(.851) than for nonwhites (.828). 
In the interest of clinical expediency (i.e., save time and reduce reliance on scoring 
schemes), the third question on the AUDIT-C which addresses episodic heavy/binge drinking 
(“AUDIT-3”) has generated interest as a single-item alcohol screening question; it generally 
demonstrates slightly lower, but highly adequate sensitivities when used alone (Bradley et al., 
2003; Bradley et al., 2007; Gordon, 2001).   
4.3.3.4 Additional independent variables 
Sociodemographic data were extracted from a comprehensive standard instrument developed by 
the Center for Research in Chronic Disorders at the University of Pittsburgh School of Nursing.  
Disease profile parameters (CD4 count, detectable/undetectable HIV RNA) and ART regimen 
characteristics were obtained from the PS-designed medical record review.  
Drug use was assessed through questions related to the frequency of use for tobacco and 
various illicit substances (marijuana/hashish, cocaine, crack, heroin, “ecstasy,” “poppers,” 
stimulants, opioids, hallucinogens, inhalants) which were added to the full AUDIT by the PS. 
For the current analysis, responses to the drug use items were dichotomized as “use” / “no use” 
for each drug. Additionally, a composite drug use score was created by summing the number of 
“use” responses (excluding tobacco) for each participant, reflecting the total number of illicit 
substances used.  
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Several psychosocial variables previously demonstrated to be related to adherence were 
also assessed. Self-efficacy, “beliefs in one’s capabilities to organize and execute the courses of 
action required to produce given attainments” (Bandura, 1997, p. 3), was assessed using the 26-
item HIV Self-Efficacy Scale (SES) developed by the PS to measure self-efficacy for ART 
medication-taking. At PS inception, no comparable measure could be found related to assessing 
self-efficacy for taking protease inhibitors. Participants were asked to rate their confidence from 
1 (not at all confident) to 10 (totally confident) in their ability to take their monitored medication 
as prescribed during the week, at work, a party, etc., as well as some general questions regarding 
their perceived ability to follow the overall medication regimen.  An overall total score and two 
subscale scores (Self-efficacy Beliefs and Outcome Expectancy) can be calculated. In each case, 
higher scores indicate greater self-efficacy. In the current study only total HIV-SES scores were 
used; the internal consistency (Cronbach’s alpha) for the total score was .947 for the sample, at 
baseline (n=288). For males, Cronbach’s alpha for the total score was .951 (n = 198) and was 
slightly lower for females (.938, n = 90). Across race, Cronbach’s alpha for the total score for 
whites was .951 (n = 118), and was slightly lower for nonwhites at .944 (n = 170). 
 Depressive symptoms were measured with the Beck Depression Inventory II (BDI-II), a 
21-item tool which assesses depressive symptomatology over the previous 2 weeks, and which 
was developed to correspond with the Diagnostic and Statistical Manual of Mental Disorders—
4th Edition (Beck, 1996). While total score cut-points are properly set based on the 
characteristics of the sample, total scores of 0-13 suggest minimal depression; 14-19 mild 
depression; 20-28 moderate depression, and 29-63, severe depression. The internal consistency 
of the BDI-II, based on Cronbach’s alpha, was .940 for the total sample at baseline (n=299). For 
males, Cronbach’s alpha for the total score was .941 (n = 205) and was slightly lower for females 
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(.939, n = 94). Across race, Cronbach’s alpha for the total score for whites was .951 (n = 118), 
and was slightly lower for nonwhites at .944 (n = 170). 
Personality characteristics were measured using the 5 domains of the NEO Five-Factor 
Inventory (NEO-FFI) (Costa & McCrae, 1992). The NEO-FFI consists of five 12-item scales 
addressing the domains of Neuroticism (anxiety, hostility, depression, impulsiveness); 
Extroversion (positive affect, assertiveness, activity, gregariousness); Openness (aesthetic 
interests; receptivity to feelings, new experiences, ideas, actions, and values); Agreeableness 
(trust, altruism, straightforwardness, modesty), and conscientiousness (competence, order, self-
discipline, achievement striving) (Costa & McCrae, 1992).  Higher scores indicate a greater 
degree of the corresponding characteristic; scale scores are not summed to produce a total score.  
In the current study, internal consistency estimates (Cronbach’s alpha) for the NEO-FFI 
scales at Baseline were as follows: Neuroticism, .853 (n = 307); Extroversion, .796 (n = 304); 
Openness, .629 (n = 303); Agreeableness, .656 (n = 306); Conscientiousness, .849 (n = 305).   
By gender, internal consistency estimates (Cronbach’s alpha) for the NEO-FFI scales at Baseline 
were as follows for males: Neuroticism, .855 (n = 211); Extroversion, .791 (n = 210); Openness, 
.665 (n = 207); Agreeableness, .670 (n = 210); Conscientiousness, .851 (n = 210).   For females, 
internal consistency estimates (Cronbach’s alpha) for the NEO-FFI scales at Baseline were as 
follows: Neuroticism, .852 (n = 96); Extroversion, .806 (n = 94); Openness, .536 (n = 96); 
Agreeableness, .637 (n = 96); Conscientiousness, .846 (n = 95).   By race, internal consistency 
estimates (Cronbach’s alpha) for the NEO-FFI scales at Baseline were as follows for whites: 
Neuroticism, .900 (n = 127); Extroversion, .836 (n = 127); Openness, .721 (n = 126); 
Agreeableness, .708 (n = 126); Conscientiousness, .841 (n = 127). For nonwhites, internal 
consistency estimates (Cronbach’s alpha) for the NEO-FFI scales at Baseline were as follows: 
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Neuroticism, .802 (n = 180); Extroversion, .762 (n = 177); Openness, .512 (n = 177); 
Agreeableness, .608 (n = 180); Conscientiousness, .857 (n = 178). 
Social support was measured with the Interpersonal Support Evaluation List (ISEL)  
(Cohen, 1985).  The ISEL contains 40 Likert-style items which assess different dimensions of 
perceived social support:  Appraisal (perceptions of having another for emotional support and to 
discuss problems with); Tangible (the perception of available material aid); Self-esteem (the 
perception of having a positive evaluation when comparing one’s self to others); and Belonging 
(the perception of having others to do things with) (Cohen, 1985).  Total and subscale scores can 
be calculated, with higher scores indicating greater perceived social support. Only total ISEL 
scores were used in the current study. 
Internal consistency (Cronbach’s alpha) for the ISEL total score and subscales scores in 
the current study at baseline were as follows: ISEL total score, .950 (n = 294); Tangible, .877 (n 
= 304); Self-esteem, .798 (n = 300); Belonging, .865 (n = 302); Appraisal, .884 (n = 307). By 
gender, internal consistency estimates for males were as follows at baseline: ISEL total score, 
.948 (n = 205); Tangible, .872 (n = 210); Self-esteem, .792 (n = 209); Belonging, .864 (n = 209), 
Appraisal, .878 (n = 211). For females, internal consistency estimates were as follows at 
baseline: ISEL total score, .955 (n = 89); Tangible, .888 (n = 94); Self-esteem, .809 (n = 91); 
Belonging, .867 (n = 93); Appraisal, .894 (n = 96). By race, internal consistency estimates for 
whites were as follows at baseline: ISEL total score, .961 (n = 120); Tangible, .911 (n = 127); 
Self-esteem, .834 (n = 123); Belonging, .895 (n = 209); Appraisal, .918 (n = 128). Internal 
consistency estimates for nonwhites were as follows at baseline: ISEL total score, .940 (n = 174); 
Tangible, .843 (n = 177); Self-esteem, .768 (n = 177); Belonging, .839 (n = 179); Appraisal, .940 
(n= 174). 
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4.3.4 Procedures 
4.3.4.1 Data preparation and screening 
Datasets by measure were de-identified and extracted from the PS master database and merged 
into a common file for analysis by the PS data manager using SPSS, version 15.0 (SPSS Inc., 
1989-2004). All data screening and analytic procedures were also conducted in SPSS by the 
principal investigator. Missing data analysis, outlier examination, and checking of statistical 
assumptions were performed prior to analysis. 
For the current study, no sampling exclusions were made based on race, gender, 
ethnicity, or sexual orientation; however, only randomized participants from the PS were 
included, i.e., individuals deemed “100% adherers” were omitted from the current analysis 
(n=8), as were individuals who were removed from medications by their physicians during the 
induction phase (n=2) and individuals who did not return the EEM cap at the end of the 
induction phase (n=2). 
Because missing or inconsistent responses on AUDIT items 1-3 would impede 
categorization of individuals as AUDIT-C positive/negative and/or AUDIT-3 positive/negative, 
PS participants with missing (n=6) or inconsistent (n=18) AUDIT data on these items at baseline 
were removed from the sample prior to analysis. Inconsistent responses included, for example, a 
response of “never” to AUDIT question 1 (“How often do you have a drink containing 
alcohol?”) and the selection of a quantity greater than zero in response to AUDIT question 2 
(“How many drinks containing alcohol do you have on a typical day when you are drinking?”).  
Four individuals were removed for missing or incomplete adherence data at baseline. The final 
sample size was comprised of 310 individuals.  
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4.3.4.2 Univariate and bivariate analyses 
Descriptive statistics (i.e., measures of central tendency and variability for continuous variables, 
frequency distributions for categorical variables) were used to characterize the sample. In order 
to reduce the influence of extreme univariate outliers, the highest three scores for dose adherence 
(scores >155%) and the three lowest scores for the HIV Self-efficacy Scale total score (31, 44, 
and 54) were score adjusted (Tabachnick & Fidell, 2001). The three dose adherence scores were 
decreased to 129%, just slightly higher than the next-highest score of 128.57. The three Self-
efficacy Scale total scores were increased to 90, 91, and 92, respectively, just slightly higher than 
the next-lowest score of 93. 
Bivariate analyses were performed to identify possible confounders and covariates. Given 
the non-normal distribution of the majority of variables, Mann Whitney U tests were used to 
assess the degree of association between continuous variables and each of the two alcohol 
screening status measures. Chi square tests of independence, Fisher’s exact test, and Spearman’s 
rank-order correlation coefficient were used for categorical variables with each of the two 
alcohol screening variables.  Across analyses, p-values <.05 were considered statistically 
significant. 
4.3.4.3 Main analyses 
A series of sequential multiple linear regression analyses were then performed in order to 
determine if AUDIT-C positive status and AUDIT-3 positive status improved the prediction of 
each ART adherence pattern after controlling for various sociodemographic, drug use, and 
psychosocial variables. Regression analyses were conducted only for adherence variables 
demonstrating significant or trend results in initial Mann Whitney U testing; no further analysis 
67 
 
of days with null dosing was performed as it was highly insignificant (this finding was not 
unexpected given that days with null dosing is subsumed under the larger category of days 
under-dosing, and given that this variable had extremely limited variability). Separate regression 
analyses were performed by group (AUDIT-C positive/negative, AUDIT-3 positive/negative) for 
each of the four remaining adherence variables, first, controlling for confounding variables, then, 
controlling for confounding variables and covariates. Due to violation in the assumption of 
normality of the residuals, in all analyses by AUDIT-C and AUDIT-3 status, reflected square 
root transformations were applied to the dose and day adherence variables, and a square root 
transformation was applied to days under-dosing.  
 For model entry, potential sociodemographic, drug use, and psychosocial confounding 
variables were required to demonstrate a significant or trend (p <.10) relationship in bivariate 
analysis with both AUDIT-C status and the given type of adherence, or with both AUDIT-3 
status and the given type of adherence. The following variables entered one or both sets of 
original regression models as potential confounders: health insurance status (insured/uninsured); 
CD4 count; crack use yes/no; marijuana use yes/no; Agreeableness score (NEO-FFI); 
conscientiousness score (NEO-FFI); and HIV Self-Efficacy Scale total score.  Significant 
confounding variables were then entered as a single block into a backward regression model 
using a p-value of .10 for excusion; confounding variables that were significant at this step were 
then retained as the first block, with AUDIT-C or AUDIT-3 status entered as the second block.  
A similar, but separate set of analyses then allowed both potential confounders and 
covariates to enter the models. For model entry, variables were considered potential covariates 
if, in bivariate analysis, they demonstrated a significant or trend (<.10) relationship with the 
adherence outcome variable of interest only. The following variables entered one or both of the 
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initial regression models as potential covariates in a single block which included any significant 
confounding variables from the previous analyses: age, race (white= 0, nonwhite = 1), HIV viral 
load (undetectable = 0, detectable = 1), and CD4 count, and health insurance status (uninsured = 
0, insured =1). All confounder and confounder-covariate models were estimated hierarchically 
yielding adjusted R-squared values and parameter estimates with 95% confidence intervals. 
Model assessment strategies included residual, outlier, and influential case and sensitivity 
analyses.  For all analyses, p-values <.05 were considered statistically significant. 
Additionally, the days over-dosing adherence variable was substantially negatively 
skewed and could not be suitably transformed. It was dichotomized as adherent/nonadherent 
using a 1-day cut point (i.e., over-dosing 1 or more days during the 14 day assessment period 
was considered nonadherent; this is equivalent to a score of 7.14% on the continuous EEM 
measure of adherence). 
4.4 RESULTS 
4.4.1 Univariate and bivariate analysis 
A series of tables present characteristics of the total sample, and by AUDIT-C status. Table 3 
presents sociodemographic and clinical characteristics. Table 4 presents a profile of alcohol and 
drug use. Adherence and psychosocial characteristics are presented in Table 5. The total sample 
was approximately two-thirds male, over half self-identified as Non-white ethnicity, and the 
median age was 44 years old. Mean AUDIT-C score was 2.16 (SD= 2.59); 27.1% and 34.2% of 
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the total sample were classified as AUDIT-C positive and AUDIT-3 positive, respectively. 
Compared to AUDIT-C negative participants, AUDIT-C positive individuals had significantly 
fewer years of formal education; were significantly more likely to have health insurance; 
significantly more likely to use drugs overall and to use marijuana, crack, cocaine, “poppers,” 
hallucinogens, and tobacco; had significantly more depressive symptoms; had significantly 
higher neuroticism scores, lower agreeableness and conscientiousness scores; had significantly 
less social support; and had significantly lower dose adherence, days under-dosing, and days 
over-dosing. Additionally, AUDIT-C positive individuals were slightly less likely to use 
stimulants, use opioids, and have lower day adherence (.05 < p < .10) compared to AUDIT-C 
negative participants.  
By AUDIT-3 status, groups were significantly different in essentially parallel fashion 
(data not shown), with additional differences noted for sex, and a trend difference noted for 
English as primary language (.05 < p < .10). AUDIT-3 positive individuals were significantly 
more likely to be men and slightly more likely to be insured. Significant differences in dose 
adherence and day adherence were detected by AUDIT-3 positive versus negative status, with a 
trend relationship for days under-dosing noted. Additionally, in contrast to AUDIT-C status, only 
trend differences (p<.10) emerged for stimulant use and depressive symptoms (.10 < p > .05), 
while differences in opioid use were nonsignificant.    
Individuals with inconsistent AUDIT-C data at either time point (n = 48) were 
significantly less likely to have health insurance, χ2 (1, N = 344) = 7.313, p = .013; significantly 
more likely to use opioids, χ2 (1, N = 339) = 5.777, p = .037; and had significantly higher 
conscientiousness scores (p = .026) compared to individuals with consistent AUDIT-C data. 
70 
 
Additionally, those with inconsistent AUDIT-C data were slightly more likely to use 
hallucinogens, χ2 (1, N = 339) = 3.672, p = .089. 
 
Table 3: Sociodemographic and clinical characteristics of the sample 
  Total 
sample 
(n=310) 
AUDIT-C 
positive 
(n=84) 
AUDIT-C 
negative 
(n=226) 
p† 
Sex Male  
Female 
68.4% 
31.6% 
73.8% 
26.2% 
66.4% 
33.6% 
.211 
Race White 
Nonwhite 
 
More than one race 
41.3% 
58.7% 
 
2.6% 
40.5% 
59.5% 
 
3.6% 
41.6% 
58.4% 
 
2.2% 
.859 
Age Mean 
SD 
Median 
43.51 
7.78 44.00 
42.54 
7.68 
43.00 
43.89 
7.81 
44.00 
.127 
Years formal education 
(n = 309) 
Mean 
SD 
Median 
13.01 
2.90 
12.00 
12.46 
3.09 
12.00 
13.22 
2.80 
13.00 
.001  
Primary language English 
Other  
98.1% 
1.9% 
100% 97.3% 
2.7% 
.195 
Marital status Currently 
married/partnered  
20.6% 17.9% 21.7% .460 
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Table 3 (continued) 
Employment Currently 
employed  
Not currently 
employed 
18.1% 
 
81.9% 
15.5% 
 
84.5% 
 
19.0% 
 
81.0% 
.470 
Number of adults in 
household (n = 308) 
Mean 
SD 
Median 
1.67 
1.90 
1.00 
1.51 
.908 
1.00 
1.73 
2.16 
1.00 
.130 
Number of children in 
household (n = 307) 
Mean 
SD 
Median 
0.33 
0.80 
0.00 
0.36 
0.83 
0.00 
0.27 
0.72 
0.00 
.356 
Health insurance Yes 
No 
93.2% 
 6.8% 
98.8% 
 1.2% 
91.2% 
 8.9% 
.020 
HIV Exposure category‡ MSM 
Heterosexual 
contact 
IVDU 
IVDU + MSM 
 
Other/Unknown 
50.4% 
31.2% 
 
13.5% 
 
2.1% 
2.8% 
44.7% 
26.3% 
 
18.4% 
 
5.3% 
5.2% 
52.4% 
33.0% 
 
11.7% 
 
1.0% 
2.0% 
.418 
.447 
 
.296 
 
.117 
.292 
Viral load undetectable?  
(n = 294) 
Yes  
No 
58.8% 
41.2% 
61.3% 
38.8% 
57.9% 
42.1% 
.608 
CD4 count (n = 285) Mean 
SD 
Median 
458 
324 
389 
423 
294 
355 
472 
397 
334 
.351 
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Table 3 (continued) 
ART medication 
(”monitored drug”) 
Combivir 
Norvir 
Truvada™ 
Reyataz™ 
8.4% 
8.1% 
7.4% 
7.1% 
   
Frequency of dosing for 
“monitored drug” 
Once daily 
Twice daily 
Three times daily 
51.0% 
46.5% 
2.5% 
50.0% 
47.6% 
2.4% 
51.3% 
46.0% 
2.7% 
.968 
Note. † Significance testing for differences between AUDIT-C positive /negative groups, assessed with Mann-
Whitney U tests for continuous variables and chi-square tests or Fisher exact test, where appropriate. 
SD= standard deviation; MSM = men who have sex with men; IVDU = intravenous drug use. 
‡Results presented for individuals reporting only one exposure category, i.e., 89.2% of total sample, 90.4% of 
AUDIT-C positive individuals, and 86.4% of AUDIT-C negative individuals 
 
 
Table 4: Alcohol and drug use in the sample 
  Total 
sample 
(n=310) 
AUDIT-C 
positive 
(n=84) 
AUDIT-C 
negative 
(n=226) 
    p† 
Drinking status Nondrinkers 
Drinkers 
37.7% 
62.1% 
0% 
100% 
51.8% 
48.2% 
.000 
AUDIT-C total Mean 
SD 
Median 
2.11 
2.59 
1.00 
5.71 
2.13 
5.00 
.84 
1.02 
0.00 
.000 
AUDIT-C status Positive 
Negative 
27.1% 
72.1% 
-- 
-- 
-- 
-- 
 
AUDIT-3 status Positive 
Negative 
34.2% 
65.8% 
95.2% 
4.8% 
88.5% 
11.5% 
.000 
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Table 4 (continued) 
  Total 
sample 
(n=310) 
AUDIT-C 
positive 
(n=84) 
AUDIT-C 
negative 
(n=226) 
    p† 
AUDIT-C Question 1      
 Never 37.7% 0.0% 51.8%  
 Monthly or less 28.4% 13.1% 34.1%  
 2-4 x/month 20.6% 40.5% 13.3%  
 2-3 x/week 7.7% 26.2% 0.9%  
 >4x/week 5.5% 20.2% 0.0%  
AUDIT-C Question 2      
 0 drinks 37.7% 0.0% 0.0%  
 1 or 2 drinks 32.9% 16.7% 38.9%  
 3 or 4 drinks 18.4% 42.9% 9.3%  
 5 or 6 drinks 7.4% 27.4% 48.2%  
 7-9 drinks 2.3% 8.3% 0.0%  
 10 or more drinks 1.3% 4.8% 0.0%  
AUDIT-C Question 3 Never 65.8% 4.8% 88.5%  
 Less than monthly 20.3% 44.0% 11.5%  
 Monthly 8.1% 29.8% 0.0%  
 Weekly 3.5% 13.1% 0.0%  
 Daily or almost 
daily 
2.3% 8.3% 0.0%  
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Table 4 (continued) 
  Total 
sample 
(n=310) 
AUDIT-C 
positive 
(n=84) 
AUDIT-C 
negative 
(n=226) 
         p† 
Drug Use, Yes Any 46.4% 69.7% 38.4%   .000 
 Marijuana 34.2% 50.0% 28.3%   .000 
 Crack  15.8% 29.8% 10.6%   .000 
 Cocaine+ 11.0% 18.1% 8.4%  .016 
 Poppers 8.4% 14.3% 6.2%  .022 
 Opioids 6.8% 10.7% 5.3%  .092 
 Stimulants 4.2% 8.3% 2.7%  .049 
 Heroin+ 3.9% 2.4% 4.4%  .404 
 Hallucinogens 1.6% 4.8% 0.4%  .020 
 Inhalants 1.3% 1.2% 1.3% .924 
 Ecstasy 0.3% 0.0% 0.4% .541 
 Tobacco 62.6% 76.2% 42.5% .003 
Note. † Significance testing for differences between AUDIT-C positive /negative groups, assessed with Mann-
Whitney U tests for continuous variables and chi-square tests or Fisher exact test, where appropriate. 
+ (n = 309) 
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Table 5: Adherence and psychosocial characteristics of the sample 
  Total 
sample 
(n=310) 
AUDIT-C 
positive  
(n=84) 
AUDIT-C 
negative  
(n=226) 
   p† 
% Dose adherence Mean 
SD 
Median 
79.41 
30.95 
92.86 
70.43 
32.68 
82.14 
82.74 
29.67 
92.86 
.001 
% Day adherence Mean 
SD 
Median 
59.71 
31.57 
71.43 
52.76 
35.03 
50.00 
62.28 
29.86 
71.42 
.055 
% Days null dosing Mean 
SD 
Median 
20.55 
26.55 
7.14 
25.16 
30.00 
14.29 
18.84 
25.01 
7.14 
.119 
% Days under-dosing Mean 
SD 
Median 
32.79 
33.16 
21.43 
42.07 
36.65 
35.71 
29.35 
31.17 
14.29 
.008 
% Days over-dosing Mean 
SD 
Median 
7.50 
10.08 
7.14 
5.16 
5.94 
7.14 
8.37 
11.12 
7.14 
.020  
BDI-II  
(Total score, n = 309)  
Mean 
SD 
Median 
16.27 
12.47 
14.00 
18.77 
13.02 
17.00 
15.35 
12.16 
12.00 
.027 
ISEL  
(Total score)  
Mean 
SD 
Median 
75.42 
23.27 
78.00 
70.74 
22.79 
74.00 
77.15 
23.62 
79.00 
.032 
76 
 
Table 5 (continued) 
  Total 
sample 
(n=310) 
AUDIT-C 
positive  
(n=84) 
AUDIT-C 
negative  
(n=226) 
   p† 
Neuroticism (n = 307) 
 
Mean 
SD 
Median 
23.26 
8.71 
24.00 
25.55 
8.00 
25.00 
22.42 
8.82 
23.00 
  .004  
Extroversion (n = 307) 
 
Mean 
SD 
Median 
25.74 
7.03 
26.00 
24.90 
7.21 
26.00 
26.05 
6.95 
26.00 
.452 
Openness (n = 307) 
 
Mean 
SD 
Median 
26.02 
5.62 
26.00 
25.88 
5.72 
25.00 
26.06 
5.59 
26.00 
.997 
Agreeableness (n = 307) 
 
Mean 
SD 
Median 
29.24 
5.49 
30.00 
27.52 
5.23 
27.00 
29.88 
5.46 
30.00 
 .001 
Conscientiousness (n = 307) Mean 
SD 
Median 
31.36 
7.10 
32.00 
29.99 
7.27 
30.00 
31.88 
6.98 
32.50 
  .019 
HIV-SES 
(Total score) 
Mean 
SD 
Median 
216.16 
36.66 
224.00 
206.02 
40.00 
215.00 
219.91 
34.70 
228.90 
 .010 
Note. † Significance testing for differences between AUDIT-C positive /negative groups, assessed with Mann-
Whitney U tests for continuous variables and chi-square tests or Fisher exact test, where appropriate.  
SD = standard deviation 
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4.4.2 Multivariate analysis with confounding variables 
In final regression models controlling only for potential confounding variables, a positive screen 
on the AUDIT-C predicted dose adherence and days under-dosing. Results from the final models 
are presented in Table 6. The overall regression equation (with confounding variables) for dose 
adherence was statistically significant F (3, 303) = 7.801, p = .000, and this model accounted for 
7.2% of the variance in dose adherence. Both individual blocks were significant for predicting 
adherence. In the first block (confounding variables), crack use and conscientiousness were 
identified as significant predictors. As the second block, AUDIT-C status increased the model R2 
by 2%.  
Similarly, the overall regression equation for days under-dosing was significant,              
F (2, 307) = 8.543, p = .000, and accounted for 5.3% of the variance in days under-dosing. 
Again, in the first block (confounding variables), self-efficacy was identified as a significant 
independent predictor, and as the second block, AUDIT-C status increased the model R2 by 
1.6%.  
A positive screen on the AUDIT-3 did not significantly predict dose adherence, day 
adherence, or days under-dosing; however, a relatively similar pattern of significant independent 
predictors emerged by type of adherence. Results for the final models are presented in Table 7. 
Additionally, in logistic regression analyses, neither AUDIT-C status nor AUDIT-3 status was 
significantly related to the dichotomized days over-dosing variable, although a trend relationship 
(p = .089) was detected for AUDIT-C status (data not shown). 
 
Table 6: Linear regression results for adherence predicted by AUDIT-C positive status controlling for statistically 
significant confounders 
 
                                                                                           b                   95% CI for b            p         R2      R2Δ 
Dose adherence†       
Block 1 Crack use  .682 (.024 to 1.340) .042 
 Conscientiousness -.044 (-.077 to -0.11) .010 .052 .052 
Block 2 AUDIT-C status  .685 (.148 to 1.223) .013 .072 .020 
Day adherence† 
Block 1 Agreeableness -.054 (-.109 to .002) .059   
 Conscientiousness -.040 (-.084 to .005) .079   
 Self-efficacy -.009 (-.017 to .000) .046 .070 .070 
Block 2 AUDIT-C status  .300 (-.350 to .951) .364 .073 .003 
Days under-dosing 
Block 1 Self-efficacy -.015 (-.025 to -.005) .002 .037 .037 
Block 2 AUDIT-C status  .962 (.136 to 1.788) .023 .053 .016 
Note. b = regression coefficient; CI = confidence interval; p = p-value;  R2 = correlation coefficient, 
squared;  R2Δ = change in R2 with addition of AUDIT screening status in Block 2 
†Signs of coefficients and CIs are negative due to reflected square root transformation of dose & day 
adherence variables.  Coding of AUDIT-C status (negative = 0, positive = 1) 
 
4.4.3 Multivariate analysis with confounding variables and covariates  
When potential covariates were also permitted to enter the models, the ability of both AUDIT-C 
status and AUDIT-3 status to predict all three types of adherence was improved.  Additionally, 
AUDIT-C status again significantly predicted dose adherence and days under-dosing, while 
AUDIT-3 status demonstrated trend significance for predicting dose adherence. Results from the 
final models are presented in Tables 8 and 9.  
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Table 7:  Linear regression results for adherence predicted by AUDIT-3 positive status controlling for 
statistically significant confounders 
 
                                                                                           b                   95% CI for b            p         R2      R2Δ 
Dose adherence† 
Block 1 CD4 count -.001 (-.001 to .000) .044   
 Crack use  .756 (.084 to 1.429) .028   
 Conscientiousness -.037 (-.071 to -.003) .032 .069 .069 
Block 2 AUDIT-3 status  .333 (-.184 to .849) .206 .075 .005 
Day adherence† 
Block 1 Agreeableness -.054 (-.110 to .001) .055   
 Conscientiousness -.039 (-.084 to .005) .080   
 Self-efficacy -.008 (-.017 to .000) .052 .070 .070 
Block 2 AUDIT-3 status  .283 (-.331 to .898) .365 .073 .003 
Days under-dosing 
Block 1 Conscientiousness -.063 (-.118 to -.008) .026   
 Self-efficacy -.012 (-.023 to -.001) .032 .054 .054 
          Block 2 AUDIT-3 status  .414 (-.377 to 1.204) .304 .057 .003 
Note. b = regression coefficient; CI = confidence interval; p = p-value;  R2 = correlation coefficient, 
squared;  R2Δ = change in R2 with addition of AUDIT screening status in Block 2 
†Signs of coefficients and CIs are negative due to reflected square root transformation of dose & day 
adherence variables.  Coding of AUDIT-3 status (negative = 0, positive = 1) 
 
 
In this series of regressions, the overall regression equation for dose adherence (with 
confounding variables and covariates) was statistically significant F (5, 286) = 8.194, p = .000, 
and this model accounted for 13.5% of the variance in dose adherence. Both individual blocks 
were significant for predicting adherence. In the first block (confounding variables plus 
covariates), undetectable viral load, white race, older age, and higher conscientiousness scores 
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remained significant independent predictors of adherence. As the second block, AUDIT-C status 
increased the model R2 by 2.5%.  
Similarly, the overall regression equation for days under-dosing was significant,              
F (4, 287) = 8.879, p = .000, and accounted for 10.9% of the variance in days under-dosing. In 
the first block (confounding variables + covariates), significant independent predictors of days 
under-dosing were detectable viral load, nonwhite race, and lower conscientiousness, and as the 
second block, AUDIT-C status increased the model R2 by 1.7%.  
4.5 COMMENT/CONCLUSIONS 
 
The degree to which alcohol added to the prediction of adherence was mixed, varying by type of 
adherence and alcohol screening status (AUDIT-C positive/negative, AUDIT-3 
positive/negative), and, according to the inclusion of confounding and covariate factors in the 
models.  In the final models, a variety of sociodemographic, clinical, and psychosocial variables 
appeared as significant independent predictors of adherence. 
Overall, the varied nature of these findings parallels that of existing studies on the 
relationship between alcohol and adherence. Other investigators who have used EEM technology 
have typically assessed dose adherence, and have reported significant, nonsignificant, and mixed 
relationships with alcohol use. Numerous EEM studies have reported alcohol consumption to be 
a significant independent predictor of adherence, along with factors such as race, age, and CD4 
count (Golin et al., 2002; Howard et al., 2002). In another, nondrinkers over the past year had 
Table 8: Linear regression results for adherence predicted by AUDIT-C positive status controlling for statistically 
significant covariates and confounders 
 
                                                                                           b                   95% CI for b            p         R2      R2Δ 
Dose adherence† 
 Block 1 Viral load detectable  .802 (.341 to 1.262) .001   
 Race  .592 (.132 to 1.051) .012   
 Age -.030 (-.060 to -.001) .042   
 Conscientiousness -.048 (-.080 to -.015) .004 .110 .110 
Block 2 AUDIT-C status .749 (2.33 to 1.266) .005 .135 .025 
Day adherence† 
Block 1 Viral load detectable 1.021 (.446 to 1.595) .001   
 Race   .684 (.117 to 1.252) .018   
 Agreeableness -.051 (-.106 to .004) .070   
 Conscientiousness -.045 (-.089 to .000) .048   
 Self-efficacy -.007 (-.015 to .002) .108 .129 .129 
 Block 2 AUDIT-C status .349 (-.302 to 1.000) .292 .132 .003 
Days under-dosing 
Block 1 Viral load detectable 1.201 (.463 to 1.938) .002   
 Race 1.010 (.276 to 1.743) .007   
 Conscientiousness -.084 (-.136 to -.032) .002 .092 .092 
Block 2 AUDIT-C status .978 (.151 to 1.805) .021 .109 .017 
Note. b = regression coefficient; CI = confidence interval; p = p-value;  R2 = correlation coefficient, 
squared;  R2Δ = change in R2 with addition of AUDIT screening status in Block 2 
†Signs of coefficients and CIs are negative due to reflected square root transformation of dose & day 
adherence variables.  Coding of AUDIT-C status (negative = 0, positive = 1) 
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Table 9: Linear regression results for adherence predicted by AUDIT-3 positive status controlling for statistically 
significant covariates and confounders 
 
                                                                                          b                   95% CI for b            p         R2      R2Δ 
Dose adherence† 
 Block 1 Viral load detectable   .788 (.323 to 1.253) .001   
 Age -.031 (-.060 to -.001) .041   
 Race  .595 (.132 to 1.058)  .012   
 Conscientiousness    - .050 (-.083 to -.018)   .003   .110   .110
Block 2 AUDIT-3 status  .431 (-.061 to .922)  .086 .119 .119
 Day adherence† 
Block 1 Viral load detectable 1.087 (.518 to 1.657)    .000   
 Race  .677 (.108 to 1.246) .020   
 Agreeableness -.057 (-.112 to -.002) .042   
 Conscientiousness -.056 (-.098 to -.013) .010 .119 .119
Block 2 AUDIT-3 status  .393 (-.214 to 1.000) .203 .124 .005
Days under-dosing 
Block 1 Viral load detectable 1.186 (.445 to 1.928) .002   
 Race 1.014 (.277 to 1.752) .007 
 Conscientiousness -.087 (-.139 to -.034)    .001  .092   .092
              Block 2 AUDIT-3 status .622 (-.161 to 1.404) .119 .100 .008
Note. b = regression coefficient; CI = confidence interval; p = p-value;  R2 = correlation coefficient, 
squared;  R2Δ = change in R2 with addition of AUDIT screening status in Block 2 
†Signs of coefficients and CIs are negative due to reflected square root transformation of dose & day 
adherence variables.  Coding of AUDIT-3 status (negative = 0, positive = 1) 
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significantly greater odds of adherence than drinkers (Holmes, Bilker, Wang, Chapman, & 
Gross, 2007). However, other researchers have found no relationship between adherence and 
alcohol use, abuse, or dependence (Halkitis, Kutnick, & Slater, 2005; Hinkin et al., 2004; 
Paterson, et al., 2000).  Finally, other studies with internally mixed results underscore the 
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presumed complexity of the alcohol-adherence relationship. For example, Arnsten and 
colleagues (2002) reported that alcohol use several times per week or every day was not 
significantly related to adherence, but significant differences in adherence did emerge between 
those who did/did not endorse an alcohol or drug coping style (i.e., those who endorsed using 
alcohol or drugs to get through problems or make themselves feel better).  Berg et al. (2004) 
detected no significant differences in median adherence rates for those with and without problem 
alcohol use (>5 drinks per occasion and/or drinking several days per week or every day), 
however, a significant interaction emerged where women with problem alcohol use were 
significantly less adherent than men with problem use. 
Other adherence investigators have used the AUDIT to determine study eligibility or 
categorize alcohol consumption patterns. Cook et al (2001) used scores of >8 on the full AUDIT 
to establish “hazardous drinking” patterns, and defined “binge drinking” as >6 drinks per 
occasion for women, and >5 drinks per occasion for women, and reported that hazardous 
drinking was significantly associated with self-reported taking of medications off schedule 
during the previous week, but not with self reports of missing a dose in the previous 24 hours. 
Additionally, binge drinking was not significantly associated with either taking medications off 
schedule or missing doses. Finally, age, race, and crack/cocaine use were also among the 
potential confounding variables controlled for in multivariate analyses; however, the particular 
variables included in each model were not specified.  Parsons, Rosof, and Mustanski (2007) used 
a cut-off score of 8 on the full AUDIT as an inclusion criterion for their study of ART adherence 
among HIV+ outpatients with existing alcohol problems; however, as one of three alcohol-
related factors, total AUDIT score was not significantly associated with odds of having perfect 
self-reported adherence over the previous 2 weeks.  
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While others have used alcohol screening tests, and specifically, the AUDIT, to 
categorize drinking patterns or generate study samples, to our knowledge, this study is the first to 
consider the ability of an alcohol screening test result (i.e., positive/negative) to predict 
medication adherence. The brevity of the AUDIT-C and the AUDIT-3 (compared to the full 
AUDIT and other alcohol screening instruments) make them particularly appealing for 
widespread use by direct care providers. The AUDIT-C and AUDIT-3 show potential as indirect 
screening tools for both at-risk drinking and ART nonadherence, understanding that by nature, 
this screening function implies the need for further, more in-depth evaluation of both behavior 
sets.  Importantly, the AUDIT-C is a screening instrument for hazardous and harmful drinking; it 
is designed to be sensitive at the potential expense of specificity, and is not diagnostic for alcohol 
abuse or dependence. Importantly, because this study sought to examine the impact of at-risk 
drinking on ART adherence (a wider spectrum than simply alcohol abuse and dependence 
disorders), we used the lower set of gender-specific scoring thresholds for the AUDIT-C, i.e., >4 
for men and >3 for women (Bradley et al; 2003; Reinert & Allen, 2007).  
The lower ability of the AUDIT-3 to provide additional prediction of adherence was 
somewhat surprising; given its embeddedness within the AUDIT-C, greater sensitivity for 
predicting adherence would be expected compared to the AUDIT-C. Despite a precedent having 
being set for the dichotomization of the AUDIT-3 in the manner selected (i.e., essentially, binge 
ever/never in the past year) (Bradley, 2007; Gordon, 2001), a different cut point, e.g., “within the 
last 3 months” (Williams & Vinson, 2001) may have yielded greater sensitivity for the detection 
of an effect on adherence. Additionally, other proponents of single question alcohol screening 
have noted improvements in sensitivity for the detection of hazardous drinking and/or alcohol 
use disorders when such questions are modified to inquire about >5 drinks per occasion for men 
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and >4 drinks for women (Bradley et al., 2003; Williams & Vinson, 2001). However, as this 
study was an analysis of existing data, such adjustments were not feasible in the current analyses. 
In the current study, the nonsignificant relationship between alcohol and some of the 
adherence variables is potentially attributable to differential effects of alcohol on different 
aspects of medication-taking; correspondingly high degrees of conscientiousness and/or self-
efficacy (despite at-risk drinking patterns); or inherent constraints of the data or methods used. 
However, still another possible explanation involves consideration of perceptions and attitudes 
about alcohol use and ART.  For example, one qualitative investigation of beliefs about alcohol, 
ART, and HIV disease progression found heavy drinkers to be significantly less likely to 
perceive  drinking alcohol with ART as harmful, and less likely to indicate that they would skip 
or miss their medication if they had been drinking (Sankar et al, 2007).  In turn, heavy drinkers 
may not be skipping or missing ART doses, and would thus, by EEM accounts, be represented as 
adherent. 
The emergence of conscientiousness and self-efficacy as significant independent 
predictors of adherence deserves comment. First, low conscientiousness has previously been 
associated with both alcohol use (Hopwood et al., 2007; Martin & Scher, 1994; Loukas, Krull, 
Chassin, & Carle, 2000) and HIV disease progression. Using the NEO-FFI, O’Cleirigh, Ironson, 
Weiss, and Costa (2007) found conscientiousness to be significantly related to change in both 
CD4 count and viral load level over a one year time span, however, neither adherence nor 
depression significantly mediated these relationships. Using the NEO Personality Inventory—
Revised (NEO-PI-R), the longer, parent instrument to the NEO-FFI, the same team also found 
conscientiousness to be significantly associated with slower rates of viral load increase over a 
longer, 4-year time span (Ironson, O’Cleirigh, Weis, Schneiderman, & Costa, 2008). These 
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findings, in conjunction with significant correlations between conscientiousness and missed ART 
doses as well as between conscientiousness and depression, social support, and cocaine/other 
substance, have raised the possibility that conscientiousness exerts its influence on HIV/AIDS 
disease progression through other meditational pathways which incorporate these variables, 
including alcohol use (O’Cleirigh, Ironson, Weiss, & Costa, 2007; Ironson, O’Cleirigh, Weis, 
Schneiderman, & Costa, 2008). Our findings further suggest the presence of interactions between 
conscientiousness, viral load, and alcohol use and further substantiate the need for meditational 
analyses to explore the specific mechanisms through which adherence, alcohol/substance use, 
psychosocial, and disease-related factors exert their influence on one another.  
Secondly, across studies, self-efficacy consistently predicts ART adherence (Ammassari, 
2002). (Catz et al., 2000; Cha et al., 2007; Halkitis et al., 2005; Johnson et al., 2006; 
Luszczynska et al., 2007; Simoni et al., 2006). The often concomitant appearance of self-efficacy 
and conscientiousness as independent predictors of adherence speaks to their partial conceptual 
overlap.  However, the two concepts do address different dimensions of individual behavior; 
self-efficacy is task-specific and reflects confidence or beliefs about one’s ability to perform a 
given behavior, while conscientiousness reflects a more global personality orientation reflecting 
attributes such as self-discipline, competence, order, and dependability. Self-efficacy may have 
failed to appear as an independent predictor of dose adherence due to the broad, relatively coarse 
calculation of this type of adherence. Another possible explanation is that the measure of self-
efficacy used in this study (i.e., HIV Self-efficacy Scale total score, as opposed to the more 
specific self-efficacy beliefs scale of the same measure) reduced the precision with which self-
efficacy could be measured. 
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The results of this study require consideration of several limitations. First, because of the 
small number of AUDIT-C positive individuals (n = 84) versus AUDIT-C negative individuals 
(n = 224), power was limited to detect differences in sociodemographic, psychosocial, and 
adherence variables by alcohol status group. In a similar vein, the effect sizes for the regression 
analyses with statistically significant results were small, ranging from .0102 – .0289, reflecting 
that alcohol screening status explained only an additional 1-3% of the variance in adherence after 
controlling for confounders and/or covariates. The corresponding clinical significance varies 
according to the medication regimen considered. For example, assuming a twice-daily one pill 
regimen and the two week assessment period, each pill would represent 3.57% of the dose 
adherence score.  Detecting an effect size of .02 would thus mean that AUDIT-C status 
explained a difference equal to less than half of a pill. Additionally, with the exception of 
AUDIT-C status predicting dose adherence after controlling for confounders and covariates (the 
most highly significant result), most of the analyses were underpowered to detect such small 
changes in the amount of variance added to the prediction of adherence by AUDIT-C. For most 
analyses (depending on the number of predictors in the model), the detectable effect size for 
achieving adequate power (80%) needed to be .025.  
Because substance use was not an initial primary variable of interest in the PS, the 
amount of variability in the sample in terms of alcohol and drug use was relatively low.  
Secondly, because of its purpose as a screening test, the AUDIT-C is designed to be sensitive at 
the expense of specificity; therefore, the number of individuals who screened positive on the 
AUDIT-C may have been inflated.  The use of gender-specific cut-offs may also have increased 
the number of false-positive screens in this study. In contrast, however, the inclusion of 
nondrinkers in the analysis, i.e., those with total scores of zero on the AUDIT-C, may have 
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artificially increased specificity. Similar considerations apply to the designation of AUDIT-3 
positive individuals. Issues related to over-sensitivity of the AUDIT-C are potentially less 
problematic in the clinical setting, where the aim might be to capture as many individuals with 
at-risk drinking patterns as possible for further alcohol evaluation or individualized adherence 
counseling. Finally, AUDIT-C and AUDIT-3 responses were extracted from responses to the full 
AUDIT. While other investigations have shown that in this format, the AUDIT-C does have high 
levels of sensitivity and specificity for at-risk drinking and alcohol use disorders (Dawson, 2005; 
Gordon, 2001), participant responses may have been different were these items administered 
independently of the remaining AUDIT items and drug-related questions. 
Several characteristics of the sample underscore the extent to which these findings may 
be generalized; first is the relatively high mean rates of adherence at baseline (79.43 + 31.63), 
though similar rates of mean dose adherence (70-80%) have been reported in other ART 
adherence studies which have used EEM (Hinkin, 2004; Golin, 2002; Paterson, 2000). 
Additionally, participants were individuals engaged in care, and highly motivated to participate 
in a long-term adherence trial. The general rate of alcohol consumption (63.3%) appears to be 
higher than rates of alcohol use among PWHIV reported previously, which range from 40-55% 
(Galvan, 20002; Tucker, 2003; Conigliaro, Justice, Gordon, & Bryant, 2006;  Arnsten et al., 
2002; Chander Lau, & Moore, 2006; Samet, Horton, Meli, Freedberg, & Palepu, 2004, Cook et 
al., 2001). Placing the sample’s rates of AUDIT-C positive (27.1%) and AUDIT-3 positive 
(34.2%) individuals in the context of previous research is considerably more challenging due to 
wide variation in definition and determination of alcohol use patterns.  Alcohol consumption 
may be categorized in terms of quantity/frequency (“moderate,” “frequent,” “heavy” drinking), 
risk (“at-risk/risky” drinking) or consequences (“problematic” drinking); in terms of DSM-IV 
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alcohol use disorders e.g., abuse/dependence), or subsumed under the broader variable of 
“substance abuse.” Again, in extant studies, rates of hazardous use and/or binge use generally 
range from 10-20% (Cook et al., 2001; Chander, Lau, & Moore, 2006; Conigliaro, 2003), but 
have been reported as high as 30% (Berg et al., 2004).  Given the AUDIT-C’s identity as a 
screening tool, and that fact that it specifically inquires about alcohol use over the past year, the 
higher rates of hazardous and binge use in this sample are not surprising. 
Future investigations should consider sampling strategies for improved variability in 
alcohol consumption patterns, the use of a modified AUDIT-3 question as described above, and 
the use of a non-derived format of the AUDIT-C and/or the AUDIT-3.  Future studies may also 
be enhanced through the use of self-report adherence data in conjunction with the use of EEM 
technology. While EEM is often considered the “gold standard” in terms of reliable and 
objective adherence assessment, and is more highly correlated with viral load and CD4 count, it 
relies on the assumption that cap openings reflect medication ingestion, and its cost often makes 
its use prohibitive in research as well as clinical practice. The use of multiple assessment 
modalities is often recommended as the ideal approach for explaining the greatest amount of 
variance in adherence (Berg & Arnsten, 2006; Pearson, Simoni, Hoff, Kurth, & Martin, 2007). 
A more nuanced understanding of the influence of alcohol on medication-taking, and 
accurate detection of problematic alcohol use and/or adherence carry additional implications for 
clinicians.  What does improved understanding and detection mean for counseling the individual 
patient about both alcohol use and adherence? In one study, interviews with these patients’ HIV 
care providers revealed that clinician rates of addressing alcohol consumption and ART varied 
widely as did the specific advice given (Sankar et al., 2007). Additionally, NIH guidelines for the 
use of antiretrovirals make limited mention of any direct impact of alcohol on ART outside of 
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recommendations to avoid the use of alcohol with Abacavir, and general recommendations for 
individuals with hepatitis B and/or hepatitis C co-infection to avoid alcohol due to increased risk 
of hepatoxicity (2008 NIH Use of ART guidelines--web). Collectively, these findings are not 
surprising given the inconclusive nature of the research on alcohol’s effects on viral replication, 
immune suppression, cognitive function, comorbid illness, and ART effectiveness (Bryant, 
2006), and underscore the need for tandem investigations on the biophysical impact of alcohol 
use in the context of HIV/AIDS. 
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5.0  MANUSCRIPT #2—AN EVALUATION OF THE PSYCHOMETRIC 
PROPERTIES AND FACTOR STRUCTURE OF THE AUDIT-C IN PERSONS WITH 
HIV/AIDS 
NOTE: This is a pre-publication version of this manuscript; please contact the 
primary author prior to citation.  
 
5.1 ABSTRACT 
Background: The Alcohol Use Disorders Identification Test—Consumption (AUDIT-C) is 
widely endorsed as a brief alcohol screening instrument for primary care patients, however, 
examinations of its psychometric properties and factor structure have been limited, particularly 
across gender and racial subgroups, and in persons with HIV/AIDS (PWHIV). Methods: 
AUDIT-C data were extracted from a randomized controlled trial which looked at the effect of 
an antiretroviral medication adherence intervention over time in PWHIV. Internal consistency 
and 3-month test-retest reliability were estimated using Cronbach’s alpha, the Spearman-Brown 
coefficient, and Wilcoxon rank-sum test. Indirect validity analysis of those with inconsistent 
AUDIT-C responses was performed with logistic regression. Multi-sample confirmatory factor 
analyses (CFAs) were conducted to replicate a single factor structure of the AUDIT-C and 
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evaluate its consistency across gender and racial (white/nonwhite) subgroups. Results: The 
AUDIT-C demonstrated adequate internal consistency (α = .835) and test-retest reliability (r = 
.734) in the total sample and gender and racial subgroups. Wilcoxon signed-rank tests test-retest 
reliability were generally nonsignficant by group, suggesting the stability of AUDIT-C scores.  
Whites showed borderline significance (Z = - 1.96, p = .055), suggesting a score change over 
time. For validity checks predicting the odds of having inconsistent AUDIT-C responses, opioid 
users had 3 times greater odds of having inconsistent AUDIT-C data [OR = 3.139, 95% CI 
(.1267 – 7.777), p =.013]. Participants with higher conscientiousness scores were also more 
likely to have inconsistent data [OR = 1.053, 95% CI (1.006 – 1.103), p = .027]. Multi-sample 
confirmatory factor analysis revealed factor invariance for sex, but the best-fitting model for race 
allowed partial invariance where AUDIT-C item 3 (episodic heavy drinking) was free to vary 
across whites/nonwhites, X2 (3, 310) = 1.818, p = .6111. Conclusion: Generally speaking, the 
AUDIT-C appears to be reliable in this sample of PWHIV. Researchers who modify the AUDIT-
C may risk compromising validity, particularly in samples including drug users. Further attention 
to the cultural equivalence of the AUDIT-C may be warranted. Findings require confirmation 
with larger samples having greater variability in alcohol use. 
5.2 INTRODUCTION 
The Alcohol Use Disorders Identification Test—Consumption (AUDIT-C) (Bush, 1998) is a 
derived form of the Alcohol Use Disorders Identification Test (AUDIT) developed by the World 
Health Organization to screen for hazardous and harmful drinking among primary care patients 
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(Babor, 2001; Saunders, 1993). While the complete AUDIT instrument is intended to assess 
three conceptually distinct factors associated with hazardous and harmful drinking, i.e., alcohol 
consumption, alcohol dependence, and alcohol-related consequences, the AUDIT-C was 
intended to be a more efficient, but equally valid tool and is thus comprised of only  the first 
three consumption–related items from the AUDIT.  Accordingly, the AUDIT-C assesses 
frequency of drinking, quantity of alcohol consumed on a typical drinking day, and the frequency 
of drinking six or more drinks on a single occasion.  
The AUDIT-C is widely recommended for alcohol screening (NIAAA, 2005), and is used 
by the U.S. Department of Veterans Affairs. While numerous sensitivity, specificity, and general 
performance analyses have been conducted on the AUDIT-C (Bradley, Bush, Epler, Dobie, 
Davis, Sporleder, Maynard, Burman, & Kivlahan, 2003, Bradley, DeBenedetti, Volk, Williams, 
Frank, & Kivlahan, 2007;  Bush, Kivlahan, McDonell, Fihn, & Bradley, 1998; Dawson, Grant, & 
Stinson, 2005; Frank, DeBenedetti, Volk, Williams, Kivlahan, & Bradley, 2008; Gordon, Maisto, 
McNeil, Kraemer, Conigliaro, Kelley, & Conigliaro, 2001), limited data exist on its 
psychometric properties (Bradley, McDonell, Bush, Kivlahan, Diehr, & Fihn, 1998), particularly 
in U.S. samples; no psychometric evaluations to date have used samples of persons with 
HIV/AIDS (PWHIV). Furthermore, prior studies have not attempted to replicate the presumed 
single consumption factor of the AUDIT-C, nor attempted to ensure the stability of such a 
consumption factor across gender and racial groups. 
The overall purpose of this study was to evaluate the reliability and factor structure of the 
AUDIT-C using a sample of persons with HIV/AIDS. In particular, we sought to: 1) generate 
reliability estimates for the AUDIT-C with attention to differences across gender and race;        
2) determine if the AUDIT-C’s single factor structure is consistent across males and females, and 
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whites and nonwhites; and 3) determine if any of the individual items on the AUDIT-C load 
differently for women and/or nonwhite individuals.  
5.3 MATERIALS AND METHODS 
5.3.1 Parent Study Overview 
This study used existing data from a randomized controlled trial entitled “Adherence to Protease 
Inhibitors” (R01-NR04749, National Institute of Nursing Research, Principal Investigator, Dr. 
Judith Erlen). The “parent study” (PS) tested the efficacy of two cognitive-behavioral ART 
adherence interventions over time and examined the impact of adherence on clinical outcomes 
and quality of life, and has been previously described in an earlier manuscript under review 
(Sections 4.3.1 – 4.3.3).  
This study used data from the Baseline and Time 2 (12 weeks-post intervention) data 
collection time points, collected by the PS from 2003-2008. All data were de-identified by the PS 
data manager according to guidelines established by the Complete Health Insurance Portability 
and Accountability Act (HIPAA) of 1996. The study thus met criteria for Exemption-4 status 
under Health and Human Services regulations in 45 CFR 46.101(b)(4), and was granted exempt 
approval by the University of Pittsburgh Institutional Review Board (IRB) (Appendix C). The PS 
was previously approved by the University of Pittsburgh IRB and other site boards. All PS 
participants provided written informed consent.  
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5.3.2 Measures 
All AUDIT-C data was extracted from the self-report version of the full AUDIT used by the PS 
to assess alcohol use. Scoring of the AUDIT-C is based on 5 Likert-style response alternatives. A 
range of 0-4 points is possible for each item; total scores thus range from 0-12.  Men with total 
AUDIT-C scores >4, and women with total scores >3 were classified as “AUDIT-C positive” 
and those with scores below the threshold were considered “AUDIT-C negative” (Bradley et al., 
2003; Bradley et al., 2007; Reinert & Allen, 2007).  All questionnaires were completed by PS 
participants in mailed packets containing all of the PS measures for that time point; participants 
received modest remuneration for packet completion and return. 
Because the AUDIT-C is comprised of only three items, individuals with missing or 
inconsistent AUDIT-C data at either time point were excluded from all of the current analyses. 
Inconsistent responses included, for example, a response of “never” to AUDIT-C question 1 
(“How often do you have a drink containing alcohol?”) along with the selection of a quantity 
greater than zero in response to AUDIT-C question 2 (“How many drinks containing alcohol do 
you have on a typical day when you are drinking?”).  The final sample for the current study 
included 310 adult outpatients with HIV/AIDS from southwestern PA and northeastern OH. 
Several modifications to the data were made for different analyses within the current 
study.  First, for the current multi-sample confirmatory factor analyses (CFAs) only, AUDIT-C 
responses for each item were collapsed (recoded) due to small numbers of participants in some 
response categories (Table 10).  Secondly, for analyses by gender and race, variables were coded 
in the following manner.  Gender was dichotomized, with males serving as the reference group. 
PS individuals self-identified as one or more of the following races by indicating Yes/No/Don’t 
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Know: “White,” “Black or African American,” “American Indian,”  “Alaska Native,” “Native 
Hawaiian or other Pacific Islander,” “Asian,” or “Other.” Race was then dichotomized by the PS 
as white/nonwhite, with white serving as the reference group. Individuals selecting more than 
one race or “Other” were considered nonwhite. Consistent with NIH categorization of race/, 
Hispanic/Latino descent was considered an ethnicity (National Institutes of Health, 2001). 
Therefore, individuals self-identifying as Hispanic/Latino selected a racial background and were 
represented within the race categories.  
Finally, the PS investigators made two modifications to the AUDIT, from which the 
current study’s AUDIT-C data were derived. First, in question 1, they omitted the command to 
skip questions 2 and 3 if the individual responded “never” to question 1. Second, they added a “0 
drinks” option to question 2, which inquires about the quantity of alcohol typically consumed.  
Other researchers have made the similar modifications to one or more AUDIT-C questions in 
order to improve item response rates and improve the clarity of the questions (Bradley et al., 
2003). For example, Gordon et al. (2001) removed the skip command but then replaced it 
because its omission had limited the number of responses to other alcohol instruments in the 
study. Others have added, deleted, or modified response options in questions 1 through 3 (Bush 
et al., 1998; Bradley et al., 1998; Bradley et al., 2003), often based on pre-testing with 
participants or on initial feedback early in the study (Gordon et al., 2001; Bradley et al., 1998). 
For example, Bradley et al. (1998) increased the final response option on question 1 from “4 or 
more times a week” to “6 or more times a week,” and added a “none” option to question 2. Many 
of these modifications are minor, but may nonetheless create additional, unanticipated problems 
with the data.  
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Data screening procedures revealed that 14% of the sample had inconsistent responses to 
the AUDIT-C at one or both time points. Three patterns of inconsistent data were detected in 
data screening. In the first pattern (81.3%), individuals acknowledged alcohol use in question 1 
(e.g., endorsed drinking “2 or 4 times a month), but then selected the “0 drinks” option in 
question 2 which asks about the number of drinks consumed on a typical drinking day. In the 
second pattern (9.3%), individuals denied alcohol use in question 1 (e.g., responded “never”), but 
then selected a typical quantity in question 2 and/or endorsed consuming 6 or more drinks on a 
single occasion in question 3. In the third pattern (9.3%), individuals denied alcohol use in 
question 1, but endorsed some degree of binge drinking in question 3.  
Because these inconsistent responses would have impeded proper categorization of 
individuals as AUDIT-C positive/negative and/or AUDIT-3 positive/negative by requiring the 
summation of  potentially invalid data in order to obtain total AUDIT-C scores, PS participants 
with inconsistent AUDIT data were removed from all analyses. Examination of group 
differences between those who had any inconsistent AUDIT-C data and those who did not 
provided an opportunity to address the validity of the instrument as inconsistent data appeared to 
be at least partially related to changes made to the AUDIT by the PS. 
 
5.3.3 Procedures 
Datasets by measure were de-identified and extracted from the PS master database/server and 
merged into a common file for analysis using SPSS, version 15.0 (SPSS Inc., 1989-2004).  
Univariate statistics, internal consistency estimates via Cronbach’s alpha, and test-retest analyses 
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via Wilcoxon signed rank test and Spearman’s r were performed using SPSS. Confirmatory 
factor analysis using path analysis was conducted using Mplus, version 5.1 (Muthen & Muthen, 
2007). The level of significance for all significance tests was set at .05. 
5.3.3.1 Reliability estimates 
Internal consistency of the total AUDIT-C and its individual items was estimated for the total 
sample and for each gender and racial group using Cronbach’s alpha and the original non-
collapsed responses to the AUDIT-C. Three–month test-retest reliability was estimated using 
Spearman’s rho and the Wilcoxon signed-rank test; nonparametric tests were required due to 
violations in the assumptions of normality in AUDIT-C total score at both time points. Because 
alcohol use over time could have potentially been influenced by the PS adherence interventions 
(particularly the individualized intervention), only participants from the PS’s usual care 
condition (n=88) were included in test-retest reliability analysis of the AUDIT-C.   
5.3.3.2 Inconsistent AUDIT-C data analysis 
A series of bivariate logistic regression models were performed in order to develop a model for 
the prediction of having inconsistent AUDIT-C data.  In data screening, an ordinal-level code 
was created where individuals were classified as having consistent data (0), inconsistent AUDIT-
C data at baseline (1), inconsistent data at Time 2 (2), or inconsistent data at both (3).  This code 
was then dichotomized as Inconsistent Yes/No, where those with consistent AUDIT-C data were 
coded 0 and individuals with inconsistent data at any or both time points were coded 1.   
Baseline sociodemographic and other variables potentially associated with lack of 
question comprehension were then entered into simple logistic regression models for the 
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prediction of having inconsistent AUDIT-C data. Univariate logistic regression analysis was 
performed using the following variables: gender; age; race (white/nonwhite); years of formal 
education; total score on the Beck Depression Inventory II (BDI-II) (Beck, 1996); the five 
subscale scores from the NEO-FFI Five Factor Personality Inventory (Neuroticism, Extraversion, 
Openness, Agreeableness, Conscientiousness) (Costa & McCrae, 1992); total score on the PS-
developed HIV Self-efficacy Scale (HIV-SES); and dichotomized drug use scores (yes/no) for 
marijuana, cocaine, crack, heroin, opioids, ecstasy, “poppers,” stimulants, hallucinogens, and 
inhalants. A full description of these measures is also included in the aforementioned manuscript 
currently under review (Sections 4.3.1 – 4.3.3). Variables reaching significance or near 
significance in these analyses   (p < .10) were then simultaneously entered into a multivariate 
model for the derivation of odds ratios. Model fit was evaluated with the Hosmer-Lemeshow test 
where a good model is reflected by a nonsignificant (>.05) chi square statistic (Tabachnik & 
Fidell, 2001). Nagelkerke’s R2 statistic provided an estimate of the proportion of variance in 
having inconsistent AUDIT-C data explained by the final model. Comparison of classification 
tables served as an indicator of the accuracy of group membership prediction. 
5.3.3.3 Confirmatory factor analysis 
Only baseline AUDIT-C data were used for confirmatory factor analysis (CFA). Two separate 
sets of multi-sample CFAs were conducted (Byrne, 1989; Joreskog, 1969); one by gender group 
(male/female), one by racial group (white/nonwhite). Variance adjusted weighted least squares 
(WLSMV) estimation was used as the AUDIT-C is based on ordinal-level data and because the 
sample size was small. Baseline models using the collapsed AUDIT-C items were created for the 
total sample, males, females, whites, and nonwhites in order to specify the model to be 
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confirmed across subgroups. Factor structures and factor loadings were then constrained to be 
equal (invariant) across gender and racial groups and these more restrictive models were 
compared to the baseline model(s).  Chi-square tests, Root Mean Square Error of Approximation 
(RMSEA), and Weighted Root Mean Square Residual (WRMR) served as goodness-of-fit 
indices for how well the proposed models corresponded to the data. Acceptable fit between the 
proposed model and the data are reflected by a nonsignificant chi-square statistic, by RMSEA 
values < .05 - .08, and by WRMR values < .90 (Loehlin, 2004; Muthen & Muthen, 2007). 
5.4 RESULTS 
In this sample of PWHIV, 68.4% of the participants were male, 31.6% were female, 41.3% were 
white, and 58.7% were nonwhite. Mean and median AUDIT-C scores at the two time points 
were identical for the total sample; M, 2.15 (SD=2.57-2.60), Mdn, 1.00 (Table 10). Overall, 
scores were significantly lower for females than for males (Mann-Whitney U =  4953.5, p = 
.036). Scores were also lower for nonwhites compared to whites, however, this difference was 
not statistically significant (Mann-Whitney U = 6069.0, p = .366).  Mean AUDIT-C scores were 
also similar across gender and racial groups over time; however, scores demonstrated an upward 
trend for males and nonwhites, and a downward trend for females and whites. Response 
distributions for individual collapsed AUDIT-C items by racial and gender groups are shown in 
Table 11.  
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Table 10: Descriptive statistics for AUDIT-C scores over time by gender and racial groups (n = 233) 
 Baseline 
AUDIT-C total scores 
 
   M                 SD     Mdn     Range 
Time 2 
AUDIT-C total scores 
(3 months) 
        M                SD             Mdn      Range 
 
Total sample  
(n = 233) 
 
2.15               2.60 
 
1.00 
 
12 
 
2.15               2.57 
 
1.00 
 
12 
Males 
(n = 158) 
2.38               2.17 2.00 12 2.44               2.64 2.00 12 
Females 
(n = 75) 
1.67               2.30 1.00 12 1.55               2.33 1.00 12 
Whites 
(n= 93) 
2.34               2.77 2.00 12 2.17               2.56 1.00 12 
Nonwhites 
(n = 140) 
2.02               2.49 1.00 12 2.14               2.59 1.00 12 
Note. Data presented are based on the 233 individuals with complete AUDIT-C data at both time points 
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Table 11: Response distributions of collapsed AUDIT-C responses by gender and racial groups 
AUDIT-C 
item† 
Collapsed 
response 
options 
Total     
n = 310 
Males 
n=212 
Females 
n=98 
p‡ Whites 
n=128 
Nonwhites 
n=182 
p+ 
Item 1—Frequency of drinking 
 Never 37.7% 32.6 % 49.0 % .024 34.4 % 40.1 % .337 
 Monthly 28.4% 36.3 % 25.5 %  33.6 % 32.4 %  
 2-4 x/month 20.6% 17.9 % 19.4 %  18.8 % 18.1 %  
 >2x/week 13.2% 13.2 %  6.1 %  13.3 % 9.3 %  
Item 2—Quantity consumed on typical drinking day 
 0 drinks  37.7% 32.5 % 49.0 % .016 34.4 % 40.1 % .622 
 1-2 drinks 32.9% 28.8 % 27.6 %  32.0 % 25.8 %  
 3-4 drinks 18.4% 23.6 % 14.3 %  18.0 % 22.5 %  
 5 or more 
drinks 
11.0% 15.1 % 9.2 %  15.6 % 11.5 %  
Item 3—Frequency of 6 or more drinks on single occasion 
 Never 65.8% 61.8 % 74.5 % .081 67.2 % 64.8 % .433 
 Less than 
monthly 
20.3% 22.2 % 16.3 %  21.9 % 19.2 %  
 Monthly or 
more 
13.9% 16.0 % 9.2%  10.9 % 15.9 %  
Note. † (Bush et al., 1998). 
‡ p-values represent significance level of chi square statistic for differences by gender for each item on the AUDIT-C. 
+ p-values represent significance level of chi square statistic for differences by race for each item on the AUDIT-C. 
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5.4.1 Reliability estimates  
5.4.1.1 Internal consistency 
Overall, internal consistency of the AUDIT-C was high, with an estimate of .838 for the total 
sample. By subgroup, estimates were slightly higher for females (.851) than for males (.831), and 
slightly higher for whites (.851) than for nonwhites (.828) (Table 12 and Table 13, respectively).  
 
Table 12: Internal consistency, inter-item correlations, and item-total correlations for the AUDIT-C by gender 
group 
Males   α = .831   
       AUDIT-C  Items (1) (2) (3) 
(1) 1.000   
(2)  .829 1.000  
(3)  .877   .782  1.000 
Item-Total Correlation              .639                    .689                         .790 
Females     α = .851    
       AUDIT-C  Items (1) (2) (3) 
(1)    1.000   
(2) .931 1.000  
(3) .916  .857 1.000 
Item-Total Correlation                 .727                     .722                             .776 
Note.  α = Cronbach’s alpha 
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Table 13: Internal consistency, inter-item correlations, and item-total correlations for the AUDIT-C by racial 
group 
Whites  α = .851   
       AUDIT-C  Items (1) (2) (3) 
(1) 1.000   
(2)  .869 1.000  
(3)  .894  .812 1.000 
Item-Total Correlation               .669                     .735                         .809 
Nonwhites  α = .828    
       AUDIT-C  Items (1) (2) (3) 
(1) 1.000   
(2)  .854 1.000  
(3)  .901  .814 1.000 
Item-Total Correlation               .664                    .669                          .778 
Note.  α = Cronbach’s alpha 
 
5.4.1.2 Test-retest reliability 
Baseline and Time 2 AUDIT-C total scores were significantly correlated at the .01 level (2-
tailed) for the total sample (rs = .734), males (rs = .785), females (rs = .620), whites (rs = .897), 
and nonwhites (rs = .649). Notably, correlations between scores at the two time points were 
lower for females than for males and for nonwhites versus whites. 
Wilcoxon signed-rank tests for total AUDIT-C scores from baseline and Time 2 were 
nonsignficant for the total sample (Z = - .643, p = .524), males (Z =  - .009, p = .996), females  
(Z = - .947, p = .350), and nonwhites (Z = - .368, p = .721), suggesting the stability of AUDIT-C 
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scores over time in these groups.  Results for whites, however, showed borderline significance  
(Z = - 1.96, p = .055), suggesting that the two sets of scores in this group increased over time. 
5.4.2 Inconsistent AUDIT-C data analysis 
Data screening procedures revealed that 14% of the sample had inconsistent responses to the 
AUDIT-C at one or both time points. In the simple logistic regression models, only three 
variables were associated with having inconsistent AUDIT-C data.  Participants who used 
opioids (morphine, methadone, codeine, oxycodone) had almost 3 times greater odds of having 
inconsistent AUDIT data [OR = 2.863, 95% CI (1.175 – 6.974), p =.021] compared to non-users, 
while participants with higher conscientiousness scores had slightly lower odds [OR = 1.048, 
95% CI (1.002-1.096), p = .041] of having inconsistent AUDIT-C data. A trend was also 
detected where hallucinogen users had greater odds of having inconsistent data [OR = 3.813, 
95% CI (.881-16.510), p = .073]. 
 Opioid use, hallucinogen use, and conscientiousness score were then entered into a 
multiple logistic regression model for the prediction of having inconsistent AUDIT-C data.  
Hallucinogen use no longer demonstrated a trend toward greater odds of having inconsistent 
AUDIT-C data and was dropped from the model.  In the final model, non-use of opioids and 
higher conscientiousness were again significant predictors of having inconsistent data; opioid 
users had over 3 times greater odds of having inconsistent AUDIT-C data [OR = 3.139, 95% CI 
(.1267 – 7.777), p =.013], while those with higher conscientiousness scores also had greater odds 
of having inconsistent data compared to those with lower conscientiousness scores [OR = 1.053, 
95% CI (1.006 – 1.103), p = .027]. The Hosmer-Lemeshow test indicated that the model was 
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nonsignificant, indicating a good fit between the model and the data, Χ2 (7, n = 336) = 2.961, p = 
.889.  While the model correctly predicted 85.4% of the cases having inconsistent AUDIT-C 
data, blindly estimating the percentage of cases would yield an even higher percentage (85.7%).  
5.4.3 Confirmatory factor analysis 
Because of the small number of items on the AUDIT-C (3), CFA baseline models for all four 
groups were “just identified,” reflecting minimally sufficient data to conduct the analyses 
because the number of data points and the number of parameters (i.e., covariances and 
correlations) were the same as the number of items. The result of being “just identified” is a 
trivially perfect fit to the data, as indicated by the chi square tests of model fit that are equal to 
0.000, with zero degrees of freedom, p-values of 0.000, as occurred with these data in each of the 
four models. Additionally, RMSEA and WRMR values were also all 0.000. 
               Across baseline models however, the collapsed AUDIT-C items were moderately well  
correlated (r = .782 - .931) and consistently loaded heavily onto a single factor, with factor 
loadings ranging from .878 - .998 (Table 14). All factor loadings were above .70 and were 
considered significant. 
Results of the CFAs by gender revealed that when the factor loadings were constrained 
across males and females, the resulting model remained nonsignificant X2 (5, 310) = 4.374, p = 
.497, suggesting a good fit with the data. Furthermore, the RMSEA value was 0.000 and the 
WRMR was .440, also suggesting a good fit.  Results of the CFAs by race indicated that when 
the factor loadings were constrained across whites and nonwhites, the resulting model remained 
WRMR was .440, also suggesting a good fit. Results of the CFAs by race indicated that when the 
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 Table 14:  Standardized factor loadings for parameter estimates by gender and racial groups 
AUDIT-C item        Males         Females      Whites   Nonwhites 
 
Item 1 (Frequency) .972 .998 .978 .972 
     
Item 2 (Quantity) .886 .934 .888 .878 
     
Item 3 (Binge) .913 .918 .914 .927 
 
 
factor loadings were constrained across whites and nonwhites, the resulting model remained 
barely nonsignificant X2 (4, 310) = 7.889, p = .957, suggesting a marginal fit with the data. 
Additionally, the RMSEA value was 0.079, essentially meeting the upper limit recommended for 
indication of a good fit, and the WRMR value was .673, suggesting a good fit. Model 
modification indices, however, specifically suggested an improved goodness-of-fit if partial 
measurement invariance was permitted, i.e., if the factor loading for AUDIT item 3 (heavy 
episodic drinking) was free to vary while the factor loadings for items 1 and 2 remained 
constrained. Review of the unstandardized factor loadings for whites versus nonwhites also 
suggested that differences in the contribution of AUDIT-C item 3 by race; λ = .935 for whites, 
and λ = 1.425 for nonwhites.  Another CFA was performed where the factor loadings for the first 
two items were constrained to be equal between the groups and the loading for the third item 
(episodic heavy drinking) was allowed to vary between the groups. The resulting chi square, 
RMSEA, and WRMR values suggested that the resulting model indicated a superior fit with the 
data, X2 (3, 310) = 1.818, p = .6111; RMSEA = 0.000, WRMR = .340, and no model 
modification indices emerged. The final model is depicted in Figure 3, with factor loadings and 
error terms for whites presented on top in each set, and those for nonwhites presented below. 
 
 
Note. In each set, factor loadings and error terms for whites are presented on top while those for nonwhites appear 
below. 
 
Figure 1: Final factor-analytic model for the AUDIT-C with partial measurement invariance 
5.5 DISCUSSION 
Alcohol use is common among persons with HIV/AIDS; 40-55% of PWHIV acknowledge some 
degree of alcohol use (Chander, Lau et al., 2006; Galvan et al., 2002; Lucas et al., 2002; Tucker 
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et al., 2003), and 10-20% of these individuals consume alcohol at hazardous or harmful levels 
(Arnsten et al., 2002; Braithwaite et al., 2005; Chander, Lau et al., 2006; Conigliaro et al., 2006; 
Cook et al., 2001; Galvan et al., 2002; Samet et al., 2004; Tucker et al., 2003). Among HIV-
infected individuals, alcohol use has been associated with decreased viral suppression and/or 
immune status (Chander, Lau et al., 2006; Conigliaro, et al., 2003; Samet et al., 2007), decreased 
survival (Braithwaite et al., 2007), increased rates of comorbid medical illness (Justice et al., 
2006), decreased neurocognitive function (Durvasula, Myers, Mason, & Hinkin, 2006), and 
potential medication interactions and toxicities (Department of Health and Human Services, 
2008). Furthermore, alcohol use is generally associated with decreased antiretroviral medication 
adherence and a dose-response effect appears to exist where greater alcohol consumption is 
associated with greater likelihood of taking medications off-schedule or missing medication 
doses/days (Braithwaite et al., 2005; Chander Lau et al., 2006; Samet et al., 2004; Tucker et al., 
2003). 
Thus, in order to select the most appropriate, patient-centered care and individualized 
adherence enhancement interventions for PWHIV, HIV/AIDS care providers need accurate and 
efficient assessment of alcohol risk behavior Conigliaro et al., 2003; Cook et al., 2001; Petry 
1999; Samet, Phillips, et al., 2004). This study is one of the few to explore the psychometric 
properties of the AUDIT-C, and to our knowledge, the only study to do so using a sample of 
PWHIV; other studies looking at the psychometrics or the performance of the AUDIT-C have 
used samples of veterans, psychiatric patients, or general primary care patients (Bradley et al., 
1998; Bradley et al., 2003; Bradley et al., 2007;  Bush et al., 1998; Dawson et al., 2005; Frank et 
al., 2008; Gordon et al, 2001).  
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Within the total sample and across subgroups of PWHIV, internal consistency estimates 
for the AUDIT-C were adequate, falling in between the range of 0.70 to 0.90 which is commonly 
considered strong without being redundant (Nunnally & Bernstein, 1994). Other internal 
consistency estimates for the AUDIT-C have not been reported by gender or race and are derived 
from European and Asian samples; these Cronbach’s alphas range from 0.56 to 0.91 (Bergman 
and Kallmen, 2002; Gomez et al, 2005; Rumpf, Hapke, Meyer, & John, 2002; Tsai, Tsai, Chen, 
& Liu, 2005). Several studies of the full AUDIT have reported reliabilities by subscale, and 
describe alpha coefficients ranging from 0.74-0.85 for the consumption subscale, i.e., AUDIT 
items 1 to 3 (Chung, Colby, Barnett, & Monti, 2002; Maisto, Conigliaro, McNeil, Kraemer, & 
Kelley, 2000; Shields, Guttmannova, & Caruso, 2004).  
Test-retest reliability of the AUDIT-C was adequate for the total sample, males, and 
whites, but dipped below the commonly accepted standard of 0.70 in females and nonwhites.  
Two other studies (one of which used a U.S. sample) have also evaluated the AUDIT-C’s test-
retest reliability.  One study using a sample of U.S. male veterans reported a similar range of 
findings; individual item test-retest reliabilities ranged from 0.65 to 0.85 over 3 months (Bradley 
et al., 1998). In a Swedish sample drawn from the general population, test-retest reliability for 
the entire AUDIT-C was 0.93 over a 3 to 4 week period (Bergman & Kallmen, 2002).  
The reliability estimates obtained in this study must be interpreted with caution for 
several reasons. The three month span used in this study is longer than is commonly 
recommended (3-4 weeks) for test-retest analysis (Carmines & Zeller, 1979); however, the three 
month time frame is similar to that used by Bradley and colleagues (1998). If the analysis had 
shown significant differences in scores over time, concerns about maturation effects 
(participants’ drinking patterns changing over time) may be more of a consideration. Also, using 
111 
 
only control subjects for test-retest analyses limited power, and may not have entirely reduced 
any potential influence of the larger trial on alcohol consumption patterns. Simply through PS 
participation, individuals assigned to usual care may nonetheless have had additional attention 
drawn to optimal health behaviors and altered their alcohol consumption or the reporting of their 
drinking. 
The results of the analysis of inconsistent AUDIT-C data suggest that at least for these 
data, having inconsistent AUDIT-C data cannot actually be well-differentiated on the basis of 
opiate use/nonuse and conscientiousness score. Thus, it remains unclear why a sizable 
percentage of PS participants inconsistently responded to the AUDIT-C items. Several other 
possible explanations exist.  First, the possibility exists that individuals with inconsistent 
AUDIT-C data are different from those with consistent data in some other (unobserved) manner 
such as health literacy or cognitive function status. Second, although participants completed PS 
questionnaires at home, at their leisure, the large number of PS questionnaires in the packet at 
each time point may have contributed to participant fatigue and improper reading of the AUDIT-
C questions.  Finally, the overall percentage of participants having inconsistent data at one or 
both time points (13.9%), and the lack of a clear explanation for these inconsistencies suggests 
that the original wording of AUDIT-C question 2 may inadvertently lend itself to 
misunderstanding.  
The majority of inconsistent AUDIT responses involved situations where individuals 
acknowledged alcohol use in question 1 but then selected the “0 drinks” option in question 2 
which asks about the number of drinks consumed on a typical drinking day. The possibility 
exists that these individuals misread question 2, which asks, “How many drinks containing 
alcohol do you have on a typical day when you are drinking?” (Bush et al., 1998)  Perhaps some 
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individuals miss the final clause of the question, and in the presence of an available “0 drinks” 
response option, interpret the question as “How many drinks do you have on a typical day?”  
 With respect to the factor structure of the AUDIT-C, even in collapsed form, the first 
three items of the AUDIT-C are moderately well correlated and load well on a single factor. This 
reflects consistency with the original intent of the AUDIT and AUDIT-C developers, as well as 
previous investigations of the factor structure of the AUDIT. The results of the multi-sample 
CFA by racial group, however, suggest that the assumption of equivalent factor loadings on the 
AUDIT-C for whites and nonwhites was untenable. Item 3 on the AUDIT-C (episodic heavy 
drinking) may not be contributing to the consumption construct for whites and nonwhites in the 
same way. 
Previous research has detected differences in alcohol consumption patterns, drinking-
related norms, and alcohol-related problems both across and within racial groups (Caetano, 
Clark, & Tam, 1998; Galvan & Caetano, 2003; Caetano, 2003). Additionally, a large 
epidemiologic study of binge drinking in U.S. adults reported that the prevalence of binge 
drinking and the rate of binge drinking episodes (episodes/person/year) were lower for Blacks 
than for whites, and that both were highest among Hispanics (Naimi et al., 2003).  In a related 
vein, other investigations examining the sensitivity and specificity of the AUDIT-C and the full 
AUDIT have reported racial differences, but have not gone so far as to recommend different 
screening thresholds for different racial/ethnic groups (Dawson et al., 2005; Frank et al, 2008; 
Steinbauer, Cantor, Holzer, & Volk, 1998). These findings, along with the results of this 
exploratory multi-sample CFA of the AUDIT-C,  begin to suggest that perhaps the impact of 
racial differences has been under-appreciated and requires revisiting. 
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5.5.1 Limitations 
The results of this study require consideration of several limitations. Because alcohol use was not 
a primary variable of interest in the PS, the amount of variability in alcohol use in the 
moderately-sized sample was relatively low, thus requiring the collapsing of AUDIT-C response 
items for CFA.  Alcohol use was self-reported; laboratory markers, collateral information, or 
additional alcohol-related diagnoses were not available. For all analyses in the current study, the 
AUDIT-C and AUDIT-3 were derived from the full AUDIT in the PS; other investigators have 
reported that with this approach the AUDIT-C retains high levels of sensitivity and specificity 
for at-risk drinking and alcohol use disorders (Gordon et al., 2001).  However, response bias may 
nonetheless occur due to the “embeddedness” of these items amidst other questions assessing 
alcohol use (Dawson et al., 2005; Gordon et al., 2001).  Individuals who completely abstain from 
alcohol use were included in all analyses. While previous studies of alcohol screening 
instruments have both included (Williams & Vinson, 2001) and excluded “abstainers” from their 
analyses (Bradley et al., 2007; Canagasaby & Vinson, 2005; Dawson et al., 2005), it must be 
noted that their inclusion can artificially inflate rates of specificity for the AUDIT-C (Dawson et 
al., 2005). Finally, while nonwhite individuals were well-represented in the current study, this 
group consisted primarily of African Americans. Additionally, while the percentage of females 
was representative of the epidemiology of HIV/AIDS in the region, females nonetheless 
comprised only one-third of the sample. In turn, some results may not generalize to other 
nonwhite groups, to individuals identifying as Hispanic/Latino, or to women.  
Overall, results require confirmation with larger, prospective samples and samples with 
greater variability in alcohol use (e.g. perhaps via recruitment through substance abuse treatment 
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facilities or community agencies). Additionally, future investigations should consider use of a 
“non-embedded” form of the AUDIT-C; in this study and in others, AUDIT-C and AUDIT-3 
responses were extracted from responses to the full AUDIT. While other investigations have 
shown that in this format, the AUDIT-C does retain high levels of sensitivity and specificity for 
at-risk drinking and alcohol use disorders (Dawson et al., 2005; Gordon et al., 2001), participant 
responses may have been different were these items administered independently of the remaining 
PS AUDIT items and drug-related questions. 
5.6 CONCLUSIONS 
 
This study provides preliminary evidence that in general the AUDIT-C is a reliable alcohol 
screening instrument in persons with HIV/AIDS. The results of the inconsistent AUDIT-C data 
analysis suggest that researchers who make similar changes to the AUDIT-C or the full AUDIT 
may encounter problems with the validity of the instrument, particularly in samples where 
individuals use certain types of illicit drugs. The following ameliorative strategies are proposed 
for investigators who delete the “skip to” command in AUDIT question 1 and/or add a “0 drinks” 
option to AUDIT-C question 2. First, it is suggested that investigators who opt to make these 
changes carefully verify the responses to questions 1 to 3 for consistency. Additionally, various 
data collection and management programs allow pre-set data validation or conditional formatting 
parameters which deny or alert the researcher to the entry of invalid responses.  Second, 
researchers making modifications to question 2 might also consider using an interview version of 
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the AUDIT-C, which would allow clarification of ambiguous or inconsistent responses; the 
manual for the full AUDIT has an interview version which is identical to the self-report version 
and which provides simple instructions for the administrator (Babor et al., 2001). 
 A final consideration is whether or not modifications to AUDIT-C question 2 itself might 
need to be made when adding a “0 drinks” option, e.g., moving the qualifier to the beginning of 
the question so that it asks, “On a typical day when you are drinking, how many drinks 
containing alcohol do you have?” However, it remains unclear how these modifications might 
affect the reliability and validity of the instrument; thus, the previous recommendations may be 
more advisable. Future methodological or instrumentation investigations of the AUDIT-C or full 
AUDIT might incorporate a qualitative arm directly querying participants about their 
interpretation of question 2 when modifications are made, and might further evaluate the 
psychometric properties of these modified versions.   
 Finally, the AUDIT-C appears to measure the same alcohol consumption factor across 
gender and racial subgroups of PWHIV relatively consistently, although some evidence suggests 
that the understanding of, and response to, the third question on the AUDIT-C may differ across 
whites and nonwhites. Along with additional methodological investigation, further attention to 
the cultural equivalence of the AUDIT-C may also be warranted so that other clinicians and 
researchers can use the AUDIT-C with confidence across patient populations. 
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6.0  ADDITIONAL RESULTS & DISCUSSION  
This chapter provides the results for all analyses conducted as part of Specific Aim #3 and 
Secondary Aim #1. Discussion by Aim follows each set of results. 
6.1 SPECIFIC AIM #3 
Specific Aim #3 proposed to compare the effect of the structured and individualized adherence 
interventions with usual care on the antiretroviral (ART) adherence of persons with HIV/AIDS 
(PWHIV), and to determine if any effects were moderated by across alcohol screening status 
(positive/negative on the Alcohol Use Disorders Identification Test—Consumption [AUDIT-C]). 
In other words, the goal was to detect any statistically significant differences between the 
changes over time in the adherence of AUDIT-C positive individuals versus the change over 
time in the adherence of AUDIT-C negative individuals across treatment groups and across time. 
6.1.1 Results 
The compound symmetry covariance structure provided the best fit with the model (AIC = 
4818.820). Significant differences in adherence over time by group and by alcohol screening 
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status were not detected, i.e., there was no significant three-way interaction between treatment 
group, time, and alcohol screening status (being AUDIT-C positive/negative), F (2, 239.931) = 
.049, p = .952. Additionally, two-way interactions between treatment group and time, treatment 
group and alcohol screening status, and time and alcohol screening status were not appreciated 
(Table 15). However, main effects for time and alcohol screening status were significant; overall, 
adherence was significantly lower at Time 2 than at baseline, F (1, 236.287) = 25.595, p = .000, 
and was significantly lower for AUDIT-C positive individuals than for AUDIT-C negative 
individuals,   F (1, 340.338) = 12.304, p = .001. 
The mean dose adherence scores for individuals who were AUDIT-C positive decreased 
by approximately 13% from baseline to Time 2, i.e., from 70.622 (SE = 3.668) to 57.361 (SE = 
3.989). Mean dose adherence scores for individuals who were AUDIT-C negative were higher 
overall, but decreased by 10% over the two time points; from 82.499 (SE = 2.301) to 72.499 (SE 
= 2.556). A summary of fixed effects appears in Table 16; these relationships are illustrated  
graphically in Figure 4.  
6.1.1.1 Discussion 
The finding that dose adherence significantly decreased for all individuals from baseline to   
Time 2 (3 months) regardless of treatment group (usual care, individualized intervention, 
structured intervention) was somewhat unexpected, although other researchers using EEM have 
also reported initial declines in adherence, noting that adherence is also highly variable over time 
(Howard et al., 2002). It was anticipated that individuals in the intervention groups would 
demonstrate at least modest improvements in dose adherence. Given that all three groups 
demonstrated lower adherence, the possibility exists that the effect noted represents a  
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Table 15: Mixed linear model for dose adherence 
Source Numerator df 
Denominator 
df F p 
 
Intercept 
 
1 
 
293.571 
 
1275.963 
 
    .000 
Treatment group (G) 2 295.432 .965     .382 
AUDIT-C status (A) 1 340.338 12.304 .001 
Time (T) 1 236.287 25.595 .000 
G * A 2 341.292 .666     .514 
G *  T 2 236.216 .526     .592 
A * T 1 240.067 .494 .483 
G *  A *  T 2 239.931 .049 .952 
Note. Treatment group = usual care, individualized intervention, or structured 
intervention; AUDIT-C = Alcohol Use Disorders Identification Test—Consumption 
(AUDIT-C) positive/negative. 
 
 
“honeymoon phase”  where baseline adherence was artificially inflated due to particular 
assiduousness or the Hawthorne effect at the start of the trial, then declined to rates more 
representative of typical medication-taking patterns by the three-month time point. Individuals 
used the EEM cap for a one-month induction phase where only the last two weeks were used to 
determine baseline adherence. The first two weeks allowed individuals time to familiarize 
themselves with cap functioning, and to allow novelty effects to diminish. This time frame may 
not have been long enough for individuals to return to their typical patterns and rates of 
medication-taking.  
It was not surprising, however, that at both time points AUDIT-C positive individuals 
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Table 16: Summary of estimates of fixed effects for linear mixed models predicting dose adherence  
Parameter b SE (b) p 95% CI 
        LB UB 
 
Intercept 
 
53.54 
 
7.01 
 
.000 
 
39.77 
 
67.31 
 
Usual Care 
 
1.27 
 
9.34 
 
.892 
 
-17.08 
 
19.61 
Individualized 10.19 10.25 .321 -9.96 30.34 
Structured 0 0 . . . 
 
AUDIT-C  
negative 
 
 
12.93 
 
8.31 
 
.120 
 
-3.40 
 
29.26 
AUDIT-C 
positive 
 
0 0 . . . 
 
Baseline 
 
16.33 
 
6.80 
 
.017 
 
2.94 
 
29.73 
Time 2 0 0 . . . 
 
Note. B = parameter estimate; SE B = standard error of the estimate; CI = confidence interval; LB = lower bound; 
UB = upper bound. AUDIT-C negative and positive represent alcohol screening status at baseline. 
Span for baseline to Time 2  was 3 months. 
 
 
had lower dose adherence than AUDIT-C negative individuals. Although this particular analysis 
involved change in adherence over time, this finding parallels those of earlier nonparametric 
analyses where AUDIT-C positive status was associated with significantly lower baseline dose 
adherence, over-dosing, and under-dosing (Table 5), and earlier regression analyses, where  
AUDIT-C positive status significantly added to the prediction of baseline dose adherence, after 
controlling for numerous confounding variables and covariates. This finding also parallels the 
broader ART adherence literature demonstrating that overall, alcohol use tends to negatively 
impact adherence (Braithwaite et al., 2005; Chander, Lau et al., 2006; Samet, Horton et al., 2004; 
Tucker et al., 2003). 
 
 
Figure 2: Dose adherence over time by alcohol screening group 
 
6.1.1.2 Limitations 
This investigation is only able to comment on the effects of the interventions for the first time 
point, and for this particular dimension of adherence; the current study did not include additional 
time points through the 18 month duration of the PS, and did not analyze the effectiveness of the 
interventions for other types of adherence. It is possible, for example, that while the interventions 
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may not have impacted overall rates of medication taken versus medication prescribed (dose 
adherence), it may have had an impact on participants’ dosing intervals or on the percentage of 
entire days where medication was skipped. 
 The validity of these results may be limited for several reasons. First, the current model is 
based on baseline AUDIT-C status. AUDIT-C status was treated as a fixed effect but was not 
permitted to vary over time; baseline status was held constant by carrying forward this status to 
the second time point. This approach was selected in order to avoid adding additional complexity 
to the model and because of the percentage of inconsistent or missing AUDIT-C data, 
particularly at Time 2. However, the assumption that AUDIT-C status did not vary over time is 
not necessarily valid. Post-hoc analyses of individuals with complete and consistent AUDIT-C 
and adherence data at both time points (n = 233) revealed that 16.3% of the sample had a change 
in AUDIT-C status from baseline to Time 2; of these, 7.7% were characterized as AUDIT-C 
positive at baseline, but AUDIT-C negative at Time 2, and 8.6% were characterized as AUDIT-
C negative at baseline, and AUDIT-C positive at Time 2.  
Second, missing adherence data was also a problem; a total of 90 participants (27.2% of 
the sample) had missing dose adherence data at Time 2. Mixed linear models can handle missing 
data because they fit the model for the response at all time points, but they are valid only when 
the data can be said to be “missing at random” (MAR), that is, when the probability of having 
missing data does not depend on the value of the missing data itself, had it been observed (West, 
Welch & Galecki, 2006).  It is possible that the probability of having missing Time 2 adherence 
data depends not only on factors such as depressive symptoms or age, but on one’s rate of 
baseline adherence. For example, the probability of having missing adherence data at Time 2 
might increase as one’s rate of baseline adherence decreases. If this is the case, the data would 
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not be MAR or “ignorable;” models would need to be re-estimated including the missing data 
mechanism as part of the estimation process itself (Alison, 2001). A preliminary analysis of 
inconsistent AUDIT-C and missing Time 2 data follows. 
6.1.2 Missing data and generalizability of the results 
In order to address the generalizability of various findings across the current study, and to 
determine how individuals with missing adherence data might differ from those with complete 
data, a series of bivariate and multivariate logistic regression models were run in order to 
develop a predictive model for having missing Time 2 dose adherence data.  
Having Time 1 adherence data from the induction phase was a prerequisite for 
randomization; only 4 individuals were missing time 1 data. Two of these individuals were 
removed from their medication by their physicians sometime during the 1-month PS induction 
phase.  One individual did not return the EEM cap at the end of induction. Since these three 
individuals did not have baseline adherence data, they were never randomized in the PS. One 
other individual was randomized, but had missing cap data. As the current study used Time 2 
data to evaluate the effectiveness of the two adherence interventions over time versus usual care, 
missing adherence data analysis focused on the second data collection point, Time 2 dose 
adherence data. As all five types of adherence assessed in this study are derived from the same 
set of EEM cap data for each participant, the dose adherence variable was selected to represent 
adherence because it is the most commonly reported form. 
A total of 90 participants (27.2% of the sample) had missing dose adherence data at Time 
2. In data screening, a dichotomous code was created where individuals having complete 
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adherence data at Time 2 were coded 0, and where individuals with missing adherence data were 
coded 1.  Baseline values for sociodemographic and other variables potentially associated with 
missing adherence data were then entered into simple logistic regression models for the 
prediction of having inconsistent AUDIT-C data. The following variables were individually 
entered one at a time: gender; age; race (white/nonwhite); years of formal education; the Beck 
Depression Inventory II (BDI-II) total score; the five subscale scores from the NEO-FFI Five 
Factor Personality Inventory (Neuroticism, Extraversion, Openness, Agreeableness, 
Conscientiousness), the HIV Self-efficacy Scale total score; dichotomized drug use scores 
(yes/no) for marijuana, cocaine, crack, heroin, opioids, ecstasy, “poppers,” stimulants, 
hallucinogens, and inhalants. Total AUDIT-C score was also included as a variable using data 
from the 86% of participants with complete and consistent AUDIT-C data at baseline. Finally, 
baseline dose adherence scores and treatment group (usual care, individualized intervention, 
structured intervention) were also individually tested. 
In the simple logistic regression models, six (6) variables were associated with having 
missing Time 2 adherence data:  opioid use, heroin use, crack use, baseline dose adherence, 
treatment group, and Openness score.  Opioid users had almost 3.5 times greater odds of having 
missing adherence data [OR = 3.403, 95% CI (1.532– 7.561), p =.003] compared to non-users. 
The remaining three variables demonstrated trend relationships (p < .11) with having missing 
adherence data. First, participants who used heroin had almost 3 times greater odds of having 
missing data [OR = 2.951, 95% CI (1.005 – 8.666), p = .049] compared to non-users, while those 
who used crack had just over 1.5 times greater odds of having missing data [OR = 1.723, 95% CI 
(.936 – 3.172), p = .081] compared to those who did not. Second, individuals in each of the two 
intervention groups had approximately twice the odds of having missing Time 2 adherence data 
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compared to those in the group receiving usual care; individualized intervention group,           
[OR = 2.119, 95% CI (1.139 – 3.953), p = .018], and structured intervention group, [OR = 2.001, 
95% CI (1.067 – 3.752), p = .030]. 
Finally, trends were noted where individuals with higher baseline dose adherence scores 
were slightly less likely to have missing data [OR = .993, 95% CI (.986 – 1.001), p = .073], as 
were participants with higher Openness scores [OR = .964, 95% CI (.923 – 1.008), p = .107].  
Opioid use, heroin use, crack use, baseline adherence score, treatment group, and 
Openness score were then entered into a multiple logistic regression model for the prediction of 
having missing Time 2 adherence data.  In the final model, only opioid use and treatment group 
remained significant predictors of missing data. Opioid users had over 3 times the odds of having 
missing Time 2 adherence data when compared to non-users [OR = 3.041, 95% CI (1.238 – 
7.474), p = .015). Those in the two adherence intervention groups again had roughly 2 times 
greater odds of having missing Time 2 adherence data compared to the usual care group; 
individualized [OR = 2.179, 95% CI = 1.142 – 4.158), p = .018, structured [OR = 1.980, 95% CI 
(1.037 – 3.783), p = .039]. Baseline adherence again demonstrated a trend toward the prediction 
of missing Time 2 data, where those with higher baseline adherence scores had slightly lower 
odds of having missing data [OR = .993, 95% CI (.985 – 1.001), p = .079]. 
The Hosmer-Lemeshow test indicated that the model was nonsignificant, indicating a 
good fit between the model and the data, Χ2 (8, n = 334) = 6.772, p = .561. The Nagelkerke R2 
value was .083, indicating that the model explained approximately 8% of the variance in having 
missing Time 2 adherence data. This model correctly predicted only 73.7% of the cases having 
missing adherence data, only a slight improvement over a “blind” estimate of the percentage of 
cases, which was determined to be 73.4%.   
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6.1.2.1 Discussion  
The rate of missing Time 2 data in this study (27.2%) was higher than anticipated by PS 
investigators, but is not unusual for longitudinal ART trials; general rates of individuals who 
drop out or who are lost to follow-up are reported to be around 30% (Chesney, Morin & Sherr, 
2000). The correct classification of cases in the final model was only 73.7%, suggesting 
relatively weak differentiation of cases having missing Time 2 adherence data from those having 
complete adherence data on the basis of opioid use, treatment group, and baseline adherence. 
However, the significant and near-significant prediction of missing data by treatment group and 
baseline adherence, even after controlling for drug use and personality, carry substantial 
implications for earlier repeated measures analyses because they suggest that the “missingness” 
of Time 2 data may not be “missing at random,” i.e., it may be dependent on one’s baseline 
adherence rate and/or adherence intervention group assignment. It is not surprising that 
individuals with lower adherence might be more likely to have missing data at Time 2; 
individuals with suboptimal adherence may be more likely to drop out of a long-term adherence 
trial because of the very same factors contributing to their compromised medication-taking.  It is 
less clear, however, why participants in the intervention groups had twice the odds of having 
missing data than those in usual care. Perhaps the weekly contact or the nature of the 
interventions was not appealing to some individuals, namely, those who use substances. 
Missing adherence data at Time 2 is attributable to several factors:  participant attrition, a 
missed data collection with return at later time point, cap loss/malfunction, participants’ being 
off medication at Time 2, or participant death. According to PS records, over >90% of missing 
Time 2 data was due to participant drop out. The bivariate and multivariate associations between 
various types of drug use (in particular, opioid use) and missing data (primarily due to attrition) 
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are not surprising given the common difficulty of retaining substance users in clinical trials 
(Ashery & McAuliffe, 1992; Carroll, 1997).  It is noteworthy, however, that in the final model, 
while opioid use was associated with missing adherence data, heroin use was not. Despite 
similarities in their physiological mechanisms of action, the context and culture of heroin versus 
other opioid use can be quite different, resulting in different behavioral manifestations in terms 
of research participation and attrition. Based on the PS data, we were not able to determine if the 
approximately 8% of individuals in the sample endorsing opioid use at baseline were misusing 
prescription drugs, abusing diverted opiates, or enrolled in methadone or buprenorphine 
maintenance programs. Overall, the results of this study may not generalize well to individuals 
who use illicit substances. 
Howard, Cox, and Saunders (1990) describe a number of attrition prevention strategies in 
research with substance using populations, including expecting and planning for attrition, using 
collateral contacts or resources to locate lost subjects, maintaining regular contact with subjects 
every few weeks, and identifying those who are “at-risk” for attrition and focusing efforts on 
these individuals. However, not only are these strategies resource-intensive, but as Howard and 
colleagues point out, they could also feasibly compromise the integrity of treatment protocols by 
providing ongoing contact, or could compromise original randomization procedures through the 
additional attention directed towards “at-risk” participants. As drug and alcohol use were not 
initial variables of interest in the parent study, issues related to the retention of substance-using 
individuals were not a particular area of focus.  Concerns about the effects of such retention 
strategies on study integrity would have nonetheless been of particular concern to the PS, which 
tested two adherence interventions over time. All PS did receive modest remuneration with 
questionnaire and EEM cap return at each time point, and both of the PS interventions involved 
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weekly contact over 12 weeks. Given the ubiquitousness of polysubstance use among persons 
who use alcohol and drugs, even future studies focused on alcohol use and ART will likely have 
to consider the effects of drug use on study attrition, and select ameliorative strategies most 
appropriate to study aims and characteristics. 
6.2 SECONDARY AIM #1 
Secondary aim #1 was to explore whether self-efficacy mediated the effects of depressive 
symptoms, social support, and conscientiousness on dose adherence, and to determine if any 
meditational relationships were moderated by alcohol screening status (AUDIT-C 
positive/negative). 
6.2.1 Results 
Direct effects between depressive symptoms and social support could not be established; in 
bivariate correlations and simple linear regression models, BDI-II total score and ISEL total 
score did not significantly predict baseline dose adherence: depressive symptoms (rs = -.047, p > 
.05; F (1, 301) = 1.030, p = .311); social support (rs = .019, p > .05; F (1, 302) = .091,  p = .763). 
Since the presence of an initial effect to be mediated is a prerequisite for testing mediation 
(Baron & Kenney, 1986), additional analyses were not performed for these variables. 
With respect to conscientiousness, the first two conditions for mediation were met; 
conscientiousness was a significant predictor of dose adherence, F (1, 299) = 10.80, p = .001, 
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and of self-efficacy, F (1, 299) = 53.31, p = .000. The third condition required for mediation, 
however, was not met successfully; there was only a strong, near significant trend for self-
efficacy predicting adherence while controlling for conscientiousness, F (2,  298) = 7.324,  p = 
.054.  Power was sufficient (.93723) to conduct this analysis. Given the trend toward significance 
and the fact that the regression coefficient between conscientiousness and adherence did decrease 
substantially and diminish in significance when controlling for self-efficacy (Figure 1), partial 
mediation by self-efficacy was at least suggested. Because this aim was exploratory in nature, 
analysis proceeded using the Sobel test.  
Results of the Sobel test also demonstrated a trend towards significance (p=.0635) for 
partial mediation, reflecting the lack of a previous significant relationship described above and/or 
the lack of a statistically significant reduction in the size of the regression coefficient. Not 
surprisingly, these results were further confirmed by bootstrapping estimates (95% Confidence 
interval -.0317, .0001), where results varied minimally even after increasing the number of 
booststrap resamples from 3000 to 5000 or 10,000.  
Again, because this aim was exploratory and because analyses indicated strong trends, 
this mediational model was tested for moderation by alcohol use. The interaction between 
AUDIT-C status and conscientiousness, and the interaction between AUDIT-C status and self-
efficacy did not reach significance, (p=.282 and p=.730, respectively), suggesting that any near-
significant mediational role for self-efficacy did not differ by alcohol screening status. 
  
Note: The regression coefficient between conscientiousness and dose adherence controlling for adherence self-
efficacy is in parentheses. Signs for the coefficients are reversed due to transformations of self-efficacy and dose 
adherence. *** p < .001,  * p < .05 
 
 
Figure 3: Regression coefficients for the relationship between conscientiousness and dose adherence as 
potentially mediated by adherence self-efficacy 
 
 
6.2.2 Discussion 
The lack of initial significant relationships between depressive symptoms and ART adherence, 
and social support and ART adherence, differs from the findings of other investigations.  Social 
support and depression have been consistently associated with ART adherence (Ammassari, et 
al., 2002; Berger-Greenstein et al., 2007; Catz et al., 2000; Chander, Himelhoch et al., 2006; 
Vyavaharkar et al., 2007). Numerous path analyses and other modeling studies have revealed the 
parallel and inverse relationships between social support and negative affect/depressive 
symptoms, and their subsequent impact on coping, self-efficacy, and in turn, on ART adherence 
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(Simoni et al., 2006; Vyavaharkar et al., 2007; Weaver et al., 2005). Notably, the mean ISEL 
total scores observed in this total sample (M = 75.42, SD = 23.27) were considerably lower than 
those reported elsewhere, and even lower for AUDIT-C positive individuals. Additionally, the 
mean BDI-II total score was 16.27 (SD = 12.47), falling within the range commonly considered 
indicative of mild depression (Beck, 1996). Mean scores for AUDIT-C positive individuals, 
while higher, still fell within this range. These differences suggest that individuals in this sample 
may have been different from other samples of PWHIV, e.g., these individuals may have been 
experiencing less depression, may have been engaged in more depression treatment, and/or may 
have perceived having fewer or less supportive social networks. 
 The test of mediation by self-efficacy on the relationship between conscientiousness and 
dose adherence was essentially arrested by failure to meet the third Baron and Kenny (1986) 
criteria for mediation. This criterion could perhaps have been met through the use of a more 
precise and compatible measure of self-efficacy. As opposed to the total score for the HIV Self-
efficacy Scale, which includes both Self-efficacy Beliefs and Outcome Expectancy, only the 
Self-efficacy Beliefs subscale score could have been used. The near-significant trend relationship 
and the reduction in the strength of the conscientiousness-adherence relationship when 
controlling for self-efficacy suggest however, partial mediation by self-efficacy. This finding is 
not surprising; broad personality traits related to self-discipline, organization, and goal 
attainment understandably exert their effects on adherence through self-efficacy for a specific 
task such as ART dose adherence. 
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7.0  FINAL DISCUSSION AND CONCLUSIONS 
7.1 DISCUSSION 
The overall purpose of this study was to further elucidate the impact of alcohol use on the 
antiretroviral (ART) adherence of persons with HIV/AIDS (PWHIV). This study aimed to 
determine if positive alcohol screening results on the AUDIT-C added to the prediction of ART 
adherence over and above sociodemographic, psychosocial and other variables, and to examine 
the effect of two adherence-enhancement interventions over time, with additional consideration 
of the potential moderation of these effects by alcohol use. Additionally, the mechanisms 
through which alcohol affects adherence were explored through the investigation of a potential 
meditational role for self-efficacy in the relationships between depressive symptoms and 
adherence, social support and adherence, and the personality factor of conscientiousness and 
adherence.  Finally, this study appraised the psychometric properties and factor structure of the 
AUDIT-C in a sample of PWHIV in order to provide additional validation for its use as an 
alcohol screening test in this population. 
Overall, these results underscore the prevalence of alcohol use among PWHIV and, like 
other studies, generally, though somewhat inconsistently confirm the detrimental effects of 
alcohol on ART adherence. Alcohol use presumably has a negative impact on ART adherence 
for various reasons. Alcohol may impair cognitive functioning, exacerbate comorbid physical or 
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mental illness, or compromise interpersonal relationships and social support (Cook, et al., 2001: 
Hinkin et al., 2006). Additionally, people may forget to take their medication when socializing 
with alcohol or becoming intoxicated (Cook et al, 2001), or, may actively choose not to take 
their medications given beliefs about mixing ART and alcohol (Sankar et al, 2007).  
HIV care providers are encouraged to screen patients for substance use, and to screen for 
adherence on an ongoing basis (Stone, 2001). This study used an alcohol screening test (i.e., the 
AUDIT-C) to categorize alcohol consumption for the prediction of ART adherence, and in so 
doing, confirmed the findings of others who have detected a significant relationship between 
alcohol and adherence, particularly those detecting a relationship at low to moderate levels of 
consumption (Chander et al, 2006; Samet, Horton, et al., 2004; Tucker et al., 2003). The 
apparent additional prediction of adherence afforded by the AUDIT-C beyond that of 
sociodemographic, psychosocial, and other variables, draws attention to the intersection of 
substance use and chronic disease.  
The relationship between self-efficacy and medication adherence is well-established. 
Two findings from this study raise important questions about adherence intervention design, 
particularly for interventions aiming to improve adherence self-efficacy and for interventions 
being tested in samples with alcohol use patterns across the spectrum. First, the effectiveness of 
the adherence interventions was no worse for individuals who screened AUDIT-C positive than 
for those who screened AUDIT-C negative. Second, the nearly-significant mediational 
relationship between self-efficacy, conscientiousness, and dose adherence was not moderated by 
alcohol use. Together, these findings might prompt one to ask if, and exactly how, medication 
adherence interventions incorporating self-efficacy might need to vary according to the alcohol 
use status of the individual.  
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In the broader context of substance abuse, previous authors have drawn attention to the 
importance of addressing drug and alcohol problems in the context of HIV/AIDS care (Center 
for Substance Abuse Treatment, 2000; Chander, Himmelhoch et al., 2006; Willenbring, 2005), 
but findings from the current study suggest the need for additional consideration of the 
distinction between integrated care for alcohol abuse and HIV/AIDS, and integrated 
interventions for alcohol abuse and HIV/AIDS.  The efficacy of each approach, as well as the 
efficacy of one versus the other, remains unclear due to inconsistent research findings. For 
example, some studies have found no association between ART adherence and engagement in 
substance abuse treatment (Palepu et al, 2004; Thomas, 2001), while others, namely those 
involving directly observed therapy (DOT) and/or opiate substitution therapy (methadone, 
Buprenorphine) for opiate-dependent patients, suggest improved outcomes (Altice, Maru, Bruce, 
Springer, & Friedland, 2007; Lucas et al., 2007; Macalino et al, 2007; Moatti, 2002).  Still others 
report differences by gender (Turner et al., 2003).  
Additionally, only two published studies have been designed to specifically address ART 
adherence for problem drinkers (Parsons, Golub, et al., 2007; Samet et al., 2005). While both 
targeted alcohol reduction and adherence improvement, their designs differed substantially, as 
did their findings.  Nonetheless, using a timeline follow-back interview method for assessing 
adherence, Parsons and colleagues (2007) reported significantly greater reductions in alcohol at 3 
and 6 months, and improvements in self-reported dose and day adherence at 3 months.  
Conversely, using the Adult AIDS Clinical Trial Group (AACTG) adherence instruments 
(Chesney et al., 2000) with electronic event monitoring (EEM) to corroborate self-report, Samet 
et al. (2005) reported no significant improvements in ART adherence, no reduction in alcohol 
use, and no improvements in HIV/AIDS clinical markers (Appendix B). In addition to system-
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level factors (e.g. financial and human resources) and factors associated with 
sociodemographic/cultural characteristics of the target population, factors such as the severity of 
alcohol use, progression of HIV disease, and patient preference/personality may influence the 
need for an integrated alcohol-reduction/adherence-promotion approach and its potential success. 
Individualized interventions such as those in the parent study (PS) allow the opportunity for 
individuals to self-select their health-related goals and plans for achieving them, be they alcohol 
reduction and/or optimal medication-taking.  
However, in this in this sample, having inconsistent AUDIT-C data and having missing 
Time 2 adherence data were both significantly related to baseline opioid use (but not total 
AUDIT-C score), and missing Time 2 adherence data was also significantly related to treatment 
group assignment. In the broader picture, this raises questions about how to best retain substance 
users in longitudinal ART adherence trials, and/or about the appeal of certain intervention 
designs and characteristics. 
Several authors have recently recommended that ART adherence interventions also 
incorporate consideration of individual differences in personality (Cruess et al., 2007; 
O’Clereigh et al, 2007; Ironson et al., 2008; Penedo et al., 2003). Personality is typically 
considered relatively immutable, so the proposed focus is not on modifying one’s personality in 
order to promote adherence, but instead to enable a person to modify attitudes and behaviors 
given his or her basic disposition (Ironson et al., 2008). Christensen (2004) describes how 
individual differences in personality might be accounted for in adherence interventions.  For 
example, individuals high in conscientiousness (who are typically highly self-reliant) may 
benefit most from adherence interventions which allow for or expect high levels of individual 
engagement and self-management. The PS interventions addressing problem-solving and habit 
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training are likely to fit this profile. In a similar fashion, those high in Agreeableness, i.e., those 
most trusting or deferent to others, may benefit more from group or interpersonally-focused 
interventions such as peer-to-peer coaching (Christensen, 2004). While the idea that individuals 
could be matched to adherence interventions based on personality characteristics, dispositions, 
and response tendencies is appealing, applications beyond intervention selection remain under-
developed and under-described. To some extent, this idea also presupposes the availability of 
multiple intervention options and resources (in which to even refer patients) that may be realistic 
for only the more resource-endowed facilities and programs. 
Post-hoc analyses (change in AUDIT-C status from baseline to Time 2) conducted for the 
repeated measures analysis challenges the validity of the results from the mixed models.  The 
fact that 16% of individuals in the total sample changed AUDIT-C status over time suggests that 
analyses examining the effect of the interventions ideally require more complex modeling 
allowing for time-variant AUDIT-C status (as well as a missing adherence component). The test-
retest reliability estimation of the AUDIT-C is unlikely to be invalidated by these changes in 
AUDIT-C status because it examined the correlation between total AUDIT-C scores as opposed 
to AUDIT-C status at the two time points. However, these changes in AUDIT-C status do hint 
that the 3 month time frame used for the test-retest reliability may in fact be too long for this type 
of analysis due to people’s alteration in drinking patterns or quantity. On the other hand, the 
AUDIT-C may possess such high sensitivity that even small changes in drinking habits cause 
one’s screening score to change. From a clinical standpoint though, this is encouraging, as the 
AUDIT-C is meant to identify as many at-risk individuals as possible. 
    While the AUDIT-C is intended to be particularly easy for individuals to complete and 
for clinicians and researchers to administer and score, the frequency with which modifications 
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are reported and the frequency with which this particular sample had inconsistent data when such 
changes were made suggests that some of its qualities may inadvertently create more challenges 
than expected. AUDIT-C items of course, mirror those of items 1 to 3 on its parent instrument, 
the full AUDIT. Certain characteristics of these questions (e.g., containing/not containing a 
“skip” option in item 1, containing/not containing a “0 drinks” or “none” option in item 2) may 
appear to be of minor significance, but in this data set, these characteristics did appear to 
contribute to missing data and/or compromised analyses. From a clinical and research standpoint, 
the appeal of the AUDIT-3 as a single alcohol screening question again becomes apparent. The 
appropriateness of the AUDIT-3, however, naturally depends on the intended use of the data, and 
the AUDIT-3 is not without its own set of potential modifications, e.g., lowering the number of 
drinks inquired about in the binge question from 6 to <5 for men and <4 for women (Bradley et 
al., 2003). 
7.2 LIMITATIONS 
The results of this secondary data analysis study require consideration of several limitations. In 
general, variables were limited to those selected by the PS. Because alcohol use was not an initial 
primary variable of interest in the PS, the amount of variability in the sample in terms of alcohol 
use was relatively low.  Secondly, because of its purpose as a screening test, the AUDIT-C is 
designed to be sensitive at the expense of specificity; therefore, the number of individuals who 
screened positive on the AUDIT-C may have been inflated.  The use of gender-specific cut-offs 
may also have increased the number of false-positive screens in this study. In contrast, however, 
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the inclusion of nondrinkers in the analysis, i.e., those with total scores of zero on the AUDIT-C, 
may have artificially increased specificity. Similar considerations apply to the designation of 
AUDIT-3 positive individuals. Issues related to over-sensitivity of the AUDIT-C are potentially 
less problematic in the clinical setting, where the aim might be to identify as many individuals 
with at-risk drinking patterns as possible for further alcohol evaluation or individualized 
adherence counseling. Finally, AUDIT-C and AUDIT-3 responses were extracted from 
responses to the full AUDIT. While other investigations have shown that in this format, the 
AUDIT-C does have high levels of sensitivity and specificity for at-risk drinking and alcohol use 
disorders (Dawson et al., 2005; Gordon et al., 2001), participant responses may have been 
different were these items administered independently of the remaining AUDIT items and drug-
related questions. 
While EEM is often considered the “gold standard” in terms of reliable and objective 
adherence assessment, and is more highly correlated with viral load and CD4 count, EEM relies 
on the assumption that cap openings reflect medication ingestion. Additionally, its cost often 
makes its use prohibitive in research as well as clinical practice. Finally, a self-report measure 
could be coupled with EEM; the use of multiple assessment modalities is often recommended as 
the ideal approach for explaining the greatest amount of variance in adherence (Berg & Arnsten, 
2006; Pearson et al., 2007). 
Several characteristics of the sample underscore the extent to which these findings may 
be generalized. First, mean adherence rates were relatively high at baseline. For example, dose 
adherence was near 80% (M = 79.43, SD = 31.63), though similar rates of mean dose adherence 
(70-80%) have been reported in other ART adherence studies which have used EEM (Golin et 
al., 2002; Hinkin et al., 2004; Paterson et al., 2000). Additionally, participants were individuals 
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engaged in care, and highly motivated to participate in a long-term adherence trial. The general 
rate of alcohol consumption (63.3%) appears to be higher than rates of alcohol use among 
PWHIV reported previously, which range from 40-55% (Arnsten et al., 2002; Chander, Lau, et 
al., 2006; Conigliaro et al., 2006;  Cook et al., 2001; Galvan et al., 2002; Samet, Horton, et al., 
2004;  Tucker et al., 2003).  Placing the sample’s rates of AUDIT-C positive (27.1%) and 
AUDIT-3 positive (34.2%) individuals in the context of previous research is considerably more 
challenging due to wide variation in definition and determination of alcohol use patterns across 
studies.  Alcohol consumption may be categorized in terms of quantity/frequency (“moderate,” 
“frequent,” “heavy” drinking), risk (“at-risk/risky” drinking) or consequences (“problematic” 
drinking); in terms of DSM-IV alcohol use disorders e.g., abuse/dependence), or subsumed under 
the broader variable of “substance abuse.” Again, in extant studies, rates of hazardous use and/or 
binge use generally range from 10-20% (Chander, Lau, et al., 2006; Conigliaro, et al., 2003; 
Cook et al., 2001), but have been reported as high as 30% (Berg et al., 2004).  Given the 
AUDIT-C’s identity as a screening tool, and the fact that it specifically inquires about alcohol 
use over the past year, the higher rates of hazardous and binge use in this sample are not 
surprising. 
7.3 CONCLUSIONS 
In conclusion, secondary data analysis provided the opportunity to assess multiple interrelated 
aims under the umbrella of alcohol use and medication adherence. These findings carry 
implications for both clinicians and researchers interested in alcohol use and ART adherence.  
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Within the context of a systematic alcohol screening program, positive screens on the 
AUDIT-C may potentially serve as a legitimate cue to action for HIV care providers to inquire 
further not only about alcohol use, but about possible adherence challenges as well. Additionally, 
new questions are raised about the extent to which, and the ways in which adherence 
interventions may or may not need to be modified for different patient drinking statuses. For 
providers who operate out of a harm reduction model (which prioritizes the pragmatic reduction 
of problems associated with substance use over complete abstinence from use) (Miller, 2004), 
this may be encouraging, especially given that some individuals may not be willing or able to 
simultaneously address abstinence/recovery and adherence enhancement.  
The AUDIT-C appears to reliably assess alcohol use in PWHIV. However, without 
protective strategies in place, researchers who modify the AUDIT-C may risk compromising 
validity, particularly in samples which include drug users. Further attention to the cultural 
equivalence of the AUDIT-C across racial/ethnic groups may be warranted. 
All of the study findings would be strengthened by confirmation using samples having 
greater variability in alcohol use. However, the recruitment and retention of individuals who use 
alcohol is challenging, and appears to be more difficult in the context of polysubstance use. 
Future investigations should nonetheless consider sampling strategies for improved variability in 
alcohol consumption, perhaps through recruitment of HIV-positive individuals attending 
outpatient substance abuse treatment programs.  Such a recruitment strategy would allow for 
greater dimensionalization of alcohol use, e.g., through the comparison of nondrinkers, minimal 
drinkers, at-risk drinkers, and individuals with alcohol abuse or dependence diagnoses. 
Additional assessments of alcohol and drug use available through potential partnerships with 
substance abuse treatment centers would allow additional studies of the AUDIT-C’s reliability 
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and validity. In the future investigators may opt to use a modified AUDIT-3 question as 
described above, and/or a non-derived format of the AUDIT-C and the AUDIT-3.   
Increasing the alcohol use variation in the sample could also feasibly generate 
opportunities to study the intersection of some patients’ need to manage a demanding ART 
medication regimen within the context of remaining sober and working a recovery program; this 
intersection has important implications for adherence intervention design and the integration of 
multiple intervention aims. Wilson, Hutchinson, and Holzemer (2002) have proposed that the 
process of ART adherence decision-making may need to be conceptualized on a dose-by-dose 
basis akin to how recovery models conceptualize the daily management of remaining abstinent. 
This notion remains under-investigated, yet it speaks highly to the complexities and challenges 
of self-management and behavioral change in the context of multiple health and mental health 
conditions. Ultimately, the screening and detection of both at-risk drinking and adherence, with 
even the most reliable and valid of instruments, is of only limited use if the healthcare 
community is unable to adequately understand and respond to the complexities of managing 
HIV/AIDS from the patient’s lived experience. 
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APPENDIX A 
OVERVIEW OF ALCOHOL USE AND ART ADHERENCE 
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NON-INTERVENTION STUDIES REPORTING A SIGNIFICANT RELATIONSHIP BETWEEN ALCOHOL USE AND ART ADHERENCE 
 
 
Study Sample Alcohol measures/ 
operationalization 
Adherence measures/ 
operationalization 
Rates of Alcohol/Drug 
Use  
Results Comments/ 
limitations 
Braithwaite et al., 
2005 
2352 matched 
HIV+ and 
HIV- veterans, 
multi-center 
cohort 
(Veterans 
Aging Cohort 
Study—
VACS) 
 
94% male 
~88% racial 
minority 
Self-report--Time 
Line Follow Back 
(TLFB) method for 
drinking over past 
30 days  
 
“Abstainers” = no 
alcohol past 30 
days 
 
“Nonbinge” = 
alcohol consumed 
past 30 days but no 
day with >5 drinks 
 
“Binge” = >5 
drinks/day in past 
30 days 
Self-report--modified 
Time Line Follow Back 
(TLFB) method for 
medication adherence 
 
For main analyses, 
“nonadherence” = 
failure to take >1 
medication dose on 
given day; for 
secondary analyses, 
definition included late 
doses (> 2 hours after 
prescribed time) 
Alcohol consumption 
past 30 days: 
 
56.6% None 
34.5% Nonbinge 
8.9% Binge 
 
Average daily 
consumption 1-3 
standard drinks 
44% nonadherent 
(missed or late doses)  
 
Temporal effects: For 
nonbinge and binge 
drinkers, alcohol 
consumption on given 
day associated with 
decreased adherence 
on that day as well as 
the 2 days 
immediately 
thereafter. Missed 
doses most likely to 
occur on binge days, 
followed by nonbinge 
days, and non-drinking 
days (p<.0001 for 
trend).  
Dose-response effects: 
nonbinge and  binge 
drinkers had 
significantly greater 
odds of nonadherence 
(compared to non-
drinkers) 
[Nonbinge, OR=1.6 
(1.0-2.6), p =.04; 
Binge OR= 3.9, CI 
(2.1-7.4), p <.001]  
 
Did not differentiate 
between ART and 
non-ART 
medications 
 
Temporal effect 
remained significant 
after removing drug 
users.  
 
Importantly, 
nonbinge category 
captures wide range 
of consumption 
patterns.   
 
Authors 
acknowledge that 
temporal definitions 
preclude those who 
drink every day  
(thus perhaps effects 
of some forms of 
dependent drinking 
underestimated). 
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Cook et al., 2001 219 HIV+ 
outpatients 
 
72% men 
48% MSM 
42% racial 
minority 
AUDIT + 2 
quantity/frequency 
questions 
 
3 drinking patterns: 
“Binge” = >5 
drinks/sitting for 
men, >6 for women 
 
“Heavy”= >16 
drinks/month for 
men, > 12 for 
women 
 
“Hazardous” = 
AUDIT score >8 
 
Self-report 
 
“Missed dose” = missed 
>1 dose in past 24 
hours 
 
“Meds off schedule” = 
Off schedule unless 
took meds “all the 
time” or “nearly all the 
time” in past week 
 
Alcohol use in past 
year: 
 
48% None  
 
33% Mild-moderate 
 
19% “Problem 
drinking”  
(>1 of the following: 
binge drinking (17%), 
heavy drinking (10%) 
hazardous drinking 
(15%)) 
14% “missed dose(s)”  
30% “off schedule” 
 
Problem drinkers more 
likely than 
nonproblem drinkers 
to miss doses/take 
meds off schedule 
(46% vs. 26%,  
p =.019) 
 
Hazardous and heavy 
drinking were both 
significantly 
associated with taking 
medications “off 
schedule” 
[Hazardous, AOR 
2.64, CI (1.07-6.53), p 
<.05; Heavy, AOR 
4.70, CI (1.49-14.84), 
p <.05]  
 
Problem drinkers 
significantly more 
likely to report reason 
for missed doses was 
drinking and/or drug 
use (26% vs. 3%, 
p<.001) 
 
 
 
 
 
 
 
 
Independence of 
alcohol and drug 
use?  Problem 
drinkers 
significantly more 
likely to be younger 
and crack/cocaine 
users (compared to 
nonproblem 
drinkers)  
(p<.01) 
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Chander, Lau, & 
Moore, 2006 
1433 HIV+ 
outpatients 
 
64% male, 
81% African 
American 
 
“Hazardous alcohol 
use” as per NIAAA 
guidelines†  
 
“Moderate alcohol 
use” = any other 
drinking 
Self-report 
 
“Nonadherence”= >2 
doses missed in past 2 
weeks 
Overall alcohol 
consumption: 
54.2% None 
35.1% Moderate 
10.7% Hazardous 
 
Overall drug use: 
32.6% 
 
Alcohol + drug use: 
22.2% moderate 
alcohol only 
 
12.8% Moderate 
alcohol + drug use 
 
4.8% Hazardous 
alcohol only 
 
5.9% Hazardous 
alcohol + drug use 
Moderate and 
Hazardous alcohol use 
both associated with 
decreased odds of 
adherence (compared 
to No Use) [OR= 0.78, 
CI (0.64-0.95); and 
OR= 0.46, CI (0.34-
0.63), respectively] 
 
Lowest odds of 
adherence  associated 
with “hazardous 
alcohol and active 
drug use” category 
[AOR=0.32, 95% CI 
(0.21-0.51] 
“Active drug use” = 
any illicit drug use 
past 6 months (MJ, 
heroin, cocaine, etc) 
Chesney et al., 
2000 
75 HIV+ 
outpatients, 
multicenter 
cohort 
 
80% male 
68% MSM 
31% racial 
minority 
Estimated # 
drinks/month 
derived from 2 
quantity/frequency 
questions—how 
often had drink in 
past 30 days, # 
drinks typically 
consumed 
Self –report 
 
Adult AIDS Clinical 
Trials Group (AACTG) 
Adherence Instruments 
(2) 
 
“Nonadherent” = 
skipping any of one’s 
medications in the past 
2 weeks 
 
 
 
 
 
 
Alcohol use past 30 
days: 
 
32% None 
15% Once/month 
19% 2-3x/month 
20% 1-2x/week 
6%   3-4x/week 
6%   Nearly every day 
2%   Daily 
Significantly higher 
Mdn # drinks among 
nonadherent patients 
than adherent patients 
(9 vs. 2,  
p =.03) 
Pilot study for 
instruments 
 
Small sample size 
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Golin et al., 2002 117 HIV+ 
outpatients 
 
80% male,  
84% racial 
minority 
Yes/no question re: 
alcohol use in last 
30 days 
MEMS, pill count, self 
report (doses missed 
past 7 days) 
 
Composite adherence 
score derived primarily 
from MEMS (% doses 
taken/ doses prescribed 
over past 4 weeks) 
37% reported alcohol 
use in past 30 days 
Average dose 
adherence 71.3%. 
Alcohol consumption 
past 30 days 
independent predictor 
of adherence to PI or 
NNRTI--Drinkers 
significantly less 
adherent than 
nondrinkers ( p =.01) 
Quantity/frequency 
information on 
alcohol consumption 
not reported 
 
Current active drug 
use also independent 
predictor  of 
adherence (p =.05) 
Halkitis, Parsons, 
Wolitski & 
Remien, 2003 
456 HIV+ 
men, multi-
center cohort 
 
100% male 
94% MSM 
~55% racial 
minority 
Self-reported 
frequency of 
alcohol use past 3 
months; 5 point 
Likert scale then  
trichotimized as 
“no use,” 
“infrequent use,” 
“frequent use” 
Self-report 
 
# days past 30 days in 
which > 1 dose missed 
 
“Nonadherent” = 1 or 
more days in past 30 
days where dose missed 
 
 
 
Not reported 51.1% nonadherent  
 
Drinking “several 
times/week” resulted 
in significantly more 
missed days than 
infrequent drinking or  
abstaining 
 (p =.01 for both) 
 
Intoxication in past 3 
months and use of 
alcohol with sex in 
past 3 months also 
both sig. associated 
with nonadherence  
(p =.01, p=.05, 
respectively) 
 
In MV analysis: 
Adherence predicted 
by more frequent use 
of alcohol, avoidant 
coping, and sexual 
communication 
discomfort  
[R2= 49.2%;(F (3,48) 
= 15.48, p .001] 
Atypical/unclear 
operationalization of 
alcohol use; not 
clear how many 
times/week = 
frequent vs. 
infrequent 
 
48% endorsed other 
substance use; crack 
cocaine significantly 
associated with 
nonadherence  
(p =.04) 
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Holmes, Bilker, 
Wang, Chapman, 
& Gross, 2007 
116 HIV+ 
outpatients  
 
81% male, 
66% African 
American 
Not reported, 
variables simply 
listed as “no 
alcohol in past 
year,” “no current 
drug use” 
MEMS for efavirenz 
only 
 
% of prescribed doses 
taken 
 
Dichotomized as “low” 
and “high” using 95% 
cutoff 
Not reported No alcohol use in past 
year was significantly 
associated with 
adherence (53% of 
high adherers had no 
use vs. 42% of low 
adherers, p = .01)            
 
No drug use 
significantly 
associated with 
adherence (87% of 
high adherers had no 
use vs. 78% of low 
adherers, p = .02) 
 
Final logistic 
regression model 
included no alcohol &  
financial worries as 
predictors of 
adherence 
Secondary data 
analysis 
Howard et al., 
2002 
161 HIV+ 
women, multi-
center cohort 
 
100% female 
~85% racial 
minority 
22% on 
methadone 
maintenance 
 
“Alcohol intake > 
1 day/week” in 6 
months prior to 
study enrollment 
MEMS 
 
Daily adherence rate, 
composite adherence 
rate, monthly adherence 
rate  
Alcohol consumption: 
17% “> 1 day/week” 
 
Other substance use,  
6 months prior to 
study enrollment: 
9% IDU 
13% crack cocaine 
Significantly poorer  
adherence among  
women with alcohol 
use >1 day/week 
compared to those 
who did not (Mean 
adherence rate 46% 
vs. 56%, p =.02). 
 
In multivariate 
analysis, alcohol use 
>1 day/week remained 
significantly 
associated with 
adherence (p =.04) 
Atypical alcohol 
operationalization; 
potentially wide 
range of 
consumption 
patterns/quantity, 
but does suggest that 
even small amounts 
of alcohol could 
adversely impact 
adherence 
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Levine et al., 2005 222HIV+ 
outpatients 
 
80% male 
68% African 
American 
SCID; classified as 
alcohol and/or 
substance using or 
dependent if met 
criteria in past 
month 
MEMS 
 
Overall adherence rate: 
number of 
openings/number of 
prescribed doses 
21% had substance use 
disorder 
Dose adherence: 
44.9% took >90% of 
doses, 18.9% took 70-
90%. 
 
Cluster analysis—5 
clusters: 
 
Very poor adherers 
(avg 24% adherence), 
good adherers (>90%), 
sub-optimal adherers 
(<80%), moderately 
poor adherers(~50%), 
poor weekend 
adherers (75% 
weekdays, 57% 
weekends) 
 
Very poor adherers 
had significantly 
higher rates of 
substance use 
disorders (Χ2=17.0, p 
= .002) (60% vs. rates 
ranging from 17.6-
23.1%) in other groups 
 
 
 
 
 
 
 
 
 
 
 
No descriptives or 
separation of alcohol 
and drug use 
disorders in 
“substance use 
disorder”—primarily 
drugs? Alcohol? 
Both? 
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Lucas, Gebo, 
Chaisson, & 
Moore, 2002 
695 HIV+ 
outpatients 
 
62% male, 
84% African 
American 
“Substance 
use”=heroin/ 
cocaine use or 
heavy alcohol use 
(>14 drinks/week) 
in past 6 months 
 
“Nonusers”= no 
substance use at all 
surveys 
 
“Switchers” = 
switched substance 
use status >1 time 
 
“Persistent users” = 
reported substance 
use at all surveys 
Self-reported estimate 
of #pills missed in past 
2 weeks 
 
“Nonadherence”= >2 
doses missed in past 2 
weeks 
54% Nonusers 
29% Switchers 
17% Persistent users 
Significantly better 
adherence among 
nonusers who 
remained nonusers 
compared to nonusers 
who switched to using 
(p<.0001). 
 
Significantly lower 
adherence among 
users who remained 
users compared to 
users who switched to 
non-use (p<.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Independence of 
alcohol/drug use? 
(“Substance 
use”=heroin/cocaine 
use or heavy alcohol 
use) 
 
Definition of “heavy 
drinking” unlikely to 
capture many female 
problem drinkers, 
thus underestimating 
effect of alcohol on 
adherence among 
women 
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Moatti et al., 2000 164 HIV+ 
French 
outpatients 
Questionnaire 
including items on 
alcohol and drug 
use past 6 months 
Self-report 
 
“Face-to-face 
questionnaire” asking 
“daily # pills of 
prescribed and 
effectively taken “ in 
past week, plus “self-
administered 
questionnaire” with 
additional questions 
about adherence 
 
“Nonadherent” = <80% 
of doses reported taken 
or acknowledgement 
that had not been totally 
adherent” 
 
 
 
 
 
 
 
 
 
 
 
 
Not reported 35% nonadherent  
 
Risk of nonadherence 
increased by 20% for 
each additional 25 
glasses (1 glass = 2 
units) consumed each 
month 
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Murphy, Marelich, 
Hoffman, & 
Steers, 2004 
115 HIV+ 
outpatients 
 
76% racial 
minority 
Likert frequency of 
>1 drink in past 3 
months 
 
“3-day dose 
adherence” (no 
missed doses 
yesterday, day 
before yesterday, 
last Saturday)  
 
“Past-week dose 
adherence” (no 
doses missed past 
week) 
 
“Past-month dose 
adherence”  (took 
medication “all of 
the time” or “most 
of the time” past 
month) 
Self-report 
 
3 dichotomous 
measures (modified 
from AACTG 
instruments) 
 
 
Frequency of alcohol 
use (ordinal value): 
 
 Mean score 2.3, i.e., 
slightly more often 
than “once a month or 
less” 
Past-month adherence 
significantly predicted 
by alcohol use and 
social support; those 
abstaining or less 
likely to use alcohol 
were more likely to be 
adherent (p <.01) 
Enrollment targeted 
nonadherent patients 
(i.e., those missing 
doses >once/week) 
 
Gross measure of 
alcohol use, limited 
utility of  frequency 
data provided 
Palepu, Horton, 
Tibbetts, Meli, & 
Samet, 2004 
205 HIV+ 
outpatients 
79% male, 
66% racial 
minority 
 
Eligibility: 
“lifetime 
history of 
alcohol 
problems” =  
> 2 positives 
on CAGE or 
clinical 
assessment by 
investigators 
CAGE for 
eligibility  
 
Self-reported use 
alcohol/drugs in 
past 30 days 
 
Alcohol 
Dependence Scale 
(ADS) for severity 
of alcohol 
dependence  
30-day self-report  
 
“Nonadherent”= less 
than 95% adherence 
(pills taken vs. pills 
prescribed) 
Alcohol consumption 
& drug use past 30 
days: 
18% alcohol alone 
24% alcohol and 
heroin or cocaine 
 
Average daily 
consumption 6.4 
drinks 
Use of drugs or 
alcohol in previous 30 
days associated with 
poorer adherence 
[AOR= 0.17, CI (0.11-
0.28)] 
Alcohol & drug use 
combined. 
Conflation of 
past/current alcohol 
abuse and 
dependence in 
sampling criterion 
“lifetime history of 
alcohol problems”—
rate of current 
problematic alcohol 
consumption unclear 
(if only 42 % used 
alcohol in past 30 
days, 58% did not) 
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Parsons, Rosof, & 
Mustnaski, 2007 
272 HIV+ 
outpatients 
with reported 
alcohol 
problems 
 
Eligibility 
criteria: score 
of > 8 on 
AUDIT 
 
78.3% male 
89% racial 
minority 
48% MSM 
AUDIT for study 
inclusion 
 
Alcohol 
consumption via 
TLFB interview for 
# standard drinks 
consumed each day 
over past 30 days  
 
Drinker Inventory 
of Negative 
Consequences 
(DrinC) for 
negative 
consequences of 
alcohol use  
TLFB interview re: 
doses taken and missed 
over past 2 weeks 
(converted to %) 
 
“Adherence” = >95% 
of doses taken 
 
 
Not reported 57% nonadherent 
 
Number of drinks 
(p=.002) and 
Adherence confidence  
(p =.001) and were 
significant predictors 
of adherence; DrinC 
score and AUDIT 
score were 
nonsignificant 
Using cut-off score 
of 8 for AUDIT may 
only capture 
heaviest of female 
drinkers, thus 
underestimating 
effect of alcohol on 
adherence among 
women. 
Samet, Horton, 
Meli, Freedberg, 
& Palepu, 2004 
267 HIV+ 
outpatients 
81% male 
66% racial 
minority 
 
Eligibility 
criteria 
“lifetime 
history of 
alcohol 
problems” =  
> 2 positives 
on CAGE or 
clinical 
assessment by 
investigators 
CAGE for 
eligibility 
 
Quantity/frequency 
questions + 
Addiction Severity 
Index (ASI) for 
alcohol 
consumption  
 
“At-risk” drinking 
= NIAAA 
guidelines†  
 
“Moderate” 
drinking = any 
other drinking 
3-day self report, # 
missed pills  
 
“Nonadherent” = less 
than 100% adherent 
over previous 3 days 
 
Alcohol consumption: 
60% None 
24% Moderate 
16% At-risk  
44% nonadherent  
 
Alcohol consumption 
greatest predictor of 3-
day self-reported 
adherence (p  <.0001); 
abstainers had 
significantly greater 
odds of  100% 
adherence than 
moderate or at-risk 
drinkers [Abstainers 
vs. moderate drinkers, 
AOR= 3.0, CI (2.0-
4.5); Abstainers vs. at-
risk drinkers, AOR= 
3.6, CI (2.1-6.2)] 
Same sample as 
Palepu, 2004 
 
Independence of 
alcohol and drug 
use?  Drinkers 
significantly more 
likely use heroin (p 
=0.001) and cocaine 
(p=<0.0001) in 
previous 30 days 
(compared to 
nondrinkers) 
 
Conflation of 
past/current alcohol 
abuse /dependence 
in sampling criterion 
“lifetime history of 
alcohol problems”  
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Tucker et al., 2004 1889 HIV+ 
persons in 
HIV Cost and 
Services 
Utilization 
Study 
(HCSUS) 
 
78% male, 
50% racial 
minority 
Self-reported 
alcohol use past 4 
weeks—
dichotomous 
summary measure 
of “heavy 
drinking” (>5 
drinks/occasion) 
Self-report, # days 
intentionally/unintentio
nally missed ART dose 
and/or took less than 
prescribed amount in 
past week + global 
question re: # days past 
week took all meds as 
prescribed 
 
“Adherent” = no missed 
doses and all 
medications taken as 
prescribed “all of the 
time” 
6% “heavy drinkers” 
 
5% “heavy drinkers” 
and drug users” 
54% nonadherent 
 
For “heavy drinkers,” 
“difficulty getting 
medication” reported 
to be significant 
mediator between 
substance use and 
ART nonadherence  
(p =.04)  
 
For those with heavy 
drinking + drug use, 
“poor regimen fit with 
lifestyle” reported to 
be significant mediator 
(p <.01) 
Drug use 
predominantly MJ 
Tucker, Burnam, 
Sherbourne, Kung, 
& Gifford, 2003 
1910 HIV+ 
persons in 
HIV Cost and 
Services 
Utilization 
Study 
(HCSUS) 
Alcohol 
consumption past 4 
weeks: quantity/ 
frequency 
questions, then 
classified as: 
 
No drinking 
 
Nonheavy drinking 
(always <5 
drinks/day) 
 
Heavy drinking (>5 
drinks on 1-4 
occasions) 
 
Frequent heavy 
drinking (>5 drinks 
on >5 occasions) 
3 questions on 
adherence in past week: 
# days forgot dose, # 
days purposely didn’t 
take, # days took less 
than prescribed + global 
question on how many 
days took all meds 
exactly as prescribed 
 
“Adherent”= no missed 
meds and if all meds 
taken exactly as told 
“all of the time” 
Among those who 
drink, alcohol use past 
4 weeks: 
 
38% Nonheavy 
drinking  
 
9%  Heavy drinking  
 
5% Frequent heavy 
drinking 
 
28% endorsed drug 
use (mostly MJ) 
54% nonadherent;  
Alcohol use 
independently 
associated with poorer 
adherence; 
Multivariate analysis: 
all 3 levels of 
consumption 
significantly increased 
odds of nonadherence: 
 
[Nonheavy, OR=1.5, 
CI (1.2-2.0),  
p =.004); 
 
Heavy, OR=1.6, CI 
(1.1-2.3), p = .01;  
 
Freq. Heavy, OR=2.3 
CI (1.3-4.1),  
p =.004)]  
Dose-response 
relationship:  % 
adherent persons 
consistently 
decreased as alcohol 
consumption level 
increased:  52% of 
Nondrinkers 
adherent, compared 
to 43% of Nonheavy 
drinkers, 39% of 
Heavy drinkers, 
31% of Frequent 
Heavy drinkers  
 
 
153 
 
NON-INTERVENTION STUDIES REPORTING NONSIGNIFICANT OR MIXED FINDINGS ON THE RELATIONSHIP BETWEEN ALCOHOL USE 
AND ART ADHERENCE 
Study Sample Alcohol measures/ 
operationalization 
Adherence measures/ 
operationalization 
Rates of Alcohol/Drug 
Use  
Results Comments/ 
limitations 
Arnsten et al., 
2002 
85 HIV+ 
current and 
former opiate 
users  
Bronx HIV 
Epidemiologic 
Research on 
Outcomes 
(HERO) 
cohort 
 
95% on MTP 
60% male 
84% racial 
minority 
 
# drinks/wk 
 
Instrument/ 
assessment strategy 
not reported 
MEMS over 6 months 
 
Adherence rate for each 
medication =  # MEMS 
openings/ doses 
prescribed 
 
Overall Mean 
adherence rate based on 
average of adherence 
rates for all medications 
 
Estimated dose interval 
adherence =  
 
%days > 1 dose taken,  
 
% days correct dose 
taken, 
 
% days all doses taken 
within 25% of the 
correct dosing interval 
 
 
 
 
 
 
 
 
 
Average alcohol use 
during study period: 
 
58%   None 
16%   0-1drinks/wk 
14%   2-5 drinks/wk 
12%   >5 drinks/wk 
 
31% endorsed an 
“alcohol or drug 
coping style,” i.e., 
when under stress or 
dealing with an 
upsetting problem, “I 
use alcohol/drugs to 
help me get through 
it,” or “I use alcohol or 
drugs to help me feel 
better.” 
Mean overall 
adherence all meds 
53%. Mean dose 
adherence 38%. Mean 
interval adherence 
23%. 
 
Alcohol use several 
times/wk or every day 
not significantly 
associated with poor 
adherence [Mdn 
adherence rate 37% 
vs. 62%, p =.09], 
 
however, significant 
difference in 
adherence reported 
between those who 
did/did not endorse 
“alcohol or drug 
coping style” [Mdn 
adherence 28% vs. 
68%, p =.01] 
 
 
 
 
 
 
 
 
Independence of 
drug/alcohol use? 
Sample is opiate 
users/MTP 
participants 
 
40% reported active 
drug use 
(heroin/cocaine) 
during study period, 
active cocaine use 
significantly 
associated with 
poorer adherence 
[Mdn adherence rate 
27% vs. 57%,  
p =.005] 
 
“Coping style” 
results suggestive of 
personality 
differences at play? 
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Berg, et al., 2004 113 HIV+ 
outpatients in 
methadone 
program 
 
64% male 
88% racial 
minority 
“problem alcohol 
use”= >5 
drinks/occasion or 
drinking 
“frequently” (i.e., 
“several days per 
week” or “every 
day”) during 6 
month study period 
Medication event 
monitors (MEMS); 
adherence rate for each 
medication = # cap 
openings divided by # 
prescribed doses; 
average adherence rate 
= average of all 
individual medication 
adherence rates 
30% “Problem alcohol 
use” 
 
27% crack/cocaine use 
24% heroin use 
No significant 
differences in median 
adherence rate 
between those 
with/without “problem 
alcohol use” (40% vs. 
69%, p= 0.07),  
 
however, significant 
interaction emerged; 
women with “problem 
alcohol use,” 
significantly less 
adherent  than men 
with “problem alcohol 
use” (p=.046) 
Interaction effect 
arguably significant 
Catz, Kelly, 
Bogart, Benotsch, 
& McAuliffe, 
2000 
72 HIV+ 
outpatients on 
HAART 
 
87% men 
44% racial 
minority 
 
 
Frequency of 
alcohol use past 3 
months, 7-point 
Likert scale from 
no use to daily use 
Self-report 
 
# pills missed past 5 
days, # days missed 
doses over past 3 
months (7-point Likert 
scale, never to every 
day) 
 
“Nonadherent” = 
missed dose > 
once/week during past 
3 months 
Not reported 33% missed >1 dose 
in past 5 days 
 
71% missed dose in 
past 3 months:  
4% missed daily, 18% 
missed weekly, 49% 
missed monthly 
 
Adherence not 
significantly 
associated with 
frequency of alcohol 
use past 3 months (M 
frequency score 2.75 
vs. 2.85,  
p = .842) 
 
 
 
 ?Alcohol use 
dichotomized as 
yes/no  despite 7-
point scale? Analytic 
strategies not clear 
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Halkitis, Kutnik, 
& Slater, 2005 
300 HIV+ 
outpatients on 
HAART 
 
100% male 
66.3% racial 
minority 
 
TLFB interview for 
use of 10 drugs 
(including alcohol) 
2-week study 
period 
MEMS + self-report via 
computer-assisted 
survey for 2 weeks 
42.7% of total sample 
used alcohol during 2-
week study period  
 
32.7% of total sample 
reported use of 1 
substance (alcohol or 
drug) 
 
27% reported use of 
>1 substance (alcohol 
or drug) 
 
38% no use of any 
substance 
 
 
Via MEMS, 60.7% 
had adherence >95%, 
and 8.7% had 
adherence between 90-
95%.  
Via self-report, 67% 
had adherence > 95% 
     In MEMS and self-
report data, adherence 
not significantly 
related to  
alcohol use. Re: 
substance use, only 
cocaine use was 
significantly related to 
adherence (in both 
MEMS and self-report 
data) 
During 2-week study 
period  
27% used 
cocaine/crack  
26.3% used MJ  
 
Haubrich et al., 
1999 
173 HIV+ 
outpatients, 
multi-center 
cohort 
 
92% male 
70% MSM 
55% racial 
minority 
Frequency of drug 
or alcohol use on 
1-item frequency 
question (7 point 
scale less than 
once/week to daily) 
Self-reported estimate 
of % of prescribed 
medication taken in 
past 4 weeks, reasons 
for missing doses 
 
Categorized as <80%, 
80-95%, 95-99%, 100% 
 
“100% 
adherent”=patients who 
endorsed >95% 
adherent and who 
selected “never missed 
pills” on reasons 
question 
 
 
Not reported No difference in 
baseline adh among 
those who drink/use 
drugs vs. those who 
don’t (38% of 
alcohol/drug users had 
100% adherence at 
baseline versus 41% of 
nonusers). However,  
at 2 months, people 
using alcohol/drugs 
were sig. less adherent 
(>95% adherence) 
than those who did not 
(51% vs. 73%, p 
=.006). At 6 months, 
the difference was 
even more significant 
(47% vs. 84%, p 
=.003) 
Independence of 
alcohol/drug use? 
(Single question for 
both and 
amounts/types of 
substances used was 
not delineated) 
 
Complicates 
interpretation of 
results; e.g.,  alcohol 
and drug use did not 
impact adherence at 
baseline, but did at 6 
months, when % of 
users had actually 
decreased from 32% 
to 15%)  
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Hinkin et al., 2004 148 HIV+  
outpatients 
 
83% male 
83% racial 
minority 
 
Some 
veterans? 
Substance abuse 
module of SCID 
for DSM-IV 
MEMS over 4 weeks 
 
“Good adherers” = 
>95% of prescribed 
doses taken 
 
 “Poor adherers” = 
<95% of prescribed 
doses taken 
Not reported Mean dose adherence 
rate  80.7% 
 
Current alcohol 
abuse/dependence 
diagnosis not 
significantly 
associated with 
adherence   
[X2 (1,144) = 0.73,  
p =.58] 
Current drug 
abuse/dependence 
was significantly 
associated with poor 
adherence  
[X2 (1,144) = 4.6, p 
=.04] 
 
 
 
 
 
Kleeberger et al., 
2001 
539 HIV+ 
men, 
Multicenter 
AIDS Cohort 
Study 
(MACS) 
 
100% male 
16.5% racial 
minority 
Alcohol use: >or 
<14 drinks/week 
(partial NIAAA 
categorization) 
 
Specific 
instrument/assessm
ent not reported  
 
 
Self-report 
 
Adaptation of AACTG 
instruments, assessed  
2-, 3- and 4- day 
adherence with 
questions related to 
dose intensity, dose 
frequency, scheduling, 
and instructions for 
overall use 
 
“100% adherence” = 
taking all doses and # 
pills prescribed for all 
medications within 
previous 4 days 
 
 
 
 
 
 
Not reported 22.3% nonadherent 
 
Consuming > 14 
drinks/week not 
significantly 
associated with < 
100% adherence  
(OR = 1.57, p =.30) 
Extremely stringent 
definition of 
adherence 
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Lazo et al., 2007 Secondary 
data analysis 
of 2 large 
studies: 
MACS—men 
and WIHS—
women 
 
640 men, 2803 
visit-pairs 
 
1304 women, 
5972 visit 
pairs 
 
73% of men 
were white 
 
15% of 
women were 
white 
Low alcohol 
consumption = < 
drinks/day for men 
and 0-1 drinks/day 
for women 
 
Moderate-heavy 
alcohol 
consumption =  
3-4 drinks at least 
3times/month OR 
>5 drinks at a time 
but less frequently 
than once/month 
 
Binge drinking = > 
5 drinks at least 
once/month for 
men, >4 at least 
once/.month for 
women 
 
Drug use for men = 
self reported MJ, 
poppers, 
cocaine/crack, 
crytstal/meth, 
speedballs, heroin, 
XTC 
 
Drug use for 
women = MJ, 
cocaine/crack, 
heroin, 
methamphetamine 
 
 
 
Self-report 
 
AACTG instrument 
 
Adherence 
dichotomized as 100% 
or <100%  
 
100% = taking all doses 
and numbers of pills as 
prescribed 
 
WIHS study looked at 
past 3 days, MACS 
looked at past 4 days 
 
 
 
Low alcohol 
consumption: 55% 
men, 28% of women 
 
Heavy: 15% men, 8% 
women 
 
Binge:  7% men, 4% 
women 
 
Use of >2 drugs: 27% 
men, 9% women 
 
 
All 3 types of drinking 
behavior were 
significant, 
independent predictors 
of decreasing 
adherence IN 
WOMEN ONLY. 
 
Binge and low alcohol 
consumption were 
inversely related to 
adherence, and 
emerged as significant, 
independent predictors 
of increasing 
adherence IN 
WOMEN ONLY.  
 
Drug use was an 
independent predictor 
(inversely related) of 
increasing adherence 
among men and 
women.  
Secondary data 
analysis of 2 large 
studies: MACS—
men and WIHS—
women. 
 
Somewhat 
complicated 
alcohol/drug use 
categories  
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Paterson et al., 
2000 
 
81 HIV+ 
outpatients, 
veterans and 
non-veterans 
 
23% racial 
minority 
 
 
 
“Alcoholism” = >2 
positive responses 
on CAGE  
 
MEMS 
 
Adherence rate = doses 
recorded/doses 
prescribed 
 
 
13.5% “history of 
alcoholism”  (n=11) 
Average dose 
adherence 74.7%.  
In univariate analysis, 
Alcoholism not 
significantly 
associated with 
adherence [RR= 0.28, 
CI (0.04-1.9, p =.127]   
 
In multivariate 
analysis, absence of 
alcoholism not 
associated with 
adherence: [OR=5.8, 
CI (0.6-57.8), p =.13] 
 
Adequate power? 
Risk of Type II error 
given that only 11 
individuals with 
“alcoholism” 
Spire et al, 2004 445 HIV+ 
French 
outpatients on 
HAART 
(AROCO-
ANRS/EP11 
Study) 
 
78% male 
 
10 questions on 
alcohol/drug use 
over past 4 weeks 
 
<1 unit/day vs.  >1 
unit/day  
Self report 
 
4 day recall, # pills 
taken daily + 
 
global question re: 
having taken doses 
“totally,” or “partially,” 
or if they had 
“interrupted treatment.” 
 
“Adherent” if doses 
taken past 4 days = 
doses prescribed and if 
declared “totally” 
followed regimen 
 
 
At baseline, 26% 
consumed > 1 unit/day 
 
74% consumed <1 
unit/day 
26.7% nonadherent 
 
Baseline alcohol 
consumption of  >1 
unit/day of  alcohol 
not significantly 
associated with 
adherence at  
month 4 (67.2% of 
those consuming >1 
unit/day were adherent 
vs. 75.4% of those 
consuming <1 
unit/day, p =.09). 
 
However, --increasing 
one’s consumption 
level from <1 unit/day 
to >1 unit/day was 
associated with greater 
odds of adherence at  
month 4 [AOR 2.24, 
CI (1.35-3.71)] 
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Waldrop-Valverde 
et al, 2006 
57 HIV+ 
outpatients 
 
77% male 
96% racial 
minority 
 
Questionnaire 
based on SCID for 
DSM-IV, 
substance abuse 
module—included 
items on frequency, 
duration, and time 
since last use 
 
Participants 
categorized as 
yes/no re: “use of 
alcohol in past 
week” 
Self-reported 1-day 
adherence 
 
“Adherence” = 100%  
1-day adherence 
50% reported 
drug/alcohol use in 
past week 
 
Average length of 
alcohol use:  19 yrs 
 
42% nonadherent 
 
Alcohol use and drug 
use in past week not 
significantly related to 
adherence in any of 
the 3 logistic 
regression models 
tested 
 
Sample with 
longstanding 
substance abuse 
issues: 
Average length of 
use: 
heroin     13 yrs 
cocaine   14 yrs 
MJ        19 yrs 
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APPENDIX B 
ADHERENCE INTERVENTIONS FOR HIV-INFECTED PERSONS WHO USE ALCOHOL 
  
Study 
 
Samet et al, 2005 
 
Parsons, Golub, Rosof, & Holder, 2007 
Theoretical basis Readiness for change (Transtheoretical Model--Prochaska &  
DiClemente, Miller & Rollnick, etc.) 
Information-Motivation-Behavior (IMB), Motivational 
Interviewing (MI), Cognitive-Behavioral Skills Training  
Design Randomized controlled trial, intervention vs. usual care Randomized controlled trial, intervention vs. education 
Aims Improve ART adherence, reduce alcohol consumption, improve  
clinical outcomes (CD4, viral load) 
Improve ART adherence, reduce alcohol consumption, 
improve clinical outcomes (CD4, viral load) 
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Sample characteristics n=151 
HIV-infected persons with “current or lifetime history of alcohol 
abuse or dependence” (based on >2+ responses on CAGE 
questionnaire, or, clinical diagnosis made by 1  study 
investigator) ; ~80% male 
n=143 
HIV-infected persons identified as “hazardous drinkers” 
(>16 drinks/week for men, >12 drinks/week for women); 
~80% male, 94% racial/ethnic minority, Mean age 43.6 
 
 
Alcohol use measures Initial inclusion criteria as described above.  
Consumption measured by Addiction Severity Index (ASI) + 
frequency/quantity questions 
Initial inclusion criteria by AUDIT score >8; followed by 
criteria above.  Standard drinks consumed measured by 
Timeline Follow-back Interview (TLFB) for past 14 days 
Adherence measures Self-report (ACTG scale) corroborated by MEMS at certain 
timepoints 
dose adherence 
dichotomous + continuous over past 30 days,  past 3 days  
Self-report (TLFB interview) 
dose and day adherence 
% dose adherence past 14 days,  
% day adherence past 14 days 
Intervention  
duration/intensity/ 
components 
4 sessions, 15-60 minutes each  
Alcohol and substance use (readiness to change) 
Reminder device (watch with alarm) 
8 sessions, 60 minutes each (applies to both adherence 
intervention and educational intervention) 
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Review of ART efficacy 
Tailoring medication-taking to personal circumstances 
Adherence intervention:  
Alcohol use (MI) 
Tailored skills-building and self-assessment/monitoring 
modules (e.g., side effects, alcohol triggers/refusal 
strategies, social support) 
Education: 
Didactic, videotapes, discussion on HIV, ART, and 
alcohol 
 
Results No significant improvements in ART adherence, reduction in 
alcohol use, or improvements in clinical markers 
From baseline to 3 months, both groups had significant ↑ 
in % dose and % day adherence.  
 Adherence intervention group had significantly greater 
improvements in % dose adherence and % day adherence 
compared to education group.  Alcohol consumption 
significantly ↓ in both groups at 3 month and 6 month 
time points. 
 
Limitations Lower than anticipated enrollment limited statistical power 
~25% of sample received partial intervention or no intervention  
High rates of adherence at baseline; may → ceiling effect 
Low statistical power at 6 month time point due to 
attrition. Adherence effects not sustained at 6 month time 
period (may require booster sessions) 
Critique Conclusions re: need for directly observed therapy (DOT) in this 
population are somewhat premature given significant 
methodological limitations of the study and intervention 
characteristics.  
 
Intervention seems intended to be clinically feasible in terms of 
duration/intensity, and combines information needs (ART) and 
readiness to change (substance use), with practical, life-relevant 
dimensions (reminder device, tailoring to circumstances). The 
Simoni (2006) meta-analysis also reported a nonsignificant trend 
where intervention effect sizes tended to be larger in studies that 
included “didactic information on HAART” and those including 
“interactive discussion of cognitions, motivations, and 
expectations regarding adherence” (p. S31). The brief 
Intervention may be challenging to replicate in clinical 
setting.  While this intervention appeared to be more 
theoretically-driven and of greater intensity and duration 
that that described by Samet (2005), a meta-analysis by 
Amico (2006) reported that articulation of theoretical 
basis and intensity/duration of intervention were not 
related to the magnitude of effect sizes. However, 
characteristics of the intervention and the study’s low 
percentage of individuals adherent at baseline and 
intervention characteristics may partially explain the 
intervention’s apparent effectiveness.   The meta-analysis 
by Amico (2006) also reported that intervention studies 
targeting persons with low adherence at baseline showed 
larger effect sizes than those that did not enroll in this 
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intervention description provided by Samet (2005) suggests that 
didactic and motivation components were incorporated into the 
intervention, however, limited information about the theoretical 
underpinnings and specific content of the intervention leave 
questions about the role of intervention design in the study’s lack 
of significant findings.    
Criteria of “current or lifetime alcohol abuse/dependence” may 
have impacted the effect of the intervention. Other studies have 
demonstrated that adherence is different when one considers past 
vs. current use and/or different levels/patterns of alcohol 
consumption.  Information about current alcohol consumption 
patterns of the sample or what % of persons fell into each 
category/permutation was not reported.   
Lack of intervention efficacy does not appear to be related to 
depression, concurrent drug use, homelessness, disease status, pill 
burden—no significant differences between groups 
Low % of women in sample, but meta-analyses by Simoni (2006) 
manner. While the Parsons study did not target low 
adherers during enrollment, baseline adherence was 38% 
for the sample. Additionally, the study’s targeting of 
persons with alcohol problems may have served as a 
proxy for this phenomenon. The Simoni (2006) meta-
analysis also reported a nonsignificant trend where 
intervention effect sizes tended to be larger in studies that 
included “interactive discussion of cognitions, 
motivations, and expectations regarding adherence” (p. 
S31); the intervention description provided by Parsons 
(2007) appears consistent with this characteristic. 
Adherence intervention did not result in greater 
reductions in alcohol use than the education module—
may be due social desirability issues around reporting 
alcohol reduction vs. adherence improvements or that 
information alone is effective for alcohol-related 
behavior change, whereas adherence behavior change 
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and Amico (2006) both showed that gender did not appear to be 
related to intervention effect size. 
requires additional components (authors’ interpretations).  
Low % of women in sample, but meta-analyses by 
Simoni (2006) and Amico (2006) both showed that 
gender did not appear to be related to intervention effect 
size. No info on those with concurrent drug use 
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